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1 INTRODUCTION 
1.1 IgE-mediated allergy 
The prevalence of pollen and food allergy is increasing not only in developed but also 
in developing countries worldwide (Campbell & Mehr, 2015). Allergic symptoms like 
rhinitis, urticaria or anaphylaxis affect up to 370 million individuals (estimated 50% of 
total population) in Europe leading to tremendous costs in health care systems (de 
Monchy et al., 2013). Furthermore allergies have a great influence on patients’ quality 
of life for instance through strict diets to avoid allergenic food or intake of medications 
during pollen season to reduce allergic symptoms. In Europe 150-300 million 
subjects (20-40%) are allergic to pollen (Vieths et al., 2002; D'Amato et al., 2007). 
Major elicitors are pollen from trees, grasses and weeds. Food allergy affects globally 
at least 5% of adults and 8% of children, however due to lack of detailed studies 
these numbers can be imprecise (Chafen et al., 2010; Sicherer & Sampson, 2014). 
Recently it was shown that IgE sensitization to food allergens ranged from 7-24% of 
the European population depending on geographical location (Burney et al., 2014). 
However mere presence of allergen-specific IgE antibodies does not necessarily 
correlate with allergic symptoms as subjects having allergen-specific IgE may well be 
clinically tolerant (Burney et al., 2014). Overall eight food allergens cause the majority 
of food allergic reactions, particularly in children, which include allergens from plants 
such as peanuts, tree nuts, wheat and soy, together with allergens of animal origin 
including cow’s milk, egg, fish and shellfish (Bush & Hefle, 1996; Allen & Koplin, 
2012). In total, the self-reported prevalence of allergies against these foods is 
between 0.4% and 6.0% across all aged patients in Europe (Nwaru et al., 2014). 
Prevalences can vary dependent on age, geographical location, dietary exposures or 
other factors (Sicherer, 2011).   
In general an allergy is a hypersensitivity response of the immune system to normally 
innocuous proteins (Galli et al., 2008). Food allergy but also pollen allergy can follow 
the mechanism of a type I allergy resulting in an immediate, IgE driven immune 
response (Rajan, 2003). Development of type I allergies can be divided into two 
phases (Figure 1). 
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Figure 1: Pathomechanism of type I allergies. 
For details see text. Adapted from Murphy et al., 2012. 
 
In the first phase, so called sensitization, an individual is exposed to an allergen 
without causing any allergic symptoms. Allergens can enter the immune system 
through either gastric or oral mucosa, by ingestion (food allergy) or inhalation (pollen 
allergy), respectively. Allergens are taken up and processed by antigen presenting 
cells (APC). APCs are dendritic cells, macrophages or B cells which present peptides 
of digested allergens on their surface bound to major histocompatibility complex 
(MHC) class II molecules. Naïve CD4+ T helper (Th) cells circulating through blood 
stream and lymphoid organs can bind to peptide-MHC class II complexes via their 
appropriate T cell receptor resulting in proliferation of T cells and cytokine release 
(Murphy et al., 2012). Besides interaction of T cell receptor with MHC class II 
molecules, additional allergen-unspecific signals including co-stimulatory molecules 
or cell-to-cell contacts are discussed for T cell differentiation (Beier et al., 2007). 
Depending on resulting cytokine milieu a Th1 or Th2 driven immune response is 
established. Secretion of interferon (IFN)-gamma, interleukin (IL)-12 and tumor 
necrosis factor (TNF)-β is characteristic for Th1 cells while Th2 cells synthesize IL-4, 
IL-5, IL-9 and IL-13. In parallel B cells encounter their specific non-digested allergen 
and present it on their cell surface bound to their specific B cell receptor (Murphy et 
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al., 2012). These primed B cells can interact with activated Th2 cells via CD40-CD40 
ligand and CD80-CD28 interactions, respectively, causing an isotype switch from B 
cells to plasma cells producing allergen specific IgE antibodies (Poulsen & 
Hummelshoj, 2007). In contrast to Th2 cells a Th1 driven immune response causes 
synthesis of IgG antibodies. Until now it is not known how the Th1/Th2 ratio causes 
different immune responses in atopic and non-atopic individuals (Romagnani, 2004). 
Secreted IgE antibodies can enter the blood stream and finally bind to the high 
affinity receptor for IgE (FCεRI) on the surface of effector cells like mast cells or 
basophil granulocytes (Galli & Tsai, 2012). If such allergen-specific IgE antibodies 
are present an individual is sensitized to the allergen. 
In the second phase, the elicitation, a recurring contact with the allergen leads to 
allergen-induced IgE receptor complex formation. If the allergen presents at least two 
different antibody-binding sites, cross-linking of two membrane-bound IgE antibodies 
via allergen occurs. IgE cross linkage activates several signaling cascades and 
biochemical reactions resulting in degranulation and release of mediator molecules 
like histamine. Histamine immediately causes contraction of smooth muscle tissues, 
lowering of blood pressure or an increased permeability of blood vessels (White, 
1990; Broide, 2001). This may lead to local inflammation like swelling and irritation of 
oral mucosa, gastrointestinal discomfort and sometimes also systemic reactions like 
anaphylaxis. 
To date it is not known why some patients develop an allergy against normally 
harmless proteins while others do not. Several hypotheses what might contribute to 
development of allergies are discussed but underlying mechanisms are unknown. 
Often mentioned in this context is the “hygiene hypothesis” indicating a reduction of 
allergic reactions caused by exposure to infections during childhood (Strachan, 1989; 
Kay, 2001). Furthermore westernized lifestyle with change in medical treatment and 
diet, but also genetic factors, air pollution or stress as elicitors for allergies are 
discussed (Wills-Karp et al., 2001; Saxon & Diaz-Sanchez, 2005; Vercelli, 2008). 
 
1.2 IgE-mediated food allergy 
IgE-mediated food allergy can be divided in class I and class II food allergic 
reactions. Class I food allergy, classical food allergy, mainly affects young children 
whereas class II food allergy is present in adults (Egger et al., 2006). Allergic 
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reactions occur via sensitization through gastrointestinal tract in class I allergy or 
because of cross reactions between several food and pollen allergens in class II 
allergy, respectively (Breiteneder & Ebner, 2000). The latter is known as pollen-
related food allergy. Molecular reason for pollen-food allergy can be cross reactivity 
of IgE antibodies against pollen allergens with structural homologous proteins from 
plant food (Kazemi-Shirazi et al., 2000). Examples are cross reactions between birch 
pollen and several foods, celery-mugwort-spice and grass or ragweed pollen with 
fruits (Aalberse et al., 2001). Patients with pollen-related food allergies are sensitized 
to pollen allergen and can exhibit different allergic symptoms after consumption of 
plant-derived foods and food products. Frequently only weak local reactions like 
itching and swelling of tongue or lips occur, but also severe, systemic symptoms such 
as anaphylaxis and urticaria are observed usually within 2 hours after food intake 
(Ballmer-Weber et al., 2000; Ballmer-Weber et al., 2001; Kleine-Tebbe et al., 2002; 
Mittag et al., 2004a; Mari et al., 2005). As shown for type I allergies, inhalation of 
pollen allergens causes sensitization, including production of specific IgE antibodies. 
Afterwards the first oral contact with the food can be sufficient to cause an allergic 
reaction without prior sensitization to the specific food allergen. In birch pollen-related 
food allergy cross reactivity occurs between IgE directed against major birch pollen 
allergen (Bet v 1) and structurally homologous food allergens from various fruits like 
apple, apricot, cherry, peach, pear or strawberry as well as different nuts and 
legumes like peanut, hazelnut, mungbean or soybean, respectively, but also 
vegetables like carrots, celery or tomatoes can cause allergic symptoms (Vieths et 
al., 2002; Breiteneder & Mills, 2006). Both, Bet v 1 and Bet v 1-related food allergens, 
show similar IgE binding regions (epitopes) on their molecular surface causing 
antibody cross reactions. In Europe up to 70 million subjects exhibit a birch pollen 
allergy and up to 90% of patients with birch pollinosis also show a birch pollen-related 
food allergy (D'Amato et al., 2007; Geroldinger-Simic et al., 2011). Bet v 1 and its 
homologous food allergens belong to the pathogenesis related protein 10 (PR-10) 
family. PR-10 proteins are abundant in higher plants. Expression of PR-10 proteins in 
the cytosol is induced in plants upon stress conditions like wounding, microbial or 
fungal elicitors and several abiotic factors (Somssich et al., 1986; Warner et al., 1992; 
Walter et al., 1996; Robert et al., 2001). Furthermore they play a role in plant 
development (Hoffmann-Sommergruber, 2000). For Bet v 1 ribonuclease activity and, 
together with its ligand quercetin-3-O-sophoroside, a protective function against UV 
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damage was suggested (Bufe et al., 1996; Seutter von Loetzen et al., 2014). 
Furthermore for Pru av 1 from cherry and Bet v 1 binding of phytosteroids was 
suggested but specific functions for other PR-10 proteins remain elusive (Neudecker 
et al., 2001; Radauer et al., 2008). Besides a high amino acid sequence identity 
(38-67%) with Bet v 1, homologous allergens show also an identical protein folding 
(Vieths et al., 2002). Furthermore all allergens of the Bet v 1-family have a conserved 
glycine-rich P-loop region comprising amino acids 46-52 in Bet v 1 characterized as 
structural element of nucleotide binding proteins and important for IgE reactivity 
(Saraste et al., 1990; Mirza et al., 2000; Holm et al., 2004). Related allergens are for 
example Mal d 1 (apple), Pru av 1 (cherry), Cor a 1.04 (hazelnut), Ara h 8 (peanut), 
Gly m 4 (soybean), Dau c 1 (carrot) or Api g 1 (celery). Besides IgE cross reactivity, 
these food allergens can also stimulate Bet v 1-specific T cells (Fritsch et al., 1998; 
Jahn-Schmid et al., 2005). In contrast to B cell activation, T cell cross reactivity even 
persists after gastrointestinal digestion (Schimek et al., 2005). Furthermore, 
complexity of different food matrices can have a huge effect on stability and 
presentation of allergens (Grimshaw et al., 2003). 
 
1.3 Diagnosis and treatment of allergies 
For correct treatment of allergic symptoms a precise and distinct diagnosis is 
essential. For this purpose different diagnostic procedures are used today. First 
conclusions on the potential presence of allergies can be drawn by a thorough 
anamnesis usually in combination with a standardized questionnaire and patient’s 
history. Then the anamnesis needs to be verified by allergy tests. Very common are 
skin prick test (SPT) and prick to prick test (PPT). In both tests small amounts of 
allergen are applied to the skin and the size of resulting wheals is measured. 
Besides, in vitro tests are used to determine allergen-specific IgE antibodies in 
patients’ sera. One example is ImmunoCAP™ blood test (Thermo Fisher, Sweden) a 
standard diagnostic tool used in the majority of clinical laboratories. ImmunoCAP™ 
results show levels of total IgE antibodies or levels of IgE specific for allergen 
extracts or individual allergen molecules. Positive results in both, in vitro analyses 
and in vivo skin tests only point to sensitization to pollen or food allergens but not 
necessarily to an allergy. Especially for diagnosis of food allergies double-blind 
placebo-controlled food challenge (DBPCFC), first described in 1976, is considered 
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as gold standard (May, 1976). In DBPCFC the suspicious food allergen or allergenic 
food is administered in increasing doses and allergic symptoms of the patients are 
recorded. For this, clinical monitoring and safety precaution are required making 
DBPCFC very expensive and time-consuming. In general only hospitals are able to 
perform such types of food challenges. In contrast to skin testing and in vitro testing, 
not only sensitization but confirmation of the clinical relevance of food allergies is 
possible. Furthermore DBPCFC can be used to judge the severity of a food allergy 
while to date no in vitro test is available to predict severity of allergic symptoms in 
patients (Spergel et al., 2004).  
Currently allergen avoidance is the only causal treatment of food allergies. However 
food avoidance can only be guaranteed by correct food labeling and exclusion of 
hidden allergens. Treatment of allergic symptoms is possible in both pollen and food 
allergies. Medications like antihistamines, epinephrine, corticosteroids, H2 blockers 
or β2-antagonists can reduce allergic symptoms immediately (Sicherer & Teuber, 
2004). For about 100 years specific immunotherapy (SIT) is used as treatment of 
allergic symptoms caused by weed, grass or tree pollen, as well as house dust mite, 
cat dander or insect venom (Durham & Nelson, 2011). During SIT increasing 
dosages of sensitizing allergen are administered repeatedly in the so called updosing 
phase followed by maintenance phase with same dose injected monthly over 3 to 
5 years. Nowadays subcutaneous injections, as well as sublingual administration are 
possible. Goal of SIT is to shift allergic Th2 response to a more tolerant Th1-driven 
immune response and therefore decrease of IgE-mediated allergic reactions. 
Nevertheless the overall mechanism behind SIT is not completely understood. During 
SIT specific IgE levels increase first, but decrease after several months of treatment 
accompanied with the switch of B cells to produce IgG antibodies mainly of the 
subtype IgG4 (Aalberse et al., 1983; van Ree et al., 1997; Gehlhar et al., 1999). 
These IgG antibodies act as so called blocking antibodies inhibiting allergen-IgE 
interactions by competition with IgE, resulting in a reduced allergic response (James 
et al., 2011; Jutel et al., 2013). Furthermore an increase in regulatory T cells is 
observable which produce anti-inflammatory cytokines like IL-10 and TGF-β and 
suppress formation of dendritic cells (Jutel et al., 2003). IL-10 effects downregulation 
of Th2 cells and induces IgG4 and IgA antibodies (Akdis et al., 1998). TGF-β inhibits 
proliferation and differentiation of B cells and antibody response.  
SIT for treatment of food allergies was tested as sublingual immunotherapy (SLIT) 
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where the food allergen in solution is held under the tongue for some time and oral 
immunotherapy (OIT) where increasing doses of food allergen is administered orally 
(Syed et al., 2013). Both SLIT and OIT are currently not routinely used for treatment 
of food allergy because of limited success rates, lack of sustained effects and severe 
side effects.  
Major drawbacks of current SIT are besides cost-intensity and long-lasting treatment 
for the patient, the risk of systemic allergic reactions especially in OIT when treating 
food allergies with egg, peanut or milk (Jones et al., 2009; Burks et al., 2012; 
Vázquez-Ortiz et al., 2013). In addition, parallel medication has to be monitored for 
each patient and use of SIT in patients with autoimmune disorders or malignancy 
might cause life-threatening side effects. Despite the described beneficial long-term 
effect of SIT with grass pollen for example, some patients however do not respond to 
treatment (Durham et al., 2010). To date several new approaches are discussed 
which might be used in addition to SIT in the future (Akdis, 2014). For example 
recombinant allergens purified from bacterial expression systems are already used in 
clinical trials compared to crude allergen extracts, even though an authorization has 
not been granted to date (Cromwell et al., 2011). Furthermore modifications in 
recombinant allergens can reduce side effects and at the same time ameliorate 
effectiveness of SIT. One example is the use of hypoallergenic variants, peptides, 
chimeric or fused proteins which have lost their conformational B cell epitopes but still 
show linear T cell binding sites (Pree et al., 2007; Kahlert et al., 2008; Moldaver & 
Larché, 2011; Schülke et al., 2014). These variants show lower allergenicity but 
preserved T cell immunogenicity (Karamloo et al., 2005). In addition, recombinant 
allergens modified with modular antigen transporter or hypoallergenic fusion proteins 
which induce IgG blocking antibodies are discussed to date (Martínez-Gómez et al., 
2009; Focke-Tejkl et al., 2015). Furthermore several additional routes for treatment of 
allergies like epicutaneous and intralymphatic administration and use of specific 
adjuvants are discussed as potential new approaches for treatment of food allergies 
(Senti et al., 2012; Hylander et al., 2013).  
The efficacy of pollen SIT on pollen-related food allergies was analyzed in several 
studies but outcomes are contradictory (Bolhaar et al., 2004; Bucher et al., 2004; 
Mauro et al., 2011). Patients with SIT for treatment of birch pollinosis may show of 
reduction in oral allergy syndrome to apple or hazelnut but however often only a 
temporary improvement of the food allergy is observed. 
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1.4 Soybean allergy 
During recent years an increase in consumption of soybean food products like soy 
sauce, tofu or soy milk in Europe was observed. Soybean (Glycine max) is a member 
of the Fabaceae family of plants and is classified to the group of legumes. It has a 
very high total protein content of 40%. Even though more than 20 IgE-binding 
proteins from soybean are known, only eight soybean proteins are accepted so far as 
allergens by the International Union of Immunological Societies (IUIS) Allergen 
Nomenclature Sub-Committee. Soybean hull proteins Gly m 1 and Gly m 2 were 
described as responsible for asthmatic reactions in Spain (González et al., 1991; 
Codina et al., 1997). Both function as aeroallergens causing respiratory soy allergy 
and are not present in soy seeds. Gly m 3 is a profilin, while Gly m 4 belongs to the 
PR-10 protein family (Crowell et al., 1992; Rihs et al., 1999). β-conglycinin Gly m 5 
and glycinin Gly m 6 cause severe allergic reactions after ingestion and are 
suggested as markers for severe soybean allergy (Holzhauser et al., 2009; Ito et al., 
2011). Recently two additional soy allergens Gly m 7 and Gly m 8 were identified 
(Ebisawa et al., 2013).  
Gly m 4, formerly named starvation-associated message 22 (SAM22), is a Bet v 1-
homologous protein in soy causing birch pollen-related soy allergy and affects 
roughly 10% of patients with birch pollinosis (Mittag et al., 2004b). As shown for 
several PR-10 food allergens Gly m 4 can cause mild but also severe allergic 
symptoms (Kleine-Tebbe et al., 2002; Kosma et al., 2011; De Swert et al., 2012; El-
Hifnawi et al., 2012). Depending on food product and industrial processing Gly m 4 
level ranges from 0-70 milligrams per kilogram while strong heating and roasting of 
soy products completely abolish IgE binding of Gly m 4 (Franck et al., 2002; Mittag et 
al., 2004b). Gly m 4 three-dimensional structure was solved by nuclear magnetic 
resonance (NMR) spectroscopy in 2003 (PDB code 2K7H) (Neudecker et al., 2003b). 
Structural characteristics are a seven-stranded antiparallel β-sheet enwinding a long 
C-terminal α-helix and two short α-helices. A hydrophobic cleft formed inside the 
molecule shows possible ligand binding ability (Radauer et al., 2008). Gly m 4 
consists of 157 amino acids and has a molecular weight of 16.6 kDa. It shares an 
amino acid sequence identity of 48% with Bet v 1a. The biological function, as well as 
the IgE-binding regions of Gly m 4 are not known. 
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1.5 Epitopes 
The molecular structure within an allergen molecule involved in antibody binding is 
called epitope and the corresponding surface of the antibody is designated as 
paratope. Epitopes are thought to be mainly conformational indicating the importance 
of structural homology between allergens in pollen-food allergy (Ferreira et al., 1998; 
El-Manzalawy & Honavar, 2010). In conformational epitopes amino acids that are 
distributed throughout the primary structure of the allergen are localized on a 
particular region on the molecular surface of the allergen upon folding into the native 
protein conformation. In contrast sequential epitopes are comprised of a linear stretch 
of adjacent amino acids displaying an antibody-binding site (Van Regenmortel, 
1989). T cell epitopes are always linear epitopes, as during an allergic reaction T cell 
receptors only bind to peptides presented by antigen-presenting cells. In contrast 
most B cell epitopes are conformational, therefore a well-folded allergen is required 
for epitope recognition via B cells or IgE antibodies (Pomés, 2010). Usage of peptide-
based approaches e. g. phage-display technology often results in identification of 
allergen mimotopes. These are peptides mimicking an antibody-binding site of the 
allergen (Davies et al., 2000). Furthermore IgE epitopes can be either structural or 
functional. Whereas a structural IgE epitope of an antigen is described as all amino 
acids of the interface that are in close proximity to the paratope of an IgE antibody, a 
functional IgE epitope only represents individual residues accounting for most of the 
binding energy to IgE (Dall'Acqua et al., 1998). Therefore in a structural IgE epitope 
such amino acids which dominate the energetics of allergen-antibody binding are 
defined as a functional IgE epitope and substitution of these residues causes a 
decrease in binding affinity. 
 
1.6 Epitope analysis 
To date little is known about clinically relevant antibody-binding sites of allergens. 
Until know only three IgE-binding B cell epitopes and eleven B cell epitopes of 
allergens in total are verified (Pomés, 2010). With structural methods like X-ray 
crystallography and NMR spectroscopy IgE epitopes of β-lactoglobulin, Phl p 2 and 
Art v 1 as well as binding sites of Bet v 1, Api m 2, Bla g 2, Der f 1 and Der p 1, 
lysozyme, Der p 2 and Blo t 5 with Fab fragments of monoclonal IgG1 antibodies 
could be identified, respectively (Amit et al., 1986; Mirza et al., 2000; Mueller et al., 
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2001; Niemi et al., 2007; Padavattan et al., 2007; Li et al., 2008; Naik et al., 2008; 
Padavattan et al., 2009; Razzera et al., 2010; Chruszcz et al., 2012). The only known 
structurally solved epitope of Bet v 1 is the binding site with the monoclonal murine 
IgG1 Fab fragment BV16 (Mirza et al., 2000). This discontinuous epitope involves 
16 residues of Bet v 1 comprising a molecular surface area of Bet v 1 of 931 Å2. The 
majority of the epitope encompasses amino acids 42-52 including the Bet v 1 P-loop 
region. It was shown that interaction between BV16 and Bet v 1 can reduce serum 
IgE binding, suggesting a competition of Bet v 1-specific serum IgE and monoclonal 
antibody for an overlapping epitope of Bet v 1 (Spangfort et al., 1999; Spangfort et 
al., 2003). For other allergens from Bet v 1-family including Gly m 4, no epitopes 
have been identified so far. However information on the potential involvement of 
single amino acids in antibody binding of several allergens is available. For the 
identification of such residues different approaches were used in the last years.  
Generating mutational variants of allergens can be used to identify amino acids 
critical for Ig binding. For this, knowledge of protein structure is essential to choose 
appropriate candidate residues on the allergen surface for site-directed mutagenesis. 
These include mainly charged amino acids putatively crucial for allergen-antibody 
interaction. If variants show reduced antibody binding while the overall protein 
conformation is comparable to wild type allergen, the substituted amino acid might 
represent a functional epitope (see 1.5). Besides the time-consuming expression and 
purification of a large quantity of protein variants this method has another 
disadvantage because protein variants might lose their overall folding when 
structurally important residues are substituted. Therefore it is always necessary to 
verify native-like protein structures of generated allergen variants because a reduced 
Ig binding can be caused by two reasons: First, an amino acid essential for the native 
protein fold is replaced, and the modified three-dimensional structure of the allergen 
has lost a conformational epitope. Second, a residue not important for overall protein 
folding but critical for allergen-antibody interaction is mutated causing a reduction in 
Ig binding while protein structure is not affected. Mutational epitope analysis was 
used with several allergens including Api g 1, Bet v 1, Mal d 1 or Pru av 1 (Ferreira et 
al., 1996; Scheurer et al., 1999; Neudecker et al., 2003a; Holm et al., 2004; Ma et al., 
2006; Wangorsch et al., 2007; Klinglmayr et al., 2009).  
The method of peptide microarrays to identify epitopes of allergens uses chemically 
synthesized overlapping peptides covering the complete amino acid sequence of the 
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allergen (Reese et al., 2001). These peptides can be analyzed for antibody binding 
either in solution for example in enzyme-linked immuno sorbent assay (ELISA) 
measurements or bound to a solid surface in microarray format. Using peptides of 
5-15 amino acids in length linear epitopes of allergens can be identified (Vereda et 
al., 2010). However use of overlapping synthetic peptides needs to be further 
evaluated as maximum peptide length or different shifting offsets resulted in different 
identified linear epitopes (Steckelbroeck et al., 2008). 
Furthermore a combination of both experimental and computational methods for 
epitope mapping is possible. This includes usage of phage-display technology where 
a library of short peptides presented by bacterio-phages is used to identify antibody-
binding peptides, so called mimotopes (see 1.5). However it is believed that 
mimotopes represent only in part an antibody-binding site. Mimotopes can be 
mapped on allergen surface by computer-based methods to identify putative epitopes 
of an allergen (Davies et al., 2000). Phage-displayed IgE-binding peptides could be 
identified for several allergens including four PR-10 proteins (Mittag et al., 2006). In 
Ara h 8, Bet v 1, Gly m 4 and Pru av 1 three IgE-binding regions with conserved 
amino acids were mapped.  
In addition monoclonal antibodies (mAb) can be used for epitope mapping as well. 
Binding sites of allergen-specific mAb which interact with allergen-derived peptides 
were identified (Lebecque et al., 1997; Gieras et al., 2011). Furthermore inhibition 
experiments can indicate potential overlapping binding sites between mAb and 
serum IgE.  
While the methods for epitope identification described here require high experimental 
effort and a lot of time, in silico epitope predictions might be used to overcome these 
disadvantages. Up to now several algorithms exist for bioinformatical prediction of 
IgE binding sites (El-Manzalawy & Honavar, 2010; Dall'Antonia et al., 2014). 
Algorithms are based on the sequence or structure of known allergens and consider 
the physicochemical properties of amino acids, surface characteristics, distance 
values or solvent accessibility to predict epitopes. Examples are web services like 
ElliPro and DiscoTope or software programs like Mapitope (Haste Andersen et al., 
2006; Bublil et al., 2007; Ponomarenko et al., 2008). Furthermore web-based servers 
like EpiSearch or MimoPro are used to map mimotopes derived from phage-display 
experiments (Negi & Braun, 2009; Chen et al., 2011). Because of the lack of 
information on IgE epitopes, in silico analysis still needs experimental verification to 
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confirm the suitability of computational tools for the prediction of antibody-binding 
sites.  
X-ray and NMR studies of allergen-antibody complexes are the most straight-forward 
approach to identify epitopes. Both approaches provide high-resolution structures of 
complexes between allergen and antibody including molecular details of interaction. 
Furthermore both linear and conformational epitopes can be identified.  
The identification of epitopes by reduced allergen-antibody binding of recombinant 
allergen variants has two potential drawbacks. First, polyclonality of serum IgE 
makes it difficult to differentiate individual IgE epitopes in the context of total serum 
IgE antibody repertoire. Thus measuring the lack of just one particular epitope in the 
background of overall IgE binding to the allergen is technically challenging. Second, 
allergen variants might have a non-native-like protein conformation which makes 
them improper for studying conformational epitopes. To overcome these 
disadvantages epitope grafting can be used. Here, functional IgE epitopes of an 
allergen are transferred to a non-IgE-binding protein to induce antibody interaction. 
Provided that protein folding remains unaffected, IgE-binding would directly point to 
these grafted residues. Epitope grafting is contradictory to mutational analysis of 
allergens where amino acid substitutions might lead to a reduced IgE binding rather 
than induced allergen-antibody interaction. Until now epitope grafting was used to 
create chimerics between two allergens of the same protein family or by transfer of 
sequential IgE epitopes of shrimp allergen Pen a 1 onto non-allergenic mouse 
tropomyosin (Albrecht et al., 2009; Holm et al., 2011; Gepp et al., 2014). An 
alternative approach could be the use of a non-IgE-binding protein with allergen-like 
protein structure to study the impact of individual amino acids on IgE binding. 
 
1.7 NCS system 
Epitope grafting for identification of IgE-binding regions needs a structurally 
homologous protein with low IgE binding. One example in case of the Bet v 1-family 
is (S)-Norcoclaurin-Synthase (NCS) from meadow rue Thalictrum flavum (Berkner et 
al., 2007). Showing Bet v 1-type protein folding as determined by X-ray 
crystallography, NCS belongs to PR-10 family of proteins (Ilari et al., 2009). In 
contrast to most members of this protein family the biological function of NCS is 
known. It catalyzes the first step in biosynthesis of benzylisoquinoline alkaloid which 
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is condensation of dopamine and 4-hydroxyphenylacetaldehyde to (S)-norcoclaurine. 
(S)-norcoclaurine is the central precursor of all benzylisoquinoline alkaloids, a large 
group of secondary metabolites in plants (Samanani et al., 2004). Besides its 
structural homology to proteins of the Bet v 1 family, NCS only shows a sequence 
identity between 10-30% with members of PR-10 protein family. The protein has a 
molecular weight of 21 kDa and 210 amino acids in total. It was first characterized 
extensively as Δ29NCS variant with a deletion of the N-terminal signal peptide by 
Berkner et al. in 2008 (Berkner et al., 2008). This truncated variant still has additional 
amino acids on both N- and C-terminus of the protein compared to Bet v 1 and its 
homologous allergens. Interestingly, despite the structural homology with PR-10 
proteins, recombinant Δ29NCS variant exhibits no to very weak binding of Bet v 1-
specific IgE antibodies (Dissertation Berkner). Therefore Δ29NCS resembles a 
promising candidate for epitope grafting. With this approach putative epitopes from 
Bet v 1 or homologous allergens can be transferred to Δ29NCS to generate Δ29NCS 
variants that display individual allergen-derived epitopes in an allergen-type protein 
conformation. These protein variants can then be analyzed for serum IgE binding in 
order to obtain information of relevant epitopes of the respective allergen. Within 
Hanna Berkner’s PhD thesis several residues involved in binding between Bet v 1 
and BV16 epitope were grafted onto Δ29NCS. Resulting variants were analyzed 
according IgE binding with sera of birch pollen-allergic subjects. Two of these 
Δ29NCS variants showed induced IgE binding in some patients while still showing 
Bet v 1-related protein structure (Berkner et al., 2014). Therefore NCS might 
resemble a promising and emerging tool for epitope grafting with high potential for 
identification of antibody-binding sites of Bet v 1 and related allergens.  
 
1.8 Aim of the study 
Data on clinically relevant antibody-binding sites of Bet v 1-homologous allergens is 
very limited but the detailed knowledge on epitopes might lead to epitope-resolved 
diagnosis and maybe therapy of allergy. With component-resolved diagnosis (CRD) a 
differentiation between allergy and tolerance is not possible but epitope-resolved 
in vitro diagnosis might bear the potential to identify correlations with the clinical 
phenotype. Central to answering this question is the identification of the IgE epitope 
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profile and a potential correlation between clinical phenotype and IgE sensitization 
pattern. 
The present study aimed at determining the IgE epitope profile of Gly m 4 in birch 
pollen-allergic subjects with and without clinically relevant birch-associated allergy to 
soybean. For this, amino acids of Gly m 4 potentially involved in binding of IgE were 
identified by i) bioinformatic mapping of IgE-binding phage-displayed peptides and 
Gly m 4-specific peptides onto the molecular surface of Gly m 4, ii) generation of a 
protein-based epitope library utilizing recombinant variants of the Gly m 4-type model 
protein norcoclaurine synthase (NCS), and iii) generation of substitutional variants of 
recombinant Gly m 4 with reduced IgE binding capacities. The IgE epitope profiles 
obtained were supposed to be correlated to clinical symptoms and allergen-specific 
IgE levels of the study population.  
Furthermore it was intended to analyze misfolded recombinant variants of both 
Bet v 1 and Gly m 4 via immunological and physicochemical assays to evaluate IgE 
binding capacities and quality of recombinant allergen preparations.  
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2 MATERIALS AND METHODS 
2.1 Materials  
2.1.1 Hard- and software 
For generation of diagrams Microsoft® Excel 2007 (Microsoft Corporation) and data 
analysis software GraFit 5.0.13 (Erithacus Software Ltd., Surrey, UK) was used. DNA 
sequences were analyzed with Serial Cloner 2.6.1 (SerialBasics, USA). Protein 
structures were visualized and analyzed with PyMol v0.99 (DeLano Scientific LLC, 
San Francisco, CA, USA) and Swiss-PdbViewer 4.0.1 (Guex & Peitsch, 1997) while 
PyMol was also used to create figures of proteins and molecules. Relevant pdb files 
of proteins were downloaded from RCSB Protein Data Bank 
(http://www.rcsb.org/pdb/) (Berman, 2000). Modeling of protein structure was carried 
out using Phyre2 protein structure prediction server (Kelley & Sternberg, 2009) with 
the respective primary sequences of the modeled proteins downloaded from UniProt 
database (www.uniprot.org). For alignment of amino acid sequences EMBOSS 
Needle Pairwise Alignment tool provided by European Bioinformatics Institute was 
used (http://www.ebi.ac.uk/Tools/psa/emboss_needle/). For literature search and 
management, PubMed database (National Center for Biotechnology Information) and 
Citavi 4.4.0.28 (Swiss Academic Software, Wädenswil, Switzerland) were used, 
respectively. Protein characteristics were determined using Expasy Protparam online 
tool available at http://web.expasy.org/protparam/. For the calculation of solvent 
accessible surface areas of proteins POPS (Parameter OPtimsed Surfaces) 
algorithm was used (Fraternali, 2002; Cavallo, 2003). Densitometric analysis was 
done using ImageJ (Rasband, NIH, Bethesda, MD, USA) and EpiSearch algorithm 
available at http://curie.utmb.edu/episearch.html was used for mapping of 
conformational epitopes with phage-display (see 2.4.9) (Negi & Braun, 2009). 
 
2.1.2 Chemicals and reagents 
Unless otherwise stated, chemicals and reagents were purchased in pro analysis 
grade from AppliChem (Darmstadt), Carl Roth (Karlsruhe), Fermentas (St. Leon-Rot), 
Fluka (Neu-Ulm), Merck (Darmstadt), Milipore (Schwalbach), New England Biolabs 
(NEB, Frankfurt a. M.), Novagen (Darmstadt), Roche Diagnostics (Mannheim), Serva 
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(Heidelberg), Sigma-Aldrich (Steinheim), Qiagen (Hilden), Thermo Fisher Scientific 
(Schwerte) and VWR (Darmstadt). 
 
2.1.3 Commercially available systems 
Table 1: Commercially available systems and laboratory kits used. 
System/Kit Company 
BSA Standard Thermo Fisher Scientific, Schwerte 
BugBuster Protein Extraction Reagent Novagen, Darmstadt 
DNA 1 kb Plus O'GeneRuler Marker Fermentas, St. Leon-Rot 
DNA 6x Orange Loading Dye Fermentas, St. Leon-Rot 
InFusion HD EcoDry Cloning Kit Clontech, Saint-Germain-en-Laye, France 
Multicolor BroadRange SDS Marker Thermo Fisher Scientific, Schwerte 
PierceTM BCA Protein Assay Kit Thermo Fisher Scientific, Schwerte 
Ponceau S Solution Sigma-Aldrich, Steinheim 
QIAprep Spin Miniprep Kit Qiagen, Hilden 
QIAquick Gel Extraction Kit Qiagen, Hilden 
QIAquick PCR Purification Kit Qiagen, Hilden 
QuikChange Lightning Multi Site-
Directed Mutagenesis Kit 
Agilent Technologies, Santa Clara, CA, USA 
SOC medium Sigma-Aldrich, Steinheim 
 
2.1.4 Sera and antibodies 
In total, sera of 47 patients recruited in Switzerland (Prof. Ballmer-Weber, Zürich) and 
Germany (PD Dr. Kleine-Tebbe, Berlin and Prof. Treudler, Leipzig) were analyzed in 
this project. Inclusion criteria were sensitizations to Bet v 1 and Gly m 4 and no birch 
pollen-specific immunotherapy. Allergy against soybean was determined by double-
blind placebo-controlled food challenge (DBPCFC) or convincing clinical history. 
27 patients (group 1) exhibited an allergy against soybean, while 20 patients 
(group 2) showed sensitization to Bet v 1 and Gly m 4 as well, but no clinical allergy 
to soybean. With ImmunoCAP™ analysis (Phadia 250, Thermo Fisher Scientific, 
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Uppsala, Sweden, see 2.4.20) specific IgE levels against Bet v 1 (code: t215), 
Gly m 4 (code: f353) but also soybean allergens Gly m 5 (code: f431) and Gly m 6 
(code: f432), as well as total Gly m 4-specific IgG levels (code: f353) were 
determined for each individual patient. In total four serum pools consisting of equal 
ratios of three or four patients were generated, respectively. For detailed information 
on patient characteristics see chapter 3.1. Serum from a non-allergic patient was 
used as negative control and one patient with known class I food allergy to soy was 
used as positive control in immunoblot with rGly m 4. Both were available at Paul-
Ehrlich-Institut serum collection.   
For analysis of rBet v 1a and its folding variant sera of ten subjects sensitized to 
Bet v 1a or birch pollen were analyzed with convincing history of pollinosis to early 
flowering tree pollen. These patients were recruited at the University Medical Center 
Mainz Department of Dermatology, Mainz, Germany, and at the Klinik für 
Dermatologie, Venerologie und Allergologie, University of Leipzig, Germany. With 
ImmunoCAP™ analysis total IgE amount, as well as birch- (common silver birch, 
code: t3) or Bet v 1-specific IgE level (code: t215) was determined. 
Antibodies: 
Mouse anti-His6 IgG1 unconjugated/Clone 13/45/31 Dianova, Hamburg 
Mouse anti-human IgE (Fc)-HRP/Clone B3102E8 Southern Biotech, via Biozol 
Mouse anti-human IgG4 HRP/Clone C8010-S840C Southern Biotech, via Biozol 
Mouse-anti-human IgG (Fc)-HRP/Clone JDC-10 Southern Biotech, via Biozol 
Rabbit anti-Bet v 1 IgG/polyclonal antibody   ALK, Hørsholm, Denmark 
Goat anti-rabbit IgG HRP/Clone A0545    Southern Biotech, via Biozol 
 
2.1.5 Plasmids 
Table 2: Description of DNA vectors used. 
Vector Tag Resistance marker 
pET11a - Ampicillin 
pET15b N-His6 Ampicillin 
pET29b N-His6 Kanamycin 
 
All DNA vectors were purchased from Novagen (Darmstadt). 
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2.1.6 DNA oligonucleotides 
Lyophilised DNA oligonucleotides used in this study were purchased from MWG 
Eurofins Operon (Ebersberg) in HPSF purification grade and a synthesis scale of 
0.05 µmol. Subsequent Table 3 - Table 6 list all used DNA oligonucleotides. 
Table 3: Oligonucleotides used for substitutions in Δ51NCSN42/P49 model protein. 
Substitution Sequence (bp) 
K4F 5’-CAT ATG GGC GTC ACA TTT GTG ATT CAT CAT GAG-3’ (33 bp) 
V5T 5’-ATG GGC GTC ACA AAA ACT ATT CAT CAT GAG TTG-3’ (33 bp) 
I6F 5’-GGC GTC ACA AAA GTG TTT CAT CAT GAG TTG GAA G-3’ (34 bp) 
H7E 5’-GTC ACA AAA GTG ATT GAG CAT GAG TTG GAA GTT G-3’ (34 bp) 
H8D 5’-ACA AAA GTG ATT CAT GAT GAG TTG GAA GTT GCT G-3’ (34 bp) 
E11N 5’-ATT CAT CAT GAG TTG AAT GTT GCT GCT TCA GCT G-3’ (34 bp) 
D18T 5’-GCT GCT TCA GCT GAT ACT ATA TGG ACT GTT TAT AG-3’ (35 bp) 
T21K 5’-GCT GAT GAT ATA TGG AAA GTT TAT AGC TGG CCT GGC-3’ (36 bp) 
P26T 5’-ACT GTT TAT AGC TGG ACT GGC TTG GCC AAG CAT C-3’ (34 bp) 
G27D 5’-GTT TAT AGC TGG CCT GAG TTG GCC AAG CAT CTT CC-3’ (35 bp) 
G27D/A29D 5’-GTT TAT AGC TGG CCT GAG TTG GAG AAG CAT CTT CCT GAC-3’ (39 bp) 
K30N/D34K 
5’-TGG CCT GGC TTG GCC AAT CAT CTT CCT AAA TTG CTC CCT GGC GCT-3’ 
(45 bp) 
G38D 5’-CCT GAC TTG CTC CCT GAT GCT TTT GAA AAG CTA G-3’ (34 bp) 
A39S 5’-GAC TTG CTC CCT GGC TCA TTT GAA AAG CTA GAA-3’ (33 bp) 
E41K 5’-CTC CCT GGC GCT TTT AAA AAG CTA GAA AAT ATC-3’ (33 bp) 
K42S 5’-CCT GGC GCT TTT GAA TCA CTA GAA AAT ATC ATC-3’ (33 bp) 
I47E//D49N 5’-AAG CTA GAA AAT ATC GAA GGT AAT GGA GGT CCT GGT ACC-3’ (39 bp) 
D49N 5’-GAA AAT ATC ATC GGT AAT GGA GGT CCT GGT ACC-3’ (33 bp) 
D57K 5’-GGT CCT GGT ACC ATC AAA GAT ATG ACA TTT GTA-3’ (33 bp) 
P62E 5’-CCT GGC GCT TTT GAA TCA CTA GAA AAT ATC ATC-3’ (33 bp) 
G63D 5’-ATG ACA TTT GTA CCA GAT GAA TTT CCT CAT GAA TAC-3’ (36 bp) 
H67K 5’-CCA GGT GAA TTT CCT AAG GAA TAC AAG GAG AAG-3’ (33 bp) 
I74E 5’-TAC AAG GAG AAG TTT GAA TTA GTC GAT AAT GAG-3’ (33 bp) 
N78E 5’-TTT ATA TTA GTC GAT GAA GAG CAT CGT CTA AAG-3’ (33 bp) 
K84S 5’-GAG CAT CGT CTA AAG TCA GTG CAA ATG ATT GAG-3’ (33 bp) 
Q86S 5’-CGT CTA AAG AAG GTG TCA ATG ATT GAG GGA GGT-3’ (33 bp) 
L95D/G96T 5’-GGA GGT TAT CTG GAC GAT ACA GTA ACA TAC TAC ATG-3’ (36 bp) 
T98E/Y99K 5’-CTG GAC TTG GGA GTA GAA AAA TAC ATG GAC ACA ATC-3’ (36 bp) 
M101T 5’-GGA GTA ACA TAC TAC ACT GAC ACA ATC CAT GTT G-3’ (34 bp) 
T103D 5’-ACA TAC TAC ATG GAC GAT ATC CAT GTT GTT CCA AC-3’ (35 bp) 
K11N 5’-GTT GTT CCA ACT GGT AAT GAT TCA TGT GTT ATT-3’ (33 bp) 
S119T 5’-TGT GTT ATT AAA TCC ACT ACT GAG TAC CAT GTG-3’ (33 bp) 
E121K 5’-ATT AAA TCC TCA ACT AAG TAC CAT GTG AAA CCT G-3’ (34 bp) 
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H123E 5’-TCC TCA ACT GAG TAC GAA GTG AAA CCT GAG TTT G-3’ (34 bp) 
E127D 5’-TAC CAT GTG AAA CCT GAT TTT GTC AAA ATC GTT G-3’ (34 bp) 
E127D/V129E 5’-TAC CAT GTG AAA CCT GAT TTT GAA AAA ATC GTT GAA CCA C-3’ (40 bp) 
V132N 5’-GAG TTT GTC AAA ATC AAT GAA GAA CTT ATC ACC-3’ (33 bp)* 
E133Q 5’-TTT GTC AAA ATC GTT XXX GAA CTT ATC ACC ACC-3’ (33 bp)* 
P134D 5’-GTC AAA ATC GTT GAA GAT CTT ATC ACC ACC GGT TC-3’ (35 bp)* 
L135E 5’-AAA ATC GTT GAA GAA GAA ATC ACC ACC GGT TCA TTA G-3’ (37 bp)* 
I136K 5’-ATC GTT GAA GAA CTT AAA ACC ACC GGT TCA TTA GC-3’ (35 bp)* 
T138K 5’-GAA GAA CTT ATC ACC AAA GGT TCA TTA GCT GCC-3’ (33 bp)* 
A142D 5’-ACC ACC GGT TCA TTA GAT GCC ATG GCA GAC GCC-3’ (33 bp)* 
D146K 5’-TTA GCT GCC ATG GCA AAA GCC ATC TCA AAA CTT G-3’ (34 bp) 
S149E 5’-ATG GCA GAC GCC ATC GAA AAA CTT GTT CTA GAA C-3’ (34 bp) 
S157D/S159Y 5’-GTT CTA GAA CAC AAA GAC AAA TAC AAC CTC GAG CAC CAC-3’ (39 bp) 
P134E/P140S 
5’-GTC AAA ATC GTT GAA GAA CTT ATC ACC ACC GGT TCA TTA GCT GCC 
ATG GC-3’ (50 bp) 
 
Shown are forward primers with underlined triplets coding for substituted amino acids. Sequences marked with an 
* were used with Δ51NCSP134E/P140S as template with grey codons representing proline substitutions. All oligos 
were purchased from Eurofins MWG Operon. 
 
Table 4: Oligonucleotides used for infusion cloning of Gly m 4 amino acid sequence. 
Name Sequence 
Restriction 
sites 
Gly m 4 f 5’- AGA GAG GCT GAA GCT GAA TTC GGT GTT TTT ACC TTT GCA G-3’ NdeI/ 
BamHI Gly m 4 r 5’-G TTA GCA GCC GGA TCC TTA ATT ATA ATC CGG ATG-3’ 
 
Forward (f) and reverse (r) oligos used with Infusion EcoDry Cloning Kit to amplify Gly m 4-coding sequence with 
PCR after excision out of pET11a vector with NdeI and BamHI restriction enzymes. PCR product was cloned into 
pET15b vector digested with same restriction enzymes. 
 
Table 5: Oligonucleotides used for amino acid substitutions in Gly m 4. 
Substitution Sequence (bp) Comment 
E6A 
5’-GGT GTT TTT ACC TTT GCA GAT GAA ATT AAT 
AGT C-3’ (34 bp) 
- 
D27A 
5’-CTG GTT ACC GAT GCC GCA AAT GTT ATT CCG 
GCA-3’ (33 bp) 
Based on Gly m 4K32A 
K32A 
5’-AAT GTT ATT CCG AAA GCA CTG GAT AGC TTT 
AAA AG-3’ (35 bp) 
- 
D35A 
5’-ATT CCG GCA GCA CTG GCA AGC TTT AAA GCA 
GTT-3’ (33 bp) 
Based on Gly m 4K32A/S39A 
S39A 
5’-CTG GAT AGC TTT AAA GCA GTT GAA AAT GTG 
GAA GGT-3’ (36 bp) 
- 
E44SA 
5’-GCA GTT GAA AAT GTG AGC GGT AAT GGT GGT 
CCG-3’ (33 bp) 
- 
D60A 
5’-ATT ACC TTT CTG GAA GCA GGC GAA ACC AAA 
TTT GTG-3’ (36 bp) 
- 
N77K 
5’-AGC ATT GAT GAA GCC AAA CTG GGC TAC AGC 
TAT AGC-3’ (36 bp) 
- 
D92A/E95A 
5’-GGT GCA GCA CTG CCG GCA ACC GCA GCA 
AAA ATT ACA TTT GAT-3’ (42 bp) 
- 
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T93A/E95A 
5’-GCA GCA CTG CCG GAT GCA GCA GCA GCA 
ATT ACA TTT GAT-3’ (39 bp) 
Based on Gly m 4K96A 
E95A 
5’-CTG CCG GAT ACC GCA GCA AAA ATT ACA TTT 
GAT AG-3’ (35 bp) 
- 
K96A 
5’-CCG GAT ACC GCA GAA GCA ATT ACA TTT GAT 
AGC-3’ (33 bp) 
- 
K96A 
5’-CCG GCA ACC GCA GCA GCA ATT ACA TTT GAT 
AGC-3’ (33 bp) 
Based on Gly m 4D92A/E95A 
N108K 
5’-CTG GTT GCC GGT CCG AAA GGT GGT AGC 
GCA GGT-3’ (33 bp) 
- 
K118A 
5’-GGT AAA CTG ACC GTT GCA TAT GAA ACC AAA 
GGT G-3’ (34 bp) 
- 
E120A 
5’-CTG ACC GTT AAA TAT GCA ACC AAA GGT GAT 
GCA GAA CGG-3’ (39 bp) 
- 
E126A 
5’-ACC AAA GGT GAT GCA GCA CCG AAT CAG GAT 
GAA-3’ (33 bp) 
- 
K133E 
5’-AAT CAG GAT GAA CTG GAA ACC GGT AAA GCA 
AAA GC-3’ (35 bp) 
- 
Y149A 
5’-AAA GCC ATT GAA GCA GCA CTG CTG GCA CAT 
CCG-3’ (33 bp) 
- 
S111P 
5’-GGT CCG AAT GGT GGT CCG GCA GGT AAA 
CTG ACC-3’ (33 bp) 
- 
L150P 
5’-GCC ATT GAA GCA TAT CCG CTG GCA CAT CCG 
GAT-3’ (33 bp) 
- 
 
Shown are forward primers with underlined triplets coding for substituted amino acids and codons shown in italic 
representing substitutions in template not present in original Gly m 4 sequence. Template used for each 
oligonucleotide is listed in comment section while – corresponds to original Gly m 4 sequence. All oligos were 
purchased from Eurofins MWG Operon. 
 
Table 6: Oligonucleotides used for amino acid substitutions in Bet v 1a. 
Substitution Sequence (bp) 
S112P 5‘-ACA CCG GAT GGT GGT CCC ATT CTG AAA ATT AGC-3‘ (33 bp) 
R145P 5’-GGT GAA ACC CTG CTG CCT GCA GTT GAA AGC TAT-3’ (33 bp) 
 
Shown are forward primers with underlined triplets coding for substituted amino acids. All oligos were purchased 
from Eurofins MWG Operon. 
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2.2 Microbiological techniques 
2.2.1 E. coli strains and media 
E. coli strains: 
Table 7: E. coli cloning and expression strains. 
Strain Description 
BL21-CodonPlus (DE3) 
F– ompT hsdS(rB
– mB
–) dcm+ Tetr gal λ(DE3) endA Hte [argU 
proL Camr] [argU ileY leuW Strep/Specr 
BL21-CodonPlus 
(DE3)-RIPL 
F– mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacΧ74 recA1 
araD139 Δ(ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG λ- 
OneShot TOP10 
chemically competent 
F– mcrA Δ(mrr-hsdRMS-mcrBC)  φ80lacZΔM15 ΔlacΧ74 
recA1 araD139 Δ(ara-leu) 7697 galU galK rpsL (StrR) endA1 
nupG λ- 
Stellar 
F–, endA1, supE44, thi-1, recA1, relA1, gyrA96, phoA, Φ80d 
lacZΔ M15, Δ (lacZYA - argF) U169, Δ (mrr - hsdRMS - 
mcrBC),  ΔmcrA, λ– 
 
E. coli strains were purchased from Stratagene (via Agilent Technologies, Santa 
Clara, CA, USA), Invitrogen (via Thermo Fisher Scientific) and Clontech (Mountain 
View, CA, USA). 
E. coli media: 
LB medium  10 g/l Tryptone EZMix™ (Sigma-Aldrich)  
10 g/l Yeast extract EZMix™ (Sigma-Aldrich)  
5 g/l NaCl, pH 7.0 
LB agar  LB medium  
Agar-Agar 15 g/l   
antibiotics added in appropriate concentration 
 
2.2.2 Cultivation and storage of E. coli 
E. coli strains were grown in LB medium by shaking at 210 rpm at 37°C. Optical 
densities were determined by measuring absorbance at a wavelength of 600 nm. For 
selection of bacterial colonies antibiotics with a final concentration of 34 µg/ml 
chloramphenicol (Sigma Aldrich), 20 µg/ml kanamycin (Carl Roth) or 50 µg/ml 
carbenicillin (Carl Roth) were added to cultures and LB agar plates. For long-term 
storage cultures were supplemented with 10% (v/v) glycerol, snap frozen and stored 
at -80°C. 
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2.2.3 Transformation of plasmid DNA into chemically competent E. coli 
Competent E. coli cells were thawed on ice. For chemical transformation 20 µl 
bacteria suspension was mixed with 1 µl DpnI-digested DNA from mutagenesis PCR 
or 0.5 µl purified plasmid DNA and incubated on ice for 30 minutes. After heat shock 
for 30 seconds at 42°C cells were incubated on ice for 2 minutes. Subsequently 
270 µl SOC medium was added and incubated for 1 h at 37°C and 300 rpm in a 
thermal shaker (ThermoStat plus, Eppendorf, Hamburg). Transformed cells were 
selected by streaking out 100 µl of bacterial suspension on LB agar plates containing 
respective antibiotic(s) and incubation overnight at 37°C. 
 
2.2.4 Expression of proteins in E. coli 
For expression of recombinant protein from pET15b or pET29b expression plasmid, 
E. coli strain BL21-CodonPlus(DE3) or -RIPL cells were used, respectively. Open 
reading frame of Bet v 1a and Gly m 4 optimized for codon usage in E. coli was 
purchased from Genart (Life Technologies, via Thermo Fisher Scientific). An 
overnight culture of a colony was resuspended with LB and respective antibiotic(s) to 
1 L and a final OD600 of 0.2. The cells were grown at 37°C and 210 rpm. Protein 
expression was induced with a final concentration of 1 mM IPTG when OD600 
reaches 0.6-0.7. After shaking for 3 h at 37°C and 210 rpm cells were harvested by 
centrifugation (10,000 g, 15 min, 4 °C). Cell pellets were washed in dH2O and 
centrifuged (10,000 g, 15 min, 4°C) again. Pellets were either processed directly or 
stored at -80°C after snap freezing. 
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2.3 Molecular biology 
2.3.1 Preparation of chemically competent E. coli 
RF1 buffer 30 mM Potassium acetate  
10 mM CaCl2  
50 mM MnCl2  
100 mM RbCl  
15% Glycerol  
pH adjusted to 5.8 
RF2 buffer 100 mM MOPS  
75 mM CaCl2  
10 mM RbCl  
15% Glycerol  
pH adjusted to 6.5 
 
For generation of chemically competent bacteria 250 ml LB medium was inoculated 
with an overnight culture from a single colony of bacterial strain. Cells were grown at 
37°C and 350 rpm until OD600 reaches 0.5. All following steps were performed at 4°C 
or with pre-cooled materials and buffers. After centrifugation at 4°C and 5,000 g for 
10 min sedimented cells were resuspended in 100 ml cold RF1 buffer and stored on 
ice for 5 min. Pelleted cells after second centrifugation at 4°C and 4,500 g for 10 min 
were resuspended in 10 ml cold RF2 buffer followed by incubation on ice for 60 min. 
Afterwards cells were aliquoted, snap-frozen and stored at -80°C. 
 
2.3.2 Plasmid isolation 
An overnight culture (4 ml, 37°C, 210 rpm) of a cell colony in LB medium was 
harvested by centrifugation (10,000 g, 3 min, 4°C). Plasmid DNA was isolated from 
bacterial pellet using QIAprep Spin Miniprep Kit (Qiagen) according to the 
manufacturer's instructions.  
 
2.3.3 Determination of DNA concentration in solution 
DNA concentrations were determined with UV-Vis spectroscopy using a Nanodrop 
spectrophotometer (ND-1000, peQlab, via VWR) by measuring the absorbance at 
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wavelengths of 260 and 280 nm. An OD260 of 1 equals a concentration of 50 µg/ml 
double-stranded DNA. 
 
2.3.4 Restriction 
pET vectors were digested with BamHI and NdeI fast digest enzymes (Thermo Fisher 
Scientific) according to manufacturer’s instructions. 
 
2.3.5 Agarose gel electrophoreses 
TAE buffer 40 mM Tris  
20 mM Acetic acid  
1 mM EDTA 
 
To verify plasmid isolation or plasmid DNA restriction 1% agarose gels in TAE buffer 
were used. Gels were prepared and run in RGX-60 systems (Cascade Biologics, via 
Thermo Fisher Scientific) for 10 minutes at 210 V. DNA samples were mixed with 
DNA 6x Orange Loading Dye (Fermentas) and loaded onto the gel together with 2 µl 
of DNA 1 kb Plus O'GeneRuler Marker (Fermentas). Afterwards gels were stained for 
10 minutes with ethidium bromide and visualized with an Intas Gel Jet Imager 2000 
(Intas Science Imaging Instruments, Göttingen). 
 
2.3.6 Isolation of DNA from agarose gel 
After agarose gel electrophoresis DNA fragments were isolated on a UV-table (Intas 
Science Imaging Instruments) using a scalpel. DNA was extracted from agarose with 
QIAquick Gel Extraction Kit (Qiagen) according to manufacturer instructions. 
 
2.3.7 Cloning of DNA fragments into pET15b vector 
The open reading frame of Gly m 4 and Bet v 1a optimized for codon usage in E. coli 
was purchased from Geneart (Life Technologies, via Thermo Fisher Scientific) and 
inserted into pET11a vector. For cloning of linearized DNA fragments into bacterial 
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expression vector pET15b with N-terminal His-tag, In-Fusion HD EcoDry Cloning Kit 
(Clontech) was used according to manufacturer’s instructions. Briefly, pET15b vector 
with inserted DNA sequence coding for Bet v 1a was digested with BamHI and NdeI 
to remove Bet v 1a-coding sequence from open reading frame and obtain linearized 
pET15b vector. Both restriction enzymes were furthermore used to linearize pET11a 
vector and obtain DNA sequence coding for Gly m 4. Using gene-specific 
oligonucleotides (see Table 4) Gly m 4-coding sequence was PCR-amplified creating 
15 bp overlaps homologous to the ends of linearized pET15b vector. 50 ng of 
linearized pET15b vector and 50 ng of amplified Gly m 4-coding DNA fragment were 
incubated with In-Fusion HD EcoDry pellet for 15 min at 37°C and 15 min at 50°C. 
For transformation in E. coli stellar cells 2.5 µl of mixture was used. Successful 
cloning of Gly m 4-coding fragments into pET15b vector was verified by DNA 
sequencing (MWG Eurofins Operon). 
 
2.3.8 Cloning of Δ51NCSN42/P49 and Δ51NCSN42/P49 variants 
Δ51NCSN42/P49 was generated by Jasmin Nürnberg within her Master thesis in 2014 
at the Division of Allergology at the Paul-Ehrlich-Institut. Briefly, pET29a-Δ29NCS 
described by Berkner et al. (Berkner et al., 2007) was truncated by eleven amino 
acids at both N- and C-termini and two insertions/substitutions namely N42 and P49 
were introduced to adjust amino acid sequence to a typical Gly m 4-type allergen. 
 
2.3.9 Sequencing 
Sequencing of isolated plasmid DNA was done by bidirectional Sanger sequencing 
(MWG Eurofins Operon). 
 
2.3.10 Site-directed mutagenesis of DNA 
For insertion of single or multiple DNA mutations QuikChange Lightning (Multi) Site-
Directed Mutagenesis Kit (Agilent Technologies) was used. Briefly, PCR was 
performed in a total volume of 25 µl with 100 ng of plasmid DNA, 50-100 ng of 
specific forward oligonucleotide primer, 1 µl dNTP mix, 0.75 µl QuikSolution and 
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0.5 µl QuikChange Lightning (Multi) enzyme blend in 10x QuikChange Lightning 
(Multi) reaction buffer. Amplification was done in a Thermomixer comfort (Eppendorf). 
The denaturing step was carried out for 20 s at 95°C, annealing for 30 s at 55°C and 
elongation at 65°C for 30 s/kb (3 min for pET15b and pET29a). Digestion of template 
DNA was done by incubation with 1 µl DpnI enzyme for 1 h at 37°C. For 
transformation into E. coli OneShot TOP10 cells 1 µl digested DNA was used. 
Introduction of specific mutations were analyzed by DNA sequencing. 
 
2.4 Protein techniques 
2.4.1 SDS-polyacrylamide gel electrophoresis 
Sample buffer (5x) 10% (w/v) SDS  
0.1% (w/v) Bromphenol blue  
0.25 M Tris/HCl pH 6.8  
50% Glycerol  
7.7% (w/v) DTT 
SDS running buffer (10x) 0.25 M Tris  
1.92 M Glycine  
1% (w/v) SDS 
 
Recombinant proteins were analyzed under reducing conditions by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) according to the method 
described by Laemmli (Laemmli, 1970). For protein separation total bis/acrylamid 
levels of 5% for stacking and 15% for running gel were used according to 
composition shown in Table 8. 
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Table 8: Composition of stacking and running gel used in SDS-PAGE. 
 5% Stacking gel 
15% Running 
gel 
Rotiphorese® NF- 
Acrylamide/bis-solution 30 % 
1.7 ml 10 ml 
Tris/HCl 1.25 ml (pH 6.8) 5 ml (pH 8.8) 
10% SDS 0.1 ml 0.2 ml 
10% APS 0.1 ml 0.2 ml 
TEMED 0.01 ml 0.02 ml 
dH2O 6.8 ml 4.6 ml 
 
Prior to loading, protein samples were mixed with sample buffer and denatured at 
95°C for 5 min. Protein separation was performed at 100 V for 10 min and 200 V for 
45 min using Mini-PROTEAN® 3 Cell equipment (BioRad, München) and SDS 
running buffer. As a molecular weight standard, Spectra™ Multicolor Low/Broad 
Range Protein Ladder (Thermo Fisher Scientific) was used. 
 
2.4.2 Coomassie staining 
Coomassie solution 35% Methanol  
35% Glacial acetic acid  
0.2% (w/v) Coomassie Brilliant Blue (G250)  
 
Destaining solution 30% Methanol  
10% Glacial acetic acid  
 
After SDS-PAGE gels were washed for 5 min in dH2O. For coomassie staining gels 
were incubated for 3 min in coomassie solution. To remove unspecific staining, gels 
were transferred to destaining solution for several hours.  
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2.4.3 Analysis of protein expression in small-scale  
Pellet obtained from 2 ml bacterial culture (see 2.2.4) was used with BugBuster™ 
Protein Extraction Reagent (Merck Millipore) to analyze protein expression in soluble 
fraction and inclusion bodies. To resuspend cell pellet 0.25 ml BugBuster reagent 
with 0.25 µl Benzonase® Nuclease® (250 U/µl, Novagen) and 40 µl protease inhibitor 
Complete Mini EDTAfree (Roche Diagnostics) were added. Remaining steps were 
performed with same volume of BugBuster reagent and according to manufacturer’s 
instructions. Samples of soluble fraction and inclusion bodies were analyzed by SDS-
PAGE (see 2.4.1) for protein expression. 
 
2.4.4 Purification of soluble protein 
Lysis buffer 10 mM Potassium phosphate pH 7.4  
10 mM Imidazole 
Elution buffer 1 10 mM Potassium phosphate pH 7.4  
0.5 M Imidazole 
 
Bacterial pellet was resuspended in 15 ml lysis buffer with one tablet protease 
inhibitor EDTAfree (Roche Diagnostics) added. After stirring for 20 min at RT, 
DNase I (Applichem, via VWR) and lysozyme (from chicken egg white, 10,000 U/mg, 
Sigma-Aldrich) were added followed by stirring for 30 min at RT. Cells were 
homogenized in a cell disrupter (TS series, Constant Symstems Ltd., Daventry, UK) 
at 1,350 bar. After centrifugation for 15 minutes at 12,000 g and 4°C, lysate was 
filtered (0.2 µm, VWR) and incubated over night at 4°C with 3 ml Ni-beads (Ni-NTA 
Superflow, Qiagen) equilibrated in lysis buffer. Pelleted beads were used together 
with a Bioline HR glass column system (Knauer, Berlin). Target protein could be 
eluted by affinity chromatography on a HPLC Smartline System (Knauer) with elution 
buffer 1 (flow rate 0.3 ml/min, 2.5 CV). Eluted fractions were analyzed on SDS-PAGE 
and protein-containing fractions were pooled and concentrated with Centrifugal Filter 
Units (3,500 MWCO, Merck Millipore) if necessary.  
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2.4.5 Purification of proteins from inclusion bodies 
Denaturing buffer  8 M Urea  
10 mM Potassium phosphate pH 7.4  
0.5 M NaCl  
10 mM Imidazole 
 
Renaturing buffer 0.5 M Urea  
10 mM Potassium phosphate pH 7.4  
10 mM Imidazole 
 
Elution buffer 2 0.5 M Urea  
10 mM Potassium phosphate pH 7.4  
0.5 M Imidazole 
 
First steps for purification of proteins from inclusion bodies were equal to purification 
of soluble proteins except homogenization at 1,900 bar. After centrifugation for 
15 minutes at 12,000 g and 4°C, pellet was resuspended in 10 ml denaturing buffer 
and incubated over night at 4°C with 3 ml Ni-beads equilibrated in denaturing buffer. 
Pelleted beads were used together with a Bioline HR glass column system (Knauer) 
for affinity chromatography. On HPLC Smartline System (Knauer) a linear gradient 
from denaturing buffer to renaturing buffer was used to refold target protein bound to 
Ni-beads (flow rate 0.2 ml/min, gradient 2.5 CV). Afterwards protein was eluted from 
Ni-beads with elution buffer 2 (flow rate 0.3 ml/min). Eluted fractions were analyzed 
on SDS-PAGE and protein-containing fractions were pooled and concentrated with 
Centrifugal Filter Units (3,500 MWCO, Merck Millipore) if necessary. 
 
2.4.6 Size exclusion chromatography and dialysis 
Size exclusion buffer 10 mM Potassium phosphate pH 7.4 
 
Concentrated protein, from soluble fraction or inclusion bodies, eluted from Ni-affinity 
chromatography was further purified by size exclusion chromatography (BioFox 
40/1200 SEC, HPLC Smartline System, Knauer) with size exclusion buffer (flow rate 
0.3 ml/min, 2 CV). Again fractions were analyzed by SDS-PAGE and afterwards 
concentrated (Centrifugal Filter Units 3,500 MWCO, Merck Millipore) if necessary. 
After dialysis (D-Tube™ Dialyzer, MWCO 3.5 kDa, Novagen) against 4 L of 10 mM 
KPi pH 7.4 at 4°C aliquots were prepared, snap-frozen and stored at -80°C. 
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2.4.7 Cleavage of His-Tag 
His-Tag of proteins in pET15b vector was cleaved after elution from Ni-beads with 
thrombin from bovine plasma (Sigma-Aldrich). For this, roughly 8 mg of recombinant 
protein and 0.1-0.15 KU of thrombin were mixed and protein cleavage was analyzed 
by SDS-PAGE. To remove remaining thrombin enzyme and cleaved His-Tag, size 
exclusion chromatography and dialysis were performed, as described above 
(see 2.4.6). 
 
2.4.8 Measuring protein concentration 
Protein concentration could be measured with Pierce™ BCA Protein Assay Kit 
(Thermo Fisher Scientific) according to manufacturer’s instructions or by measuring 
absorbance at 280 nm using Nanodrop spectrophotometer (ND-1000, peQlab, via 
VWR). Extinction coefficient (M-1cm-1) and molecular weight (Da) of proteins were 
determined using Expasy Protparam online tool available at 
http://web.expasy.org/protparam/. 
 
2.4.9 Competitive immunoscreening of phage-displayed peptides 
Competitive immunoscreening was done as described with some modifications 
(Mittag et al., 2006; Subbarayal et al., 2013). 5 mg of Dynabeads M-280 
Tosylactivated (Invitrogen Dynal AS, Oslo, Norway) was coupled with 100 µg anti-
human IgE antibody (Southern Biotech) for 20 h at RT. After blocking for 2 h at RT, 
beads were incubated with 500 µl serum for 3 h at 4°C and washed 5 times with 
washing buffer. For first round of panning 50 µl beads were incubated with 
211 phages from 12-mer peptide library (New England Biolabs) at RT overnight. For 
amplification E. coli ER2738 cells were infected with washed phages bound to beads 
for 4 h at 37°C. Phages were precipitated and titer could be determined. For second 
round of panning 2*1011 phages from first round were incubated with serum IgE 
bound to beads. After washing bound phages were eluted competitively by 
incubation with 25 µg rGly m 4 for 1 h at RT. Eluted phages were amplified again and 
titer was determined. Single plaques on LB plates containing IPTG and Xgal were 
purified and phage DNA sequence was determined. By translation of DNA sequence, 
amino acid composition of displayed peptide was determined. To increase specificity 
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of eluted phages several modifications were added to the established protocol. First, 
number of washing steps was increased to a maximum of 20 steps. Second, different 
washing but also blocking buffers were used. Washing buffers contained PBS with 
0.05% Tween20, 0.1% BSA or both while blocking buffers with PBS and 
concentrations of 0.3% Tween20, 0.5% BSA or both were tested. Third, after each 
washing step the supernatant derived by magnetic separation was amplified and 
checked for elution of unspecifically bound phages by growing on IPTG/Xgal-plates. 
Fourth, negative selection was included, where amplified phages after competitive 
elution with rGly m 4 were incubated with magnetic beads only, followed by 
incubation with anti-human IgE-coupled beads. This way, phages binding 
unspecifically to beads and/or anti-human IgE were removed.   
Amino acid sequence of identified phages were mapped onto Gly m 4 surface using 
EpiSearch algorithm (http://curie.utmb.edu/episearch.html) (Negi & Braun, 2009). 
EpiSearch uses composition of peptide sequences as input and compares these with 
the distribution of surface-exposed amino acid patches on the allergen’s three-
dimensional structure. Results are expressed as score value for each individual patch 
on allergen surface. For mapping, default settings for 12-mer peptides were used and 
results with scores ≥1 were considered as positive putative epitopes. Three-
dimensional structure of Gly m 4 with pdb code 2K7H was used as template. 
 
2.4.10 Immunoblot 
Anode buffer 1 0.3 M Tris pH 10.4  
20% (v/v) Methanol 
Anode buffer 2 25 mM Tris pH 10.4 
20% (v/v) Methanol 
Cathode buffer 40 mM 6-Aminohexanoic acid pH 7.6  
20% (v/v) Methanol 
Blocking buffer TBS with 0.3% Tween20™ 
Washing buffer TBS with 0.05% Tween20™ 
Incubation buffer TBS with 0.05% Tween20™, 0.1% BSA 
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Proteins separated after SDS-PAGE (see 2.4.1) were transferred to a nitrocellulose 
membrane (0.2 µm, Whatman, via Sigma-Aldrich) using semi-dry blotting. 
Nitrocellulose membrane was equilibrated for 30 min in anode buffer 2, while filter 
papers (GB003, Whatman) were briefly dampen with anode buffer 1, anode buffer 2 
or cathode buffer, respectively. Protein transfer occurred for 1 h at constant current of 
0.8 mA per cm2 of gel. To verify quantitative blotting, transferred proteins could be 
stained with 0.1% (w/v) Ponceau S Solution in 5% acetic acid (Sigma-Aldrich). 
Afterwards membrane was blocked for unspecific binding with blocking buffer for 1 h 
at RT and cut into strips of 0.3 cm width each. After incubation for 10 min in washing 
buffer 120 µl of primary antibody or serum diluted 1:10 in incubation buffer were 
added for at least 1 h. Membrane was washed 5 times with washing buffer for 5 min 
each. Secondary HRP-coupled mouse anti-human IgE antibody (Southern Biotech, 
via Biozol, Eching) diluted 1:10,000 in incubation buffer was added to the membrane 
for 1 h. After washing chemiluminescence of horseradish peroxidase (HRP)-
conjugated antibodies was detected using LumiGLO Reserve™ Chemiluminescent 
Substrate Kit (KPL, Gaithersburg, MD, USA) and Imager system Fusion FX (Vilber 
Lourmat, Eberhardzell) or Curix 60 processor (AGFA, Leverkusen) and Hyperfilm MP 
(Amersham, via GE Healthcare, Freiburg) together with Hypercassette 
Autoradiography Cassettes (Amersham, via GE Healthcare). In case secondary 
antibody with AP conjugation was used staining was performed with BCIP (5-bromo-
4-chloro-3'-indolyphosphate) and NBT (nitro-blue tetrazolium) solution for 30 s. 
Staining was stopped with dH2O and membrane was scanned. For detection of IgG 
binding to rBet v 1a and rBet v 1aS112P/R145P variant on nitrocellulose membranes, 
Bet v 1-specific polyclonal rabbit IgG (ALK) was diluted 1:10,000 in incubation buffer 
and added for 1 h. Bound IgG was detected with goat-anti-rabbit IgG conjugated with 
horseradish peroxidase (Southern Biotech, via Biozol) diluted 1:10,000 in incubation 
buffer as described above. 
For parallel detection of IgE binding different strips were incubated in the same 
detection solution containing serum diluted 1:10 in incubation buffer. Each strip was 
derived from an immunoblot with a different antigen, competing for IgE present in 
serum samples. Residual steps of immunoblotting were carried out as described 
above. 
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2.4.11 Dot blot 
Dot blot analysis of proteins was carried out according to immunoblotting described in 
chapter 2.4.10, but without prior SDS-PAGE and semi-dry blotting. In contrast 1 µg of 
each recombinant protein was spotted directly on nitrocellulose membrane. After 
15 min air-dried membranes could be stained with Ponceau S solution to check for 
presence of membrane-bound protein. Afterwards membrane was blocked and 
incubated with 50 µl 1:10 diluted serum as described for immunoblot. 
Chemiluminescence was detected with 1:10,000 diluted secondary HRP-coupled 
mouse anti-human IgE antibody (Southern Biotech, via Biozol) in incubation buffer 
(see 2.4.10), LumiGLO Kit and Imager system. Analysis of densitometry was 
evaluated using ImageJ (Rasband, NIH, Bethesda, MD, USA). 
 
2.4.12 Enzyme-linked immunosorbent assay (ELISA) 
Coating buffer PBS 
Washing buffer PBS with 0.05% Tween20™ 
Blocking buffer PBS, 2% BSA 
Incubation buffer PBS with 0.05% Tween20™, 0.1% BSA 
Substrate solution 210 mM Potassium citrate pH 3.9 
1 mM TMB 
0.01% H2O2 
 
With Enzyme-linked immunosorbent assay (ELISA) binding between antibodies and 
antigens can be analyzed on solid phase. 50-200 ng of recombinant allergen was 
adsorbed over night at RT to microtiter plates (Maxisorp, Nunc, Wiesbaden) in a total 
volume of 100 µl/well coating buffer. Plates were washed four times with 300 µl 
washing buffer. After blocking for 2 h at RT with 100 µl/well blocking buffer, primary 
antibody or serum diluted in incubation buffer was added. Plate was washed on 
ELISA washer and incubated for 1 h with 100 µl/well secondary HRP-coupled mouse 
anti-human IgE antibody (Southern Biotech, via Biozol) diluted 1:1,000 in incubation 
buffer. For visualization 100 µl/well 3,3′,5,5′-tetramethylbenzidine (Roth) was used as 
substrate for the horseradish peroxidase and the absorbance at 450 nm was 
measured after stopping the reaction after 10 min with 25% H2SO4 on 
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SpectraMax 250 Microplate Reader (Molecular Devices, Biberach an der Riss). Non-
specific binding of secondary antibody was analyzed in control reaction without 
adding primary antibody or serum, respectively. 
 
2.4.13 ELISA-Inhibition 
ELISA-Inhibition was performed according to ELISA method described in 2.4.12 with 
slight modifications. After coating and blocking, dilutions of serum and inhibitor pre-
incubated for 1 h were added. In general one dilution of serum was mixed with 
several concentrations of allergen inhibitor to analyze inhibition reaction between 
serum IgE, coated allergen and inhibitor. After incubation for 3 h at RT plates were 
washed and protocol follows the one described above. Control reactions contained 
unspecific binding of secondary antibody where no serum and inhibitor were added, 
as well as maximal binding control of serum IgE without adding allergen inhibitor. 
 
2.4.14 IgE depletion experiments 
For measuring inhibition of IgE binding between NCS variants and rGly m 4 IgE 
depletion experiments were used. 200 ng/well rGly m 4 were coated over night at 
4°C in microtiter plates (Maxisorp, Nunc) in PBS. Plates were washed and blocked 
according to section 2.4.12. In parallel, different amounts of rGly m 4, ΔNCSN42/P49, 
ΔNCSN42/P49 variants or BSA were incubated with 300 µl 1:10 diluted serum for 3 h 
followed by precipitation of allergen-antibody complexes with Ni-beads (Ni-NTA 
Superflow, Qiagen). Supernatant containing unbound IgE antibodies was removed 
and added to blocked wells of ELISA plates. After incubation for 1.5 h plates were 
washed and bound IgE was measured with HRP-conjugated secondary antibody as 
described for ELISA (see 2.4.12). Residual IgE binding of supernatants to plate-
coated rGly m 4 was calculated by comparing IgE binding to rGly m 4 upon depletion 
with control protein BSA set to maximum IgE binding (100%). 
 
2.4.15 Mediator release from humanized Rat Basophilic Leukaemia (RBL) cells 
Mediator release assay was performed according to protocol established by Vogel 
et al. (Vogel et al., 2005). Briefly, transfected RBL-2H3 cells expressing α-chain of 
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human FcεRI were passively sensitized with serum IgE antibodies (dilution 1:40). 
After washing of the cells, addition of different concentrations of allergen or allergen 
mixtures induced cross-linking of receptor-bound IgE antibodies causing cell 
degranulation. Degranulation was quantified by photometric measurement of β-
hexosaminidase in culture supernatants. Percentage of released β-hexosaminidase 
was calculated compared to total degranulation of cells lysed with Triton X-100 
(Sigma-Aldrich) and corrected for spontaneous release of cells incubated with serum 
only. 
 
2.4.16 Circular dichroism spectroscopy 
Far UV circular dichroism (CD) spectra of purified proteins were recorded using a 
Jasco J-810 spectropolarimeter (Japan Spectroscopic, Gross-Umstadt). 
Measurements were performed at 293 K and constant nitrogen flow rate in 1 mm 
quartz cuvettes with a band width of 1 nm and a sensitivity of 100 mdeg. Each 
measurement comprised the average of 10 repeated scans between 255 and 185 nm 
at a scanning speed of 50 nm/min. Proteins were analyzed at concentrations of 5 to 
10 µM in 10 mM potassium phosphate buffer at pH 7.4. Spectrum of buffer alone was 
subtracted. Results are shown as mean residual ellipticity. 
 
2.4.17 NMR spectroscopy 
NMR buffer 20 mM Sodium phosphate pH 7.0 
0.04% Sodium azide 
10% D2O 
 
NMR samples were prepared in NMR buffer containing 30 µM of recombinant 
protein. Standard 1D-1H spectra with WATERGATE solvent suppression were 
recorded on a Bruker Avance 700 MHz spectrometer at 298 K (Piotto et al., 1992). 
NMR data were processed and visualized with the Bruker spectrometer software 
TopSpin. NMR analyses were performed by Dr. Christian Seutter von Loetzen, 
Dr. Kristian Schweimer and Prof. Paul Rösch at the Department of Biopolymers of 
the University of Bayreuth. 
 
2 Materials and Methods  45 
 
2.4.18 Dynamic light scattering 
The hydrodynamic radii (RH) of proteins were analyzed with dynamic light scattering 
(DLS). Protein samples with concentrations of at least 5 µM were used after 
centrifugation at 4°C and 16,000 g for 15 min in Zetasizer Nano-ZS (Malvern, 
Herrenberg) at 25°C and a wavelength of 633 nm. Three individual measurements 
with 10 runs each were carried out in UV micro cuvettes (Carl Roth) with a layer 
thickness of 10 mm. 
 
2.4.19 Mass spectrometry 
Recombinant proteins were separated by SDS-PAGE, stained with coomassie, 
excised and subjected to liquid chromatography mass spectrometry (LC-MS) 
analysis. MS analyses were performed by Luisa Schwaben and Dr. Andreas Reuter 
at the Proteomics Core Facility of the Paul-Ehrlich-Institut. The experimental 
procedures will be described to an extent that allows the reader to assess the validity 
of the results.  
In gel digestion: 
Destaining solution  40% Ethanol, 50mM NH4HCO3 
Reduction solution 65 mM DTT in 50 mM NH4HCO3 
Alkylation solution 260 mM Iodoacetamide in 50 mM NH4HCO3 
Elution buffer 25 mM NH4HCO3, 10% acetonitrile 
 
The protein spots were excised and destained three times for 15 min in destaining 
solution. Reduction and alkylation of cysteine residues was carried for 15 minutes at 
200 rpm (thermomixer, Eppendorf) with reduction and alkylation solution, 
respectively. The gel plugs were dehydrated with 100% acetonitrile, vacuum dried 
(Savant Speed Vac®, Thermo Fisher Scientific) and were rehydrated in 
25 mM NH4HCO3 containing 75 ng/μl of trypsin (trypsin from porcine pancreas, 
Sigma-Aldrich). After initial digestion for 3 h at 37°C, elution buffer was added and 
further digestion was allowed over night at 37°C in a thermal cycler (Bibby Scientific, 
Staffordshire, UK). The digestion was stopped by adding of 5% formic acid to a 
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volume of 10% of the total digestion mixture. The samples were stored at -80°C until 
further MS analyses. 
LC-MS analyses: 
Trypsin digested proteins were analyzed using the nanoACQUITY® UPLC online 
coupled with nano ESI interface to a Q-TOF MS (Synapt, Waters, Manchester, UK). 
The solvent system consisted of solvent A (water with 0.1% (v/v) formic acid), and 
solvent B (acetonitrile with 0.1% (v/v) formic acid). Peptides were initially trapped on-
line at a flow rate of 5 µl/min using the trap column (nanoACQUITY Trap C18, 5 µm 
particle size, 180 µm × 20 mm). The peptide mixture was separated using a 
reverse-phase analytical column (nanoACQUITY C18, 1.7 µm particle size, 
100 µm × 100 mm; Waters) at a flow rate of 0.5 µl/min. The solvent composition was 
at 97% A for 1 min, followed by a linear gradient to 60% A for 30 min, and continued 
with 95% B for 1 min. The column was subsequently equilibrated at 97% A for 
18 min. Glu-1-Fibrinopeptide at 1pmol/µl, delivered from the auxiliary pump of the 
nanoACQUITY® UPLC at a 0.5 µl/min flow rate to the reference sprayer of the 
interface was measured every 20 sec to serve as a lock mass during the entire 
sample run. The mass spectrometer was operated in data independent MSE mode at 
a positive polarity and V mode (Silva et al., 2005; Silva et al., 2006). Scan rate was 
set to 0.4 sec. The collision energy was at a constant value of 4 V during low-energy 
scans and ramped from 15-30 V during high energy scans. Data were acquired from 
50 to 1,990 m/z. 
Data processing and database search: 
Raw data files were processed using ProteinLynx Global Server (PLGS) version 2.4 
(Waters). The processing parameters were set as follows: Retention time window, 
chromatographic peak width and MS TOF resolution were set to automatic, lock 
mass for charge state +1 and for charge state +2 were defined as 684.3469 Da and 
785.8426 Da, respectively. Low energy threshold was set to 250.0 counts, elevated 
energy threshold to 100.0 counts and intensity threshold to 1,500 counts. The search 
parameters for protein identification were a maximum of one missed cleavage site, a 
minimum of three fragment ion matches per peptide, a minimum of seven fragment 
matches per protein and a minimum of one peptide match per protein with a set false 
positive rate of 4%. Carbamidomethylation of cysteine (C) was defined as a fixed 
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modification. Variable modifications were restricted to deamination of asparagine (N) 
and glutamine (Q), and oxidation of methionine (M). The identities of the recombinant 
proteins were confirmed searching an in-house database consisting of the UniProt 
database (as of May 2011, restricted to reviewed entries of eukaryotic organisms) 
and the amino acid sequences of recombinant Gly m 4 wild type (internal accession 
number PEI015; UniProt accession number P26987), recombinant Gly m 4S111P/L150P 
(internal accession number PEI059), recombinant Bet v 1a (internal accession 
number PEI037; UniProt accession number P15494), recombinant Bet v 1aS112P/R145P 
(internal accession number PEI043) and recombinant Gly m 4 11-fold mutant 
(internal accession number PEI014). 
 
2.4.20 Determination of allergen-specific antibodies 
Specific IgE and IgG antibodies to recombinant allergens were quantified by 
ImmunoCAP™ using an ImmunoCAP™ 250 instrument (Thermo Fisher Scientific, 
Uppsala, Sweden). ImmunoCAP™ measurements were performed by Michaela 
Gubesch at the Paul-Ehrlich-Institut. 
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3 RESULTS 
3.1 Study population 
Sera of 47 patients were included in the study (Table 9). All patients were sensitized 
to both Bet v 1 and Gly m 4. Inclusion criteria were an allergy against birch pollen and 
specific IgE against soybean allergen Gly m 4, as determined by ImmunoCAP™. 
27 patients (group 1) exhibit an allergy against soybean as determined by double-
blind placebo-controlled food challenge (DBPCFC) or convincing clinical history of 
severe symptoms upon consumption of soybean containing food. The symptoms 
after soybean consumption in group 1 ranged from mild to severe reactions 
emphasizing clinical relevance of Gly m 4-related soy allergy. Mild symptoms like 
blisters, conjunctivitis, drowsiness, gastrointestinal discomfort, hoarseness, nasal 
secretion, oral allergy syndrome (OAS) and rhinitis were observed. 70% of patients 
(19/27) showed severe reactions to soy like dyspnea, flush, face swelling, throat 
tightness or urticaria. Group 2 comprised 20 patients with sensitization to Bet v 1 and 
Gly m 4 as well, but without any allergic symptoms upon consumption of soybean 
containing protein as confirmed by food challenge. Due to low available volumes of 
several sera two serum pools were generated in group 1 and 2, respectively. Serum 
pool No. 40 was made out of three sera from soybean allergic patients (No. 40 a, b, 
c) while serum pool No. 41 consisted of four sera from soybean positive sera 
(No. 41 a, b, c, d). Both serum pools No. 43 and 44 were made out of four soybean 
negative sera (No. 43 a, b, c, d and No. 44 a, b, c, d), respectively. Some 
experiments in this study were performed with a pool of all patients of group 1 or 
group 2, respectively. Patients’ characteristics and results of ImmunoCAP™ 
measurements are summarized in Table 9. 
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Table 9: Characteristics of serum donors of this study.   
Allergen-specific IgE and IgG of sera of patients sensitized to Gly m 4 with (A, patients 1-41) and without (B, 
patients 16-50) birch-related allergy to soy and clinical symptoms after DBPCFC with soybean protein are shown. 
A  ImmunoCAP™ 
  
sIgE for birch and soybean allergic patients 
[kUA/L] 
tIgG 
[mgA/L] 
Patient 
No. 
Symptoms to soybean 
(DBPCFC or case history) 
Bet v 1 
(class) 
Gly m 4 
(class) 
Gly m 5 
(class) 
Gly m 6 
(class) 
Gly m 4 
1 OAS, TT 90.4 (5) 8.64 (3) 0.02 (0) 0.03 (0) 14.5 
2 OAS >100 (6) 46.3 (4) 0.08 (0) 0.08 (0) 7.3 
3 OAS 67.8 (5) 14.5 (3) 0.00 (0) 0.01 (0) 27.6 
4 OAS, F, C >100 (6) >100 (6) 0.47 (1) 0.77 (2) 13.6 
5 OAS, RH, TT, H 33.5 (4) 14.2 (3) 0.01 (0) 0.01 (0) 5.4 
7 OAS, TT, H 28.3 (4) 8.69 (3) 0.00 (0) 0.00 (0) 3.9 
8 F, OAS, B 31.3 (4) 9.84 (3) 0.01 (0) 0.02 (0) 2.9 
9 OAS 14.6 (3) 3.93 (3) 0.00 (0) 0.00 (0) 5.2 
10 n.d. 7.48 (3) 3.34 (2) 0.00 (0) 0.00 (0) 6.6 
11 OAS 84.1 (5) 22.6 (4) 0.00 (0) 0.01 (0) 36.9 
13 OAS >100 (6) 23.7 (4) 0.06 (0) 0.08 (0) 16.0 
22 OAS 52.9 (5) 3.85 (3) 0.00 (0) 0.02 (0) 8.2 
28 DY, HU 42.7 (4) 9.98 (3) 0.00 (0) 0.00 (0) 8.0 
30 FS, DY, HU 48.8 (4) 11.4 (3) 0.01 (0) 0.02 (0) 6.5 
33 FS, OAS, TT 8.02 (3) 4.00 (3) 0.00 (0) 0.00 (0) 8.2 
34 GD 0.01 (0) 0.00 (0) 0.00 (0) 0.01 (0) 6.6 
35 FS, OAS, DY, DR, GD, NS 25.3 (4) 7.09 (3) 0.00 (0) 0.00 (0) 9.7 
36 FS, OAS, TT, HU, DR 33.9 (4) 11.2 (3) 0.00 (0) 0.01 (0) 7.8 
37 FS, OAS, TT, HU, GD 13.8 (3) 2.68 (2) 0.00 (0) 0.00 (0) 35.8 
38 FS, OAS, TT 58.1 (5) 22.9 (4) 0.03 (0) 0.02 (0) 5.7 
40 Serum pool, 3 patients 40.1 (4) 7.76 (3) 0.01 (0) 0.02 (0) 13.1 
a FS, OAS, TT, DR, GD 
     
b FS, OAS, TT 
     
c FS 
     
41 Serum pool, 4 patients 22.8 (4) 5.95 (3) 0.02 (0) 0.02 (0) 9.9 
a FS, OAS, HU, DR      
b FS, OAS, TT      
c FS, OAS, TT, DY      
d FS, OAS, TT      
 
B  ImmunoCAP™ 
sIgE for birch allergic patients without 
soybean allergy [kUA/L] 
tIgG 
[mgA/L] 
Patient 
No. 
Symptoms to soybean 
(DBPCFC) 
Bet v 1 
(class) 
Gly m 4 
(class) 
Gly m 5 
(class) 
Gly m 6 
(class) 
Gly m 4  
16 - 49.5 (4) 7.18 (3) 0.00 (0) 0.00 (0) 36.9 
20 - 28.5 (4) 5.42 (3) 0.01 (0) 0.03 (0) 26.5 
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24 - 10.9 (3) 3.66 (3) 0.00 (0) 0.00 (0) 15.3 
25 - 7.64 (3) 1.22 (2) 0.18 (0) 0.21 (0) 61.3 
26 - >100 (6) >100 (6) 0.08 (0) 0.10 (0) 14.7 
27 - >100 (6) 55.9 (5) 0.16 (0) 0.24 (0) 6.1 
43 - Serum pool, 4 patients 30.6 (4) 6.04 (3) 0.17 (0) 0.26 (0) 9.1 
44 - Serum pool, 4 patients 18.3 (4) 0.65 (1) 0.07 (0) 0.14 (0) 6.6 
45 - 6.07 (3) 1.32 (2) 0.00 (0) 0.03 (0) 7.5 
46 - 8.89 (3) 0.94 (2) 0.00 (0) 0.00 (0) 4.5 
47 - 47.4 (4) 17.7 (4) 0.00 (0) 0.00 (0) 7.3 
48 - 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 4.0 
49 - >100 (6) 3.31 (2) 0.04 (0) 0.02 (0) n.d. 
50 - >100 (6) 21.1 (4) 0.04 (0) 0.02 (0) n.d. 
 
Sera No. 40, 41, 43 and 44 are pools of three (No. 40) or four (No. 41, 43, 44) individual soybean positive or 
negative sera, respectively. Specific IgE levels were measured in kUA/L with resulting CAP class shown in 
parentheses. Gly m 4-specific total IgG levels were measured with a 1:10 dilution of sera in mgA/L with a 
Phadia250 ImmunoCAP™. Abbreviations of clinical symptoms: B – blisters; C – conjunctivitis; DR – drowsiness, 
vascular dysregulation; DY – dyspnea; F – flush; FS – face swelling; GD – gastrointestinal discomfort, vomiting; 
H – hoarseness; HU – hives, urticaria; NS – nasal secretion, nasal congestion; OAS – oral allergy syndrome; 
RH – rhinitis; TT – throat tightness, swallowing discomfort; n.d. – not determined. 
 
Specific IgE (sIgE) to Bet v 1 and Gly m 4 in the sera of the study population were 
quantified by ImmunoCAP™. Overall 94% of sera (34/36) had increased (CAP 
class ≥ 3) allergen-specific IgE levels to Bet v 1. A slightly increased median level of 
Bet v 1-specific IgE of 37.0 kUA/L for group 1 (0.01 to >100 kUA/L) compared to 
29.6 kUA/L (0 to >100 kUA/L) in patients merely sensitized but without allergy to soy 
(group 2) was determined. Furthermore almost all sera (34/36, 94%) had specific IgE 
antibodies against Gly m 4 indicating a sensitization to the Bet v 1-homologous 
soybean allergen. Gly m 4-specific median IgE levels of 9.3 kUA/L (0 to >100 kUA/L) 
in group 1 and 4.5 kUA/L (0 to >100 kUA/L) in patients without soybean allergy 
(group 2) were measured. In both groups of the study population 22 (group 1) and 14 
(group 2) sera with CAP classes from 0 to 6 for sIgE against Gly m 4 were present. 
For two patients (No. 34 and 48) no sIgE antibodies against Bet v 1 and Gly m 4 
could be detected. Serum of patient 34 has already been used in Kleine-Tebbe et al. 
in 2002 (Kleine-Tebbe et al., 2002) as serum of a subject sensitized to Bet v 1 and 
with symptoms after soybean consumption. In addition patient 48 had no IgE against 
Gly m 4 or Bet v 1 but had been clinically characterized as allergic to soy. To exclude 
a class I soybean allergy 36 sera of group 1 and 2 were analyzed for specific IgE 
levels against soybean allergens Gly m 5 and Gly m 6. In total 95.5% (21/22) of 
patients in group 1 and 100% (14/14) of patients in group 2 had very low amounts of 
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sIgE (CAP class 0) against both Gly m 5 and Gly m 6. Only patient 4 had CAP 
class 1 for Gly m 5 and CAP class 2 for Gly m 6, respectively, indicating a possible 
class I food allergy to soy. However very high serum levels of IgE against Bet v 1 and 
Gly m 4 (>100 kUA/L) in this patient suggest a birch-related rather than a classical 
soybean allergy. Analyzing the total Gly m 4-specific IgG levels of group 1 and 
group 2, a comparable median amount of 8.1 mgA/L and 8.3 mgA/L of IgG was 
measured, respectively. Gly m 4-specific IgG levels range from 2.9 to 36.9 mgA/L for 
group 1 and 4.0 to 61.3 mgA/L for group 2.  
To further analyze Gly m 4 and soybean-specific IgE levels sera of group 1 and 2 
were analyzed in immunoblot (Figure 2). IgE binding of each serum to 0.33 µg 
rGly m 4 and 6.7 µg soybean extract was detected at different exposure times to 
compare IgE signal intensities derived from rGly m 4 and soy extract, respectively. 
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Figure 2: Binding of serum IgE to rGly m 4 and soybean extract.  
Sera of patients sensitized to Gly m 4 with (group 1) and without (group 2) allergy to soy were analyzed in IgE immunoblot. Ponceau S stainings of immunoblots with rGly m 4 (A) 
and soybean extract (B) are shown. In total, 6.7 µg of rGly m 4 and 134 µg of soybean extract were blotted. (C) Detection of IgE binding to rGly m 4 after an exposure of 1 min. (D) 
Detection of IgE-binding proteins in soybean extract after 15 s of exposure. For both blots patients of group 1 and 2 were analyzed with numbers indicated. Each serum was used 
in 1:12 dilution and incubated over night with 0.33 µg rGly m 4 or 6.7 µg soybean extract (total protein). Serum of a patient with clinically confirmed soybean allergy (+) and serum 
of a non-atopic individual (-), both available from Paul-Ehrlich-Institut serum collection, as well as buffer (b) were used as controls. 
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With Ponceau S one transferred protein band at 17 kDa representing recombinant 
Gly m 4 was stained (A). In contrast analysis with soybean extract resulted in several 
bands at different molecular weights representing numerous proteins present in soy 
extract (B). According to inclusion criteria and the results of ImmunoCAP™ analyses 
all patients had Gly m 4-specific IgE antibodies. In immunoblot, however, IgE binding 
to rGly m 4 could be detected only in 95% (21/22) of sera in group 1 and 64% (9/14) 
of sera in group 2. In total, in sera of six patients no IgE binding to rGly m 4 could be 
detected in immunoblot analysis. These were serum of patient 34 for group 1 and 
sera of patients 25, 45, 46, 48 and 49 for group 2. These patients had no (No. 34 and 
48) or low levels (No. 25, 45, 46 and 49) of Gly m 4-specific IgE according to 
ImmunoCAP™ and might be below detection limit for IgE antibodies with 
immunoblotting and used serum dilution.  
Soybean extract contained several IgE-binding proteins. In immunoblot analysis sera 
of several patients, for example patients 5, 40, 41 and 43 had IgE binding to 
numerous of these soybean proteins especially with higher molecular weight 
compared to Gly m 4 (17 kDa). IgE signals in the range of 50-70 kDa might be 
related to monomers of soy seed storage proteins Gly m 5 and Gly m 6 with 
molecular weights of the native oligomers of 140-180 kDa and 300-380 kDa, 
respectively. Furthermore presence of antibodies directed against cross-reactive 
carbohydrate determinants (CCD), carbohydrate moieties of allergenic molecules, 
which might be able to induce allergic response, are possible. Some patients with 
sIgE against Gly m 4 showed no IgE binding at 17 kDa in immunoblot with soybean 
extract probably due to the very low amount of Gly m 4 in soybean extracts which 
might be under the detection limit for some of the sera tested. Patient 34 had IgE 
against several proteins of the soybean extract including a weak signal at a molecular 
weight of about 17 kDa comparable to Gly m 4. This is consistent with the results of 
ImmunoCAP™ analysis where no sIgE against Gly m 4 as well as Bet v 1 was found. 
 
3.2 Preliminary epitope profile of Gly m 4 
To identify amino acids of Gly m 4 that are involved in immunoglobulin E binding a 
combination of experimental and theoretical approaches was carried out. Thus, data 
on potential epitopes from screening of a phage-displayed peptide library for Gly m 4-
specific IgE-binding, bioinformatical approaches as well as published data on 
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putative antibody-binding sites of allergens homologous to Gly m 4 were considered 
to generate a preliminary epitope profile of Gly m 4 that was to be analyzed 
experimentally in more detail. 
 
3.2.1 Mapping of putative IgE-binding peptides onto Gly m 4 surface 
To identify peptides that bind Gly m 4-specific IgE of serum from subjects with birch-
related soy allergy I made use of an already published protocol using a phage-
displayed peptide library (Mittag et al., 2006). In this approach phage-displayed 
peptides are bound by immobilized serum IgE and competitively eluted by 
recombinant Gly m 4 (see 2.4.9). Eluted phages are amplified and the amino acid 
composition of the displayed dodecapeptide is determined by DNA sequencing and 
translation of the peptide-encoding DNA sequence. The peptide sequence is then 
mapped onto the protein surface of Gly m 4 with the web server EpiSearch to localize 
putative IgE-binding surface areas of the allergen (Negi & Braun, 2009).  
In this study phage-display was performed with two rounds of panning as described 
(see 2.4.9). Despite of several modifications in phage-display protocol the number of 
false-positives could not be reduced. Furthermore about 20% of false-positives were 
also observed when buffer or a non-atopic serum control instead of a serum 
containing Gly m 4-specific IgE antibodies was used. This indicates an unspecific 
interaction of phages with any of the materials used in experimental setup. Possible 
unspecific binding of phages might occur with magnetic beads or anti-IgE antibodies. 
According to this, the phage-display approach was no longer pursued. Instead 
i) already published mimotope data by Mittag et al. where 21 peptides for soybean-
allergic patients were identified and re-analyzed as described above (see Table A 1 
in the appendix) (Mittag et al., 2006) and ii) an alternative bioinformatical approach 
was used in which 7-mer peptides representing the total amino acid sequence of 
Gly m 4 were chosen and mapped with an off-set of one amino acid as potential IgE-
binding mimotopes onto the molecular surface of Gly m 4 using EpiSearch as 
described (see 2.4.9). Both approaches use peptides as input, either identified 
experimentally via phage-display or based on amino acid sequence, followed by 
mapping of peptide sequences onto molecular surface of Gly m 4 to identify putative 
conformational epitopes. This is in line with the mechanism of an allergic response 
where the food allergen is digested into small peptides during gastrointestinal uptake. 
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These peptides are then presented e. g. on the surface of dendritic cells interacting 
with T cells resulting finally in an allergic response to the respective food. The 
analysis resulted in a total number of 152 peptides representing 270 potential 
epitopes distributed over 39 patches on the molecular surface of Gly m 4 (see Table 
A 2 in the appendix). For both analyses those predicted epitopes that were largely 
overlapping were combined and assigned a particular potential epitope with a 
specific center amino acid (Table 10 and Figure 3). A detailed overview of all 
mimotopes and their corresponding residues identified with theoretical and 
experimental mapping is shown in Table A 1 and Table A 2 in the appendix. 
Table 10: Predicted epitopes of Gly m 4.  
Gly m 4 peptides Phage-displayed peptides 
Center 
residue 
No. of 
mapped 
peptides 
% of 
total 
mapped 
peptides 
Center 
residue 
No. of 
mapped 
peptides 
% of 
total 
mapped 
peptides 
94 45 30 94 6 29 
119 37 24 119 6 29 
29 19 19 37 4 19 
37 19 13 30 2 10 
150 14 9 29 1 5 
30 12 8 150 1 5 
 
Shown are six putative epitopes with their respective center residues obtained upon bioinformatic mapping of 
peptide sequences onto the molecular surface of Gly m 4. For theoretical and experimental approach a total 
number of 152 Gly m 4-specific peptides and 21 phage-displayed peptides were mapped using the EpiSearch 
algorithm. Experimentally determined IgE-binding peptide sequences were taken from Mittag et al. 2006. 
 
3 Results    56 
 
 
Figure 3: Comparison of predicted epitopes between theoretical and experimental mapping on Gly m 4.  
Potential epitopes of Gly m 4 with respective center residues (red) identified most frequently in the bioinformatical 
approach using the EpiSearch algorithm. Amino acids shown in green were identified with both, while blue amino 
acids were predicted by Gly m 4-specific peptides only. 
 
Interestingly putative epitopes identified most frequently in the bioinformatical 
approach were also identified with the experimentally observed peptides by 
Mittag et al. (Table 10) (Mittag et al., 2006). Center residues 94 and 119 of putative 
epitopes were identified with 30% and 24% in the theoretical and with 29% each of 
the total number of peptides analyzed in the experimental approach. Four center 
residues resulting from experimental approach were identified with more than one of 
the total 21 eluted peptides. These center residues are 30, 37, 94 and 119 and were 
also identified with high frequency in theoretical approach. Furthermore both 
approaches showed comparable frequencies of mapped peptides for these center 
residues with ratios experimental/theoretical of 0.97 (29%/30%), 1.21 (29%/24%), 
1.46 (19%13%) and 1.25 (10%/8%) for 94, 119, 37 and 30, respectively. Two 
mimotopes with center residues 29 and 150 were further mapped with more than one 
peptide using theoretical approach. Both were also identified as mimotopes with 
phage-display each comprising one mapped peptide. Ratios experimental/theoretical 
are 0.26 (5%/19%) and 0.56 (5%/9%) for center residues 29 and 150, respectively. 
Each predicted epitope consists of 8-17 amino acids with a total number of 
69 different amino acids identified as putative relevant in IgE binding. Interestingly, 
overall results concerning mimotopes and respective center residues are comparable 
in both approaches. The information on potential epitopes obtained with the analysis 
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described here was also considered for the selection of suitable candidate molecules 
for comprehensive epitope analysis of Gly m 4 as described in the next section.  
 
3.2.2 Rational mutagenesis and known epitope data 
In addition to the peptide-based epitope analysis in the previous section a rational 
approach to select amino acids potentially involved in antibody binding based on the 
known three-dimensional structure of Gly m 4 was followed. Gly m 4 consists of 
158 amino acids of which 79 amino acids are surface-exposed (with ≥20 Å2 
accessible surface area) comprising a total surface area of 6313.6 Å2 from 9118.7 Å2 
of total protein surface. For subsequent mutational epitope analysis in which 
individual amino acids were analyzed for their impact in IgE binding the following 
criteria were considered to ensure maintenance of Gly m 4-type conformation: i) the 
surface-exposed area of individual amino acids must be larger than 111 Å2 (Lins et 
al., 2003). Thus alanines and glycines were not included. ii) proline was excluded 
from the analysis because of its high impact on secondary structure topology, 
iii) amino acid side chains must be capable of undergoing hydrogen bonds and/or 
electrostatic interactions (charged, uncharged, polar and aromatic amino acids), 
iv) side chains of iii) must not be involved in intramolecular interactions (H-bonds or 
salt bridges) and v) amino acids exposed to the intramolecular hydrophobic cleft were 
excluded.   
In addition to the selection criteria above and results obtained by peptide-based 
epitope analysis (see 3.2.1), published data on single amino acids potentially 
involved in antibody binding of Bet v 1 or Bet v 1-homologs were evaluated and also 
considered (Scheurer et al., 1999; Mirza et al., 2000; Neudecker et al., 2003a; 
Spangfort et al., 2003; Holm et al., 2004; Jahn-Schmid et al., 2005; Wiche et al., 
2005; Wangorsch et al., 2007; Gieras et al., 2011; Hecker et al., 2012). Taken 
together, a total number of 51 amino acids were considered suitable for a 
comprehensive epitope analysis of Gly m 4 (Table 11). 
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Table 11: Amino acids of Gly m 4 potentially involved in IgE binding. 
 
Amino 
acid  
 
Amino 
acid 
 
Amino 
acid 
Non-polar 
F3 
Polar 
T116 
Acidic 
D124 
F5 N128 E126 
Y156 Q129 D130 
Polar 
T4 
Acidic 
E6 E131 
N10 D7 D140 
T17 D25 E147 
T24 D27 D155 
N28 D35 
Basic 
K20 
S36 E44 K32 
S39 E59 K38 
N42 D60 K54 
N46 E71 K64 
S81 E75 K96 
S83 D92 K118 
T93 E95 K133 
T98 D100 K136 
N108 E120 K144 
 
51 amino acids as constituents of putative epitopes of Gly m 4 for IgE were chosen according to epitope mapping, 
rational considerations and published data. Amino acids are sorted by the polarity and charge of their side chains. 
 
In Figure 4, 51 amino acids selected for epitope analysis are shown. The candidate 
residues are distributed over the complete Gly m 4 primary structure (Figure 4 A). In 
total, 61% (31/51) of residues considered for putative IgE binding are charged 
(aspartate (11x), glutamate (10x) and lysine (10x)), 33% (17/51) are polar (threonine 
(6x), asparagine (6x), serine (4x) as well as glutamine (1x)) and 6% (3/51) show non-
polar side chains (phenylalanine (2x) and tyrosine (1x)). The distribution of the 
selected candidate residues on the molecular surface of Gly m 4 is shown in Figure 
4 B. 
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Figure 4: Amino acids of Gly m 4 selected for mutational epitope analysis.  
(A) Gly m 4 amino acid sequence with 51 candidate residues colored in red. Secondary structures of β-strands 
(grey) and α-helices (underlined) are shown. (B) Surface representation of Gly m 4 with views turned in 90° 
rotation clockwise. (C) Top view. (D) Bottom view. Colored amino acids represent chosen 51 candidate residues: 
non-polar - yellow; polar - green; acidic - red; basic - blue. Pictures were generated with PyMOL surface 
presentation using Gly m 4 pdb file 2K7H. 
 
3.3 Generation of a Gly m 4-specific epitope library for IgE 
To analyze the potential impact of the 51 amino acids of Gly m 4 selected in the 
previous section on binding serum IgE of birch-associated soy allergic subjects, a 
recombinant model protein with Gly m 4-type conformation but no/low IgE-binding 
capacity was used. Norcoclaurine synthase (NCS) from the meadow rue (Thalictrum 
flavum) has Gly m 4-type protein conformation, low amino acid sequence homology 
to Gly m 4 (20.4% sequence identity) and no known allergenic properties (Ilari et al., 
2009; Berkner et al., 2014). These characteristics make NCS an ideal model protein 
to analyze the impact of individual amino acids of Gly m 4 on serum IgE-binding. For 
this, single amino acids of NCS were replaced with structurally homologous amino 
acids of Gly m 4. Provided that the Gly m 4-type protein fold of NCS is not altered 
upon amino acid substitution, serum IgE-binding of such a NCS protein variant would 
directly point to a specific role of the substituted Gly m 4-specific amino acid in IgE 
interaction of Gly m 4 (Figure 5). 
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Figure 5: Principle of epitope grafting using NCS as Gly m 4-type model protein.  
(A) Gly m 4-type model protein NCS (grey) with no/low IgE-binding capacity. (B) IgE antibodies bind to a specific 
epitope (orange) of Gly m 4 (red). (C) Transfer of amino acids from an IgE epitope of Gly m 4 to NCS induces 
IgE-binding of the Gly m 4-type NCS variant and enables the analysis of the impact of individual amino acids of 
Gly m 4 in serum IgE-binding. Pictures were generated with PyMol. 
 
Two NCS model proteins were used in this study. Δ51NCSN42/P49 was generated with 
a total length of 160 amino acids harboring two specific amino acid 
insertions/substitutions typical for Gly m 4-homologous allergens. The protein was 
also truncated N- and C-terminally to adjust it to a typical length of Bet v 1-type 
allergens (Nürnberg, 2014, Master thesis). Furthermore Δ51NCSN42/P49 shows two 
gaps in C-terminal α-helix most probably due to two proline residues at positions 134 
and 140 (pdb: 2VNE) (Ilari et al., 2009). Therefore Δ51NCSN42/P49/P134E/P140S was 
generated in this study to replace the two prolines that do prevent the formation of a 
continuous C-terminal helix typical for Bet v 1-type proteins. The structural alignment 
of Δ51NCSN42/P49, Bet v 1a and Gly m 4 is shown in Figure 6. With the two NCS 
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model proteins a library of recombinant NCS variants harboring potential epitope 
residues of Gly m 4 was generated. 
 
Figure 6: Secondary structure and structural alignment of Δ51NCSN42/P49, Bet v 1a and Gly m 4, 
respectively.  
(A) Overlay of secondary structure topologies of Δ51NCSN42/P49 (blue), Bet v 1a (green, pdb: 1BV1) and Gly m 4 
(red, pdb: 2K7H). (B) Structural sequence alignment of Δ51NCSN42/P49, Bet v 1a and Gly m 4 with β-strands (grey) 
and α-helices (underlined) indicated. Amino acid identities to Δ51NCSN42/P49 are 19.5% (Bet v 1a) and 20.4% 
(Gly m 4), respectively. Overlay of Δ51NCSN42/P49, Bet v 1a and Gly m 4 was generated with PyMol while 
EMBOSS Needle Pairwise Alignment tool provided by European Bioinformatics Institute was used for alignment 
of amino acid sequences. 
 
A basic concept in this work is the understanding of a functional epitope as described 
by Dall’Acqua et al. where a single residue within a structural IgE epitope dominates 
the energetics of allergen-IgE binding (Dall'Acqua et al., 1998). Therefore the grafting 
of a single amino acid from Gly m 4 onto non-IgE binding NCS model protein might 
mimic an antibody-binding site of Gly m 4 resulting in specific binding of serum IgE. 
In the rest of the study the procedure of grafting amino acid(s) which evoke IgE 
binding is considered as the generation of a (putative) functional epitope bearing in 
mind that a single residue per se does not bind IgE, but its introduction might adapt 
the molecular surface of NCS more similar to Gly m 4 thus enabling the interaction of 
such a modified NCS variant with Gly m 4-specific IgE antibodies (Figure 7). 
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Figure 7: Structural changes upon grafting of amino acid F3 from Gly m 4 to NCS.  
Surface representation of Δ51NCSN42/P49 (A), Gly m 4 (B) and Δ51NCSF3/N42/P49 (C). Green circle highlights grafted 
amino acid F3 in Gly m 4 and Δ51NCSF3/N42/P49 as well as corresponding residue in Δ51NCSN42/P49. Colored 
atoms represent: oxygen – red, nitrogen – blue. Pictures were generated with PyMOL surface presentation. 
 
The structural-homologous grafting of the single amino acid F3 from Gly m 4 into 
NCS model protein not only changes the molecular surface at this position in NCS 
but also introduces structural changes in the arrangement of adjacent residues 
thereby leading to a potential epitope-like molecular surface that might result in 
serum IgE binding.  
In this study, site-directed mutagenesis of NCS resulted in a total number of 
48 different variants containing all 51 residues chosen as potential amino acids 
involved in binding of IgE (see Table 11). Most variants of the NCS library were 
generated with single amino acid substitutions while eight NCS variants comprised 
two substitutions each. Furthermore, one variant with five substituted residues 
(Δ51NCSN42/E44/N46/P49/K54) was included in screening as it contains 75% of the 
experimentally determined epitope of mouse Bet v 1-specific monoclonal antibody 
BV16. This particular epitope of Bet v 1 is highly similar to the corresponding region 
of Gly m 4 and has been recently analyzed as corresponding Δ29NCS variant with 
Bet v 1-type protein fold as determined by CD and NMR spectroscopy and the 
capability to bind IgE of birch-allergic patients (Berkner et al., 2014). All amino acids 
of NCS that are structurally homologous to the individual amino acids of Gly m 4 
potentially involved in IgE-binding are listed in Table 12. 
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Table 12: Candidate residues of Gly m 4 and their corresponding amino acids of Δ51NCS.  
 
Amino acid 
 
Amino acid 
Gly m 4 Δ51NCS Gly m 4 Δ51NCS 
Non-
polar 
F3 K4 
Acidic 
E75 N78 
F5 I6 E120 H123 
Polar 
T4 V5 D124 E127 
N10 E11 D124/E126 E127/V129 
T17 D18 D130 P134 
T24 P26 E131 L135 
S36 A39 D140 A142 
S39 K42 E147 S149 
N46 D49 
Basic 
K20 T21 
S81 K84 K32 D34 
S83 Q86 K38 E41 
T98 M101 K54 D57 
N108 K111 K64 H67 
T116 S119 K118 E121 
N128 V132 K133 I136 
Q129 E133 K136 T138 
Acidic 
E6 H7 K144 D146 
D7 H8 
Mixed 
F5/D100 I6/T103 
D25 G27 N28/K32 K30/D34 
D25/D27 G27/A29 E44/N46 I47/D49 
D35 G38 D92/T93 L95/G96 
E59 P62 E95/K96 T98/Y99 
D60 G63 D155/Y156 S157/S159 
E71 I74 N42/E44/N46/P49/K54 5x 
 
Amino acids are sorted by their specific side chain characteristics as shown in Table 11. Variants with two amino 
acid substitutions belonging to different groups of amino acids are listed as mixed residues. Each aa of Gly m 4 
as well as the corresponding structural homologous residue in Δ51NCS that was replaced for the Gly m 4-specific 
residue is shown. In total 48 Δ51NCS variants were generated by site-specific mutagenesis with Δ51NCSN42/P49 or 
Δ51NCSN42/P49/P134E/P140S as template. 
 
3.4 Screening of the NCS protein library for serum IgE-binding 
3.4.1 A murine monoclonal antibody-binding epitope of Bet v 1 also binds serum IgE 
Gly m 4-specific amino acids N42, E44, N46, P49 and K54 grafted onto NCS model 
protein were shown to induce binding of IgE of sera from birch pollen-allergic 
subjects to the Δ29NCS variant (Berkner et al., 2014). Furthermore IgE cross-
reactivity between Bet v 1-homologous food allergens from soy and hazelnut 
harboring these amino acids was observed. To analyze sera of birch allergic patients 
with (group 1) and without (group 2) soybean allergy for IgE-binding to the epitope of 
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monoclonal antibody BV16, the optimized recombinant variant 
Δ51NCSN42/E44/N46/P49/K54 was used. Observed binding of IgE antibodies compared to 
model protein Δ51NCSN42/P49 indicated presence of serum IgE able to bind grafted 
residues. Immunoblots with recombinant Δ51NCSN42/P49 and Δ51NCSN42/E44/N46/P49/K54 
variants and sera of group 1 and 2 are shown in Figure 8. 
 
Figure 8: Δ51NCSN42/E44/N46/P49/K54 binds IgE of several sera of birch allergic patients with and without 
soybean allergy. 
Patients sensitized to Bet v 1 and Gly m 4, with (group 1) and without (group 2) clinically confirmed soybean 
allergy were analyzed in immunoblot. IgE binding to reference model protein Δ51NCSN42/P49 (lane a) and epitope-
presenting variant Δ51NCSN42/E44/N46/P49/K54 (lane b) is shown. Each serum was used in a 1:20 dilution with patient 
number indicated at each blot. Patients are sorted for positive IgE response (upper panel) and no IgE response 
(lower panel). 
 
Several patients had IgE antibodies against the particular epitope presented by the 
Δ51NCSN42/E44/N46/P49/K54 variant. In total, 41% (9/22) of patients sensitized and 
allergic to soy (group 1) and 29% (4/14) of patients sensitized but without soybean 
allergy (group 2) showed binding of serum IgE to Δ51NCSN42/E44/N46/P49/K54 variant, 
respectively. In comparison to Δ51NCSN42/P49 reference, Δ51NCSN42/E44/N46/P49/K54 
harbors three additional grafted residues of Gly m 4, namely E44, N46 and K54 
which seem to be important for IgE binding at least in some of the patients’ sera 
analyzed. Frequency of IgE binding to Δ51NCSN42/E44/N46/P49/K54 combining both 
groups is 36% (13/36) in immunoblot, which is much lower compared to previous 
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ImmunoCAP™ analyses showing 71% (50/70) of birch pollen-allergic subjects with 
IgE binding to grafted BV16-binding epitope (Berkner et al., 2014). One possible 
explanation might be the higher sensitivity of ImmunoCAP™ compared to 
immunoblot analyses. 
 
3.4.2 Screening of a NCS protein library for functional IgE epitopes 
To identify further functional IgE epitopes of Gly m 4, the generated library of NCS 
proteins was used (see 3.3). Thus each of the 48 recombinant NCS variants was 
expressed in small-scale culture and bacterial lysates were analyzed for IgE binding 
with sera of soy allergic subjects (group 1) and sera of subjects non-allergic to soy 
(group 2) in immunoblots. As IgE epitopes of Bet v 1 and its homologues are 
conformational, observed IgE binding to NCS variants under these conditions would 
point to stably Gly m 4-type refolding of NCS variants. Figure 9 shows an exemplary 
SDS-PAGE of several NCS variants after cell lysis with crude bacterial lysates plotted 
which were also used in immunoblot analysis below. 
 
Figure 9: Expression of reference model protein Δ51NCSN42/P49 and Δ51NCSN42/P49 variants in E. coli. 
Coomassie-stained gel of bacterial lysates of E. coli expressing recombinant model protein Δ51NCSN42/P49 and 
Δ51NCSN42/P49 variants presenting Gly m 4-specific amino acids D35, E71, T98, N108 and T116 upon SDS-
PAGE. Shown are soluble fractions (SF) and inclusion bodies (IB) of small-scale expressions in E. coli obtained 
by cell lysis using BugBuster extraction kit. Arrow heads (◄) mark expressed target proteins. 
 
All recombinant Δ51NCSN42/P49 variants were expressed almost exclusively as non-
soluble proteins in inclusion bodies. Therefore, in immunoblotting estimated 
comparable amounts of crude inclusion body protein fraction of each NCS variant 
was analyzed. As reference protein, bacterial lysate of Δ51NCSN42/P49 showing no or 
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very low IgE-binding capacity was used. By quantitative comparison of IgE signal 
intensities observed with the NCS variants to reference protein Δ51NCSN42/P49, amino 
acids potentially involved in Gly m 4-specific IgE binding could be identified. With this 
initial screening a patient-specific profile of potential Gly m 4-specific functional IgE 
epitopes could be identified which can be used as initial results for detailed analyses 
afterwards. As an example, Figure 10 shows the initial screening of all NCS variants 
together with serum 33 (group 1) and 49 (group 2). 
 
Figure 10: Screening of NCS library with patient’s serum No. 33 (A) and 49 (B). 
Shown are Ponceau S-stained Δ51NCSN42/P49 proteins as well as corresponding IgE signals obtained by 
immunoblotting. Sera of patient No. 33 (A, sensitized and soy allergic, group 1) and 49 (B, sensitized, no soybean 
allergy, group 2) were used in a 1:10 dilution. Gly m 4-specific amino acid(s) presented by Δ51NCSN42/P49 variants 
are indicated while 5x resembles Δ51NCSN42/E44/N46/P49/K54 variant. Protein used at the very right end of each blot 
resembles Δ51NCSN42/P49 control protein necessary for analysis of each blot. NCS variants with positive IgE 
binding signals compared to control protein are highlighted. 
 
For patient 33 a total number of 31 putative IgE-binding NCS variants could be 
identified resulting in 31 putative functional IgE epitopes. Furthermore, serum 33 has 
IgE antibodies directed against Δ51NCSN42/E44/N46/P49/K54 variant, confirming results 
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obtained by immunoblotting with purified protein (cf. Figure 8). In contrast no sIgE 
directed against Δ51NCSN42/E44/N46/P49/K54 could be detected in serum of patient 49 but 
a total number of 20 putative functional IgE epitopes. In this way all 36 sera of 
group 1 and 2 were screened and the results of all identified putative functional IgE 
epitopes are summarized in Table 13. 
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Table 13: Putative functional IgE epitopes of Gly m 4. 
 
48 Δ51NCSN42/P49 variants presenting indicated Gly m 4-specific amino acid(s) were analyzed in immunoblotting with sera of birch allergic patients with (22 sera, group 1) or without 
(14 sera, group 2) soybean allergy. IgE signals of variants were compared with Δ51NCSN42/P49 control protein on each blot and variants with positive IgE binding signal are colored 
in orange. Gly m 4-specific amino acids presented by Δ51NCSN42/P49 model protein are listed from N- (left) to C-terminus (right) with amino acids identical in Gly m 4 and Bet v 1a 
colored in green. 5x represents Δ51NCSN42/E44/N46/P49/K54 variant. Patients are listed in group 1 and group 2 according to clinical reactivity to soybean shown in Table 9. 
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In total 48 NCS variants were screened with 36 sera comprising group 1 and 2. 
96% (46/48) of NCS variants bound IgE from sera of at least one patient compared to 
reference protein Δ51NCSN42/P49 resulting in the identification of 46 putative functional 
IgE epitopes. 48% (22/46) of the NCS variants generated presented amino acids 
homologous between Gly m 4 and Bet v 1a, while 52% (24/46) of identified putative 
functional IgE epitopes were Gly m 4-specific. Only Δ51NCSN42/P49/E95/K96 and 
Δ51NCSN42/P49/D140 did not bind IgE from any of the sera analyzed. Average number 
of putative functional epitopes for each serum is comparable between both groups 
showing 21 and 18 identified putative epitopes for patients with and without clinical 
soy allergy, respectively. The range of 12 to 32 putative functional epitopes identified 
for patients with soybean allergy was larger than 14-26 putative functional epitopes 
for patients sensitized but not allergic to soy. Two NCS variants Δ51NCSF5/N42/P49/D100 
and Δ51NCSF3/N42/P49 bound serum IgE of all sera tested, whereas NCS variants 
Δ51NCSK20/N42/P49, Δ51NCSD25/D27/N42/P49, Δ51NCSN28/K32/N42/P49, Δ51NCSN42/P49/D60 
and Δ51NCSN42/P49/N128 bound serum IgE of at least 75% of all sera. 39% (18/46) of 
the NCS library bound serum IgE of more than 50% of the study population. 
Reference protein Δ51NCSN42/P49 showed weak IgE binding with sera of several 
patients most likely because of identical amino acids between Δ51NCSN42/P49 and 
Gly m 4 or Bet v 1a primary sequence with possible importance for interaction with 
IgE antibodies. In total Δ51NCSN42/P49 shares 31 and 35 residues with Gly m 4 and 
Bet v 1a respectively, whereas 15 and 16 amino acids might be involved in IgE 
binding because of their side chains (E, F, H, K, N, S, T, Y). A complete analysis of 
the IgE binding frequency of study groups 1 and 2 is shown in Figure 11 A and B. 
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Figure 11: IgE binding frequencies of Δ51NCSN42/P49 variants presenting Gly m 4-specific amino acid(s) are 
highly individual.  
IgE binding frequency in % of all tested Δ51NCSN42/P49 variants presenting Gly m 4-specific amino acid(s) with 
subjects sensitized and soy allergic (A) and subjects without soybean allergy (B). Variants are listed from N- (left) 
to C-terminus (right) with respective Gly m 4 residues grafted. 5x represents Δ51NCSN42/E44/N46/P49/K54 variant. 
Dotted line represents an IgE binding frequency of 50%. 
 
Two variants were identified as positive only with sera of one group of patients. NCS 
variants Δ51NCSN42/P49/D92/T93 and Δ51NCSN42/P49/E147 bound IgE only with three sera 
of patients sensitized and soy allergic each. In contrast Δ51NCSN42/P49/N108 bound 
only IgE antibodies in one serum of a patient without soybean allergy. Despite of 
these three NCS variants there were no obvious different characteristics observable 
regarding the distribution of Gly m 4-specific putative functional IgE epitopes between 
birch-soy allergic and Gly m 4-sensitized patients only. Rather, every patient 
exhibited an individual pattern of putative functional IgE epitopes which did not 
correlate to specific clinical symptoms. In Figure 12 all identified putative functional 
epitopes, as well as functional epitopes identified with patients 33 and 49 are shown 
on Gly m 4 protein. 
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Figure 12: Putative functional IgE epitopes of Gly m 4. 
Surface areas of putative functional IgE epitopes of Gly m 4 identified by screening of the Δ51NCSN42/P49 epitope 
library with representative sera of patients with (patient 33) and without (patient 49) allergy to soy. In total 
47 putative functional epitopes were found (A). 31 putative functional IgE epitopes for patient 33 (B) and 
20 putative functional IgE epitopes for patient 49 (C) are indicated. Protein models were generated with PyMOL 
surface presentation using Gly m 4 pdb file 2K7H. 
 
Putative functional IgE epitopes (see definition in section 3.3 and Figure 7) identified 
by screening the NCS library were distributed all over Gly m 4 molecule and covered 
about 45% (4112.8 Å2) of surface accessible protein surface area. Only two larger 
patches not involved in IgE binding in this analysis were presented by surface areas 
consisting of parts of β-strands 4 and 5 as well as β-strands 6 and 7. These 
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segments of the Gly m 4 sequence showed many glycine, alanine and valine 
residues which putatively do not interact with antibodies, as well as amino acids K69 
or K114 homologous in NCS model protein and Gly m 4. When comparing NCS 
binding of sera of patients 33 and 49, respectively, differences as well as similarities 
in the distribution of putative functional IgE epitopes became evident. For patient 33, 
31 putative functional epitopes covering 26% (2342.6 Å2) of total protein surface were 
found. For patient 49, 20 putative functional epitopes were identified resulting in 
coverage of 17% (1528.2 Å2) of the Gly m 4 surface. This causes larger surface 
areas not involved in IgE binding for patient 49 compared to patient 33. Concordant 
between both patients are surface patches around short α-helices or β-sheets 1, 6 
and 7. In detail these are amino acids F3, N10 and K20 for short α-helices and 
N28/K32, T98, D100/F5 and T116 for β-sheets. The initial results obtained by 
screening of NCS with immunoblot are further analyzed in subsequent sections of 
this study.  
All identified amino acids were clustered to six putative IgE-binding areas since such 
spatial arrangement results in a maximum number of virtual epitopes on total Gly m 4 
surface enabling a simultaneous binding of antibodies to at least two areas (Figure 
13) which is a prerequisite for the allergic reactions initiated via Gly m 4-induced IgE 
cross-linking on activated basophils and mast cells (cf. Figure 1). Residues at the 
intersection of two virtual epitope areas might represent amino acids belonging to 
more than one of the six hypothetical IgE-binding areas. These putative functional 
IgE epitopes (I-VI) cover 3-11% of total protein surface and span a molecular surface 
of 311.4-967.3 Å2 each while consisting of 3-10 amino acids. Epitope I consists of 
amino acids F3, T4, F5, E6, D7, D124, E126, N128 and Q129 comprising portions of 
Gly m 4 N-terminus and loop 9 connecting last β-strand with long C-terminal α-helix. 
In close proximity epitope II is located with most residues belonging to C-terminal 
helix (D130, E131, K133, K136, K144 and E147) expanded with two asparagines 
N10 and N108. Epitope III consists of amino acids T17, K20, T24, D25, D27, N28 
and K32 forming main parts of both short α-helices as well as E75 and residues 
D155 and Y156 at C-terminus of Gly m 4 sequence. Residues D35, S36, K38, S39, 
E59, D60, K64, D92 and T93 together comprise epitope IV mainly located at loops 3 
and 5. Epitope V presents residues grafted onto Δ51NCSN42/E44/N46/P49/K54 variant 
showing parts of structurally solved BV16 epitope located in the conserved p-loop 
region. Formed by parts of β-sheets 4-7 epitope VI constitutes amino acids E71, S81 
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S83, T98, D100, T116, K118 and E120. Secondary structure of Gly m 4 with putative 
IgE epitopes I-VI is shown in Figure 13. 
 
 
Figure 13: Six putative IgE epitopes of Gly m 4. 
Putative functional IgE epitopes of Gly m 4 were combined. (A) Surface representation of six (I-VI) identified 
putative IgE epitopes of Gly m 4 with views turned in 90° rotation clockwise. (B) Top view. (C) Bottom view. 
Colors represent putative IgE epitopes: I (red) – F3, T4, F5, E6, D7, D124, E126, N128, Q129; II (dark pink) – 
N10, N108, D130, E131, K136, K144, E147; III (blue) – T16, K20, T24, D25, D27, N28, K32, E75, D155, Y156; IV 
(yellow) – D35, S36, K38, S39, E59, D60, K64, D92, T93; V (green) –E44, N46, K54; VI (cyan) – E71, S81, S83, 
T98, D100, T116, K118, E120. Pictures were generated with PyMOL surface and cartoon presentation using 
Gly m 4 pdb file 2K7H. 
 
IgE binding frequencies of the six putative epitopes calculated by individual NCS 
variants recognized by serum IgE most frequently was 100% (36/36) for epitopes I, 
III, and VI, 81% (29/36) for epitope IV, 67% (24/36) for epitope V and 56% (20/36) for 
epitope II. A summary of putative epitopes with assignment of all identified functional 
IgE epitopes as well as possible combinations of six epitopes allowing simultaneous 
binding of two IgE antibodies is shown in Table 14 A and B. 
 
 
 
 
3 Results    74 
 
Table 14: Putative functional IgE epitopes of Gly m 4 and their combinations allowing simultaneous 
binding of IgE antibodies. 
A    
IgE epitope Amino acids 
Number 
[aa] 
Frequency 
[%] 
I 
F3, T4, F5, E6, D7, D124, E126, 
N128, Q129 
9 100 
II 
N10, N108, D130, E131, K133, K136, 
K144, E147 
8 56 
III 
T17, K20, T24, D25, D27, N28, K32, 
E75, D155, Y156 
10 100 
IV 
D35, S36, K38, S39, E59, D60, K64, 
D92, T93 
9 81 
V E44, N46, K54 3 67 
VI 
E71, S81, S83, T98, D100, T116, 
K118, E120 
8 100 
 
B       
IgE epitope I II III IV V VI 
I -      
II - -     
III + + -    
IV + + + -   
V + + - + -  
VI - + + + + - 
 
(A) Putative epitopes I-VI with all amino acids listed. IgE binding frequencies of the six putative epitopes were 
calculated by individual NCS variants recognized by serum IgE most frequently (substituted amino acids are 
underlined). Colors correspond to epitope patches shown in Figure 13. (B) Possibility of two putative epitopes 
binding their respective IgE antibodies is indicated with (+) or (-) whereas (+) indicates that simultaneous binding 
of two IgE antibodies is possible and (-) indicates two epitopes which are in close proximity to each other 
preventing simultaneous binding of IgE antibodies. 
 
3.5 NCS protein variants with grafted epitope patches 
3.5.1 Generation and characterization of multiple NCS variants 
To experimentally verify the putative functional IgE epitopes identified in the previous 
section a more thorough analysis of purified recombinant NCS variants was 
necessary. For this, NCS variants combining individual and multiple potential IgE 
binding sites were generated (Table 15). A Gly m 4-type secondary structure of the 
NCS variants was evaluated by circular dichroism (CD) analysis of the purified model 
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proteins. However only eleven (variants 1-11) out of 14 variants generated showed 
Gly m 4-type CD spectra and were included in the further epitope analyses.  
Table 15: Gly m 4 epitopes presented by recombinant NCS variants presenting Gly m 4-specific amino 
acid(s).  
ΔNCSN42/P49 
variants 
Grafted amino acids Epitope patches 
1 F3, F5, E6, D124, E126 I 
2 
D25, D27, N28, V29, K32, A152, D155, 
Y156 
III 
3 K38, S39, E59, D60, K64 IV 
4 E44, N46, K54 V 
5 
N10, D130, E131, K133, K136, K144, 
E147, A148 
II 
6 K32, E44, N46, K54, D60, E120, E126 I, III, IV, V, VI 
7 F3, K38, D60, N128 I, IV 
8 T24, S36, S81, D124 I, III, IV, VI 
9 T4, T17, N46, S83 I, III, V, VI 
10 
F5, T17, T24, S36, K64, S81, K118, D124, 
K133 
I, II, III, IV, VI 
11 
T4, T17, K32, N46, E75, S83, D100, 
D124, E126, K144 
I, II, III, V, VI 
12 F3, N10, N28, K32, K38, D60, N128 I, II, III, IV 
13 
D7, D25, D27, D35, E44, N46, K54, E71,  
E120, E147 
I, II, III, IV, V, VI 
14 
F5, K20, K38, E59, D60, D100, Q129,  
D155, Y156 
I, III, IV, VI 
 
Δ51NCSN42/P49 variants 1-5 and 7-14 as well as Δ29NCSN42/P49 variant 6 with grafted amino acids from six putative 
Gly m 4 epitopes for IgE (color code as shown in Table 14). 
 
In total, three to ten amino acids were grafted from Gly m 4 to NCS model protein to 
create NCS variants with putative IgE-binding epitopes. Five variants displayed 
amino acids corresponding to one individual IgE epitope patch (I, II, III, IV or V) 
identified previously (see Table 14 A). Remaining six NCS proteins displayed 
combinations of different IgE binding sites identified. These multiple epitope variants 
combine 2-5 different epitope patches, respectively. Except 
Δ29NCSK32/E44/N46/K54/D60/E120/E126 which is based on Δ29NCSN42/P49 template, all 
further NCS variants were generated using Δ51NCSN42/P49 as model protein. 
Subsequently, all NCS variants are designated as ΔNCSN42/P49_1 to ΔNCS N42/P49_11 
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according to their description listed in Table 15. In Figure 14 secondary structures of 
Δ51NCSN42/P49 and variants of model protein are shown with functional epitopes 
indicated. 
 
Figure 14: Secondary structure topologies of Δ51NCSN42/P49 model proteins presenting individual and 
multiple IgE binding sites of Gly m 4. 
ΔNCSN42/P49 variants 1-5 present individual epitopes while variants 6-11 combine different IgE epitopes of 
Gly m 4. The amino acids are colored according to their epitope affiliation shown in Figure 13.  
 
In total, all eleven putative IgE epitopes cover 35% (3199.4 Å2) of total protein 
surface but each single epitope only matches a small surface patch of NCS 
(242.8-861.1 Å2). For analysis of their IgE-binding potential all ΔNCSN42/P49 variants 
were expressed and purified to homogeneity from E. coli. Purification was performed 
as described in 2.4.5 using affinity chromatography with C-terminal His-tag 
characteristic for pET29a vector followed by size exclusion chromatography. Total 
protein yield was about 20 mg out of 1 L of expression culture. Figure 15 shows 
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purified Δ51NCSN42/P49 model protein as well as eleven ΔNCSN42/P49 variants 
generated.  
 
Figure 15: Purity of Δ51NCSN42/P49 and ΔNCSN42/P49 variants. 
Purified ΔNCSN42/P49 variants presenting individual or multiple IgE epitopes of Gly m 4 were analyzed in 
Coomassie-stained gels upon SDS-PAGE. Lanes 1 to 11 represent corresponding ΔNCSN42/P49_1-11 variants. 
Arrow heads (◄) mark recombinant target proteins: 
ΔNCSN42/P49_1=Δ51NCSF3/F5/E6N42/P49/D124/E126, 
ΔNCSN42/P49_2=Δ51NCSD25/D27/N28/V29/K32/N42/P49/A152/D155/Y156, 
ΔNCSN42/P49_3=Δ51NCSK38/S39/N42/P49/E59/D60/K64, 
ΔNCSN42/P49_4=Δ51NCSN42/E44/N46/P49/K54, 
ΔNCSN42/P49_5=Δ51NCSN10/N42/P49/D130/E131/K133/K136/K144/E147/A148, 
ΔNCSN42/P49_6=Δ29NCSK32/N42/E44/N46/P49/K54/D60/E120/E126, 
ΔNCSN42/P49_7=Δ51NCSF3/K38/N42/P49/D60/N128, 
ΔNCSN42/P49_8=Δ51NCST24/S36/N42/P49/S81/D124, 
ΔNCSN42/P49_9=Δ51NCST4/T17/N42/N46/P49/S83, 
ΔNCSN42/P49_10=Δ51NCSF5/T17/T24/S36/N42/P49/K64/S81/K118/D124/K133, 
ΔNCSN42/P49_11=Δ51NCST4/T17/K32/N42/N46/P49/E75/S83 /D100/D124/E126/K144. 
 
Variants showed high purity with minor degradation products according to SDS-
PAGE in five of purified ΔNCSN42/P49 variants (ΔNCSN42/P49_1, 3, 6, 9 and 10). PR-10-
type secondary structures of the ΔNCSN42/P49 variants were observed by CD 
spectroscopy (Figure 16). 
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Figure 16: Circular dichroism of ΔNCSN42/P49 variants. 
CD spectra of Δ51NCSN42/P49 and eleven corresponding ΔNCSN42/P49 variants each recorded at 20 °C and 10 µM 
protein concentration in 10 mM potassium phosphate buffer at pH 7.4. Spectra are presented as mean residual 
ellipticity*10
-3
 at a given wavelength and are baseline corrected. 
 
All recombinant ΔNCSN42/P49 variants showed comparable secondary structure 
elements with Δ51NCSN42/P49 model protein as determined with CD spectroscopy. 
Spectra indicate a high content of both α-helical regions and β-strands. Some minor 
differences between variants were observable especially around maxima at 210 and 
194 nm. This might result from minor changes in protein concentration or small 
impurities left in protein samples. All in all, CD spectra of the ΔNCSN42/P49 variants 
suggested that the amino acid substitutions did not induce relevant alterations to the 
Gly m 4-type secondary structure of the proteins. 
 
3.5.2 Analysis of grafted epitope patches for binding serum IgE 
All purified ΔNCSN42/P49 variants with Gly m 4-type CD spectra were tested for serum 
IgE binding in a dot blot analysis. As reference proteins Δ51NCSN42/P49 as well as 
Δ29NCSN42/P49 (Berkner et al., 2014) were used showing no or very low IgE binding 
to sera from sensitized subjects. Figure 17 A shows a sketch of the dot blot set-up 
with ΔNCSN42/P49 variants analyzed for IgE binding with each patients’ serum. Figure 
17 B shows nine examples of dot blots obtained by incubation with sera of 
patients 11, 30, 33, 36, 37, and 41 for subjects sensitized and soy allergic (group 1) 
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as well as patients 20, 26 and 49 for subjects with no related soybean allergy 
(group 2), respectively, as well as non-atopic serum control. 
 
Figure 17: Set-up of the dot blot analysis and serum IgE binding of ΔNCSN42/P49 variants. 
(A) Dot blot membranes were subdivided into 13 segments of 1x1 cm each. 1 µg of respective ΔNCSN42/P49 
variant was plotted and binding of serum IgE was detected. (B) Binding of serum IgE to ΔNCSN42/P49 variants. 
Representative examples of the study group and a non-atopic control are shown. Patients’ numbers (P11, P20, 
P26, P30, P33, P36, P37, P41 and P49) are indicated at each blot. 
 
3 Results    80 
 
All IgE signals were quantified by densitometry (Figure 18). Each spot was quantified 
at three different exposure times and mean value as well as standard deviation was 
calculated. Intensities of each variant were correlated to mean values of 
Δ51NCSN42/P49 model protein plus three times standard deviation which was set to 1. 
IgE signals obtained with study population were identified as positive, if mean values 
minus standard deviation are above (>1) signal of Δ51NCSN42/P49 model protein plus 
three times standard deviation. Results obtained by quantification of IgE binding with 
all patients are shown in Figure 18.  
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Figure 18: IgE binding to ΔNCSN42/P49 variants quantified by densitometry. 
Sera of subjects sensitized to Bet v 1 and Gly m 4 with (A, 22 subjects) and without (B, 14 subjects) soybean allergy are shown with relative signal intensities in arbitrary units (AU). 
Intensities of each dot blot signal were quantified with ImageJ by analysis of three different exposure times. Mean values and standard deviations were correlated to mean values 
of Δ51NCSN42/P49 plus three times standard deviation which was set to 1 (dotted line). Signals were considered as positive, if mean values minus standard deviation are higher 
than 1. X-axis: 1-11 represent variants ΔNCSN42/P49_1-11 introduced above. 
3 Results    83 
 
Evaluation of IgE signals revealed different IgE binding patterns in both groups. 
Altogether 39% (14/36) of all sera showed more than three positive IgE signals. Only 
for one patient of the study population no IgE signal could be identified as positive 
(patient 47) while serum of subject 35 had IgE against a total number of seven 
different ΔNCSN42/P49 variants. Mean values for number of identified IgE-binding 
ΔNCSN42/P49 variants were 3.8 for patients with and 2.2 for patients without soybean 
allergy. Patients with soybean allergy had identical IgE signals in patients 2, 38 and 
41, patients 5 and 22, patients 7 and 9, as well as in patients 36, 37 and 40, with five 
(ΔNCSN42/P49_4, 6, 7, 9 and 10), one (ΔNCSN42/P49_7), three (ΔNCSN42/P49_7, 9 and 
10) and four (ΔNCSN42/P49_4, 7, 9 and 10) IgE-binding ΔNCSN42/P49 variants identified, 
respectively. Further twelve patients with soybean allergy showed individual IgE-
binding patterns. For patients without soybean allergy only four different IgE epitope 
patterns were identified. Patient 16 showed IgE binding to five ΔNCSN42/P49 variants 
(ΔNCSN42/P49_4, 6, 7, 9 and 10), while patients 27 and 48, as well as patients 46, 49 
and 50 had positive signals with only two (ΔNCSN42/P49_7 and 10) and one 
ΔNCSN42/P49 variant (ΔNCSN42/P49_7), respectively. For the remaining six patients of 
this group (patients 20, 24, 25, 26, 43 and 44) same three IgE-binding ΔNCSN42/P49 
variants (ΔNCSN42/P49_4, 7 and 9) could be observed. As already shown for 
immunoblot analysis several weak IgE binding signals can be observed with 
Δ51NCSN42/P49 and Δ29NCSN42/P49 possibly due to identical amino acids between 
NCS and Gly m 4 or Bet v 1a (see 3.4.2). IgE binding frequencies of all ΔNCSN42/P49 
variants regarding both groups of patients are shown in Figure 19. 
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Figure 19: IgE binding frequencies of ΔNCSN42/P49 variants. 
IgE binding frequencies of eleven generated ΔNCSN42/P49 variants are shown for patients with (A) and without 
soybean allergy (B). Frequencies were calculated as percentage of analyzed patients (A: 22, B: 14 subjects, 
respectively). 1-11 represent variants ΔNCSN42/P49_1-11 introduced above. 
 
IgE binding frequencies differed markedly between subjects with (Figure 19 A) and 
without (Figure 19 B) soybean allergy. NCS variant identified with highest frequency 
was ΔNCSN42/P49_7 in both groups of patients with frequencies of 95% (21/22) for 
patients with and 86% (12/14) for patients without soybean allergy. In addition to 
ΔNCSN42/P49_7, IgE binding frequencies ≥50% were observed for ΔNCSN42/P49_4 
(50%, 11/22), 9 (68%, 15/22) and 10 (73%, 16/22) in patients with and for 
ΔNCSN42/P49_4 (50%, 7/14) and 10 (71%, 10/14) in patients without soybean allergy. 
ΔNCSN42/P49_6 and 8 showed IgE binding in 36% (8/22) and 32% (7/22), while 
residual variants ΔNCSN42/P49_1, 3, 5 and 11 only bound IgE in <10% of patients with 
soybean allergy. For patients without soybean allergy IgE binding frequencies <10% 
were identified for ΔNCSN42/P49_6 and 9 while residual six ΔNCSN42/P49 variants 
showed no IgE signals in any sera of this group. Only ΔNCSN42/P49_2 had no IgE 
binding with any of used sera. Comparing both groups of patients, major differences 
were observed with ΔNCSN42/P49_9 showing an IgE binding frequency of 68% in 
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patients with and only 7% in patients without soybean allergy. ΔNCSN42/P49_9 
revealed a sensitivity of 68% and a specificity of 93% resulting in a positive (PPV) 
and negative predicted value (NPV) of 94% and 65%, respectively. Therefore 
residues presented by ΔNCSN42/P49_9 might be more relevant in the group of subjects 
with compared to patients without clinically confirmed soybean allergy and 
ΔNCSN42/P49_9 might be used as biomarker to differ between soybean allergic 
patients and subjects only sensitized to Gly m 4. Assembling data of all patients 
irrespective of their clinical reactivity to soy some differences are observable between 
majorities of NCS variants. Variants ΔNCSN42/P49_1, 2, 3, 5, 8 and 11 showed IgE 
binding with less than 20% of all patients while the remaining variants ΔNCSN42/P49_4, 
6, 7, 9 and 10 bound IgE of 25-92% of all subjects. Summary of identified IgE 
epitopes with all analyzed patients is shown in Table A 3. 
 
3.5.3 Depletion of IgE binding to Gly m 4 
Analysis of eleven ΔNCSN42/P49 variants revealed six putative IgE epitope patches on 
Gly m 4. To verify if NCS variants and respective epitope patches bind Gly m 4-
specific IgE, serum IgE depletion experiments were performed. Briefly, prior to 
analysis of binding between IgE and rGly m 4, serum was preincubated with 
rGly m 4, Δ51NCSN42/P49 or a mixture of ΔNCSN42/P49 variants. Resulting allergen-IgE 
complexes were precipitated via allergen’s His-Tag and serum supernatant was 
analyzed for Gly m 4-specific IgE binding using ELISA. Results of these depletion 
experiments are shown in Figure 20. 
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Figure 20: Depletion of IgE binding to rGly m 4. 
Pooled sera of patients with (black) and without (grey) birch-related allergy to soy were incubated with rGly m 4 or 
ΔNCSN42/P49 variants prior to precipitation of the His-tagged proteins via Ni-NTA. Subsequently the supernatants 
were analyzed for Gly m 4-specific IgE binding. Serum without depleted IgE antibodies shows IgE binding to 
rGly m 4 and was set to 100%. Percentage of IgE binding to rGly m 4 is shown for incubation with Δ51NCSN42/P49 
control, a mixture of all eleven generated ΔNCSN42/P49 variants and rGly m 4. To present the same number of all 
IgE epitopes Δ51NCSN42/P49 and rGly m 4 as well as each variant were used in equimolar amounts (epitope-wise). 
 
Without prior depletion of serum IgE antibodies, a maximum binding between Gly m 4 
and IgE was observable with both groups of patients and set to 100%. Irrespective of 
the clinical reactivity to soy incubation of serum pools with Δ51NCSN42/P49 caused a 
slight reduction of Gly m 4-specific IgE binding. In detail a reduction of IgE binding to 
80.0 ± 7.7% for patients with soy allergy and 78.3 ± 7.8% for patients without allergy 
to soybean was observed, respectively. This slight reduction in binding is likely 
caused by minor IgE interaction of model protein Δ51NCSN42/P49 with several patients 
because of identical amino acids in Δ51NCSN42/P49 and Gly m 4 or Bet v 1a sequence 
as already shown in 3.4.2 and 3.5.2. In contrast a strongly reduced IgE binding to 
rGly m 4 was observable when serum IgE was depleted by ΔNCSN42/P49 variants or 
rGly m 4 itself. By addition of all NCS variants (ΔNCSN42/P49_1-11) representing six 
distinct IgE epitopes a remaining IgE binding of 20.0 ± 5.3% for the group of patients 
with soy allergy was determined. In contrast subjects sensitized but not clinically soy 
allergic showed a reduction in IgE binding to 30 ± 5.3% with eleven ΔNCSN42/P49 
variants. Both reductions indicate the Gly m 4 specificity of the identified interactions 
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between ΔNCSN42/P49 variants and serum IgE antibodies in both groups of patients. 
Depletion of IgE with rGly m 4 caused an even increased reduction in IgE binding as 
shown for ΔNCSN42/P49 variants. In detail, IgE binding to rGly m 4 was reduced to 
almost 2.7 ± 2.1% caused by prior depletion with the same allergen using pool of 
sera from patients showing soybean allergy. A comparable reduction to 7.6 ± 3.0% in 
IgE binding to rGly m 4 was observable by Gly m 4 depletion with patients sensitized 
but without soy allergy. The observed differences in IgE binding between rGly m 4 
and all ΔNCSN42/P49 variants might indicate the presence of further IgE epitope(s) not 
identified yet or might reflect a decreased affinity in binding between IgE and 
ΔNCSN42/P49 variants compared to IgE and rGly m 4 in both groups. 
 
3.6 Analysis of putative functional IgE epitopes of rGly m 4 
3.6.1 Generation and characterization of rGly m 4 
Recombinant Gly m 4 was expressed with cleavable N-terminal His-tag in E. coli as 
both, soluble and insoluble (inclusion bodies) protein. rGly m 4 was purified to 
homogeneity (see 2.4.4) as soluble protein with a total protein yield of about 20 mg/L 
bacterial suspension (Figure 21). 
 
Figure 21: Purity of recombinant Gly m 4. 
Purified rGly m 4 after small-scale expression in E. coli analyzed in Coomassie-stained gels upon SDS-PAGE. 
Shown are soluble fraction (lane 1) and inclusion bodies (2) obtained by cell lysis using BugBuster extraction kit 
and purified rGly m 4 (3). For BugBuster analysis, loaded volume of inclusion body preparation was 3 times the 
volume of soluble fraction. Arrow head (◄) marks rGly m 4 protein.  
 
To analyze structural integrity of recombinant Gly m 4, secondary and tertiary 
structure was determined by CD and 1D-1H-NMR spectroscopy (Figure 22). 
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Furthermore potential protein oligomerisation/aggregation was addressed by dynamic 
light scattering (DLS). 
 
Figure 22: Secondary and tertiary structure of rGly m 4 and rBet v 1a. 
(A) Overlay of secondary structure topologies of rGly m 4 (red) and rBet v 1a (green) generated with PyMOL. (B) 
Circular dichroism of rGly m 4 and rBet v 1a (10 µM each). (C) 1D-
1
H-NMR of 40 µM of rGly m 4 (left panel) and 
30 µM rBet v 1a (right panel). 
 
rGly m 4 had typical Bet v 1-type conformation with a high content of both β-sheets 
and α-helices as determined in circular dichroism. With 1D-1H-NMR spectroscopy the 
native Gly m 4 protein conformation was confirmed, as the NMR signals indicated a 
high degree of resonance dispersion at 8.5-6.5 ppm and 4.5-0.5 ppm characteristic 
for amid protons and α-protons, as well as protons of methyl groups resulting from 
secondary structure elements. Additional signals are present in both rBet v 1a and 
rGly m 4 below 0.5 ppm, above 8.5 ppm and between 5.0-6.5 ppm and only appear 
in well-folded proteins with existing secondary and tertiary structure. Dynamic light 
scattering analysis revealed a hydrodynamic radius (RH) of 2.81 ± 0.27 nm (rGly m 4) 
which was slightly higher compared to RH (rBet v 1a) of 2.49 ± 0.39 nm (Ferreira et 
al., 1993). Differences might result from additional amino acids in Gly m 4 sequence 
representing linker and adjacent His6-tag residues causing an increased 
hydrodynamic radius. Nevertheless RH indicated a monodisperse distribution of 
rGly m 4 as monomeric protein in solution with no aggregates detectable. 
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3.6.2 Characterization of substitutional rGly m 4 variants 
To test the impact of amino acids on Gly m 4-specific IgE binding identified with the 
NCS model system (3.2.2) several multiple substitutional rGly m 4 variants were 
generated (Table 16). 
Table 16: Generated variants of rGly m 4. 
Name 
Number of 
substitutions 
Amino acid substitutions 
rGly m 4_4x 4 T93, E95, K96, E120 
rGly m 4_9x 9 E6, K32, S39, D60, T93, E95, K96, E120, E126 
rGly m 4_10x 10 E6, D27, K32, D35, S39, D60, D92, E95, K118, E126 
rGly m 4_11x 11 
E6, D27, K32, D35, S39, D60, D92, E95, K118, E126, 
Y149 
rGly m 4_14x 14 
E6, D27, K32, D35, S39, E44S, D60, N77K, D92, E95, 
N108K, K118, E126, K133E 
 
Substituted amino acids of each variant are shown. If not stated otherwise, amino acids were changed to alanine. 
Amino acids are colored according to their predicted epitope assignment (see Figure 13). 
 
All of the substituted residues correlate to the putative IgE epitopes identified with 
NCS model protein analysis (3.4.2) and are shown in Figure 23. 
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Figure 23: Secondary structure topologies of rGly m 4 and substitutional variants. 
Shown are secondary structural elements and substituted residues of 4x (blue), 9x (green), 10x (red), 11x (yellow) 
and 14x (purple) Gly m 4 variants as well as their corresponding molecular surface. Molecules were generated 
with PyMOL and pdb code 2K7H with front view (0°) shown. 
 
Amino acids E6 and E126 correspond to epitope I, N108 and K133 to epitope II, D27 
and K32 are parts of epitope III, D35, S39, D60, D92 and T93 correspond to 
epitope IV, E44 to epitope V and K118 and E120 to epitope VI, respectively. Amino 
acids E44, N77, N108 and K133 were already identified as parts of IgE-binding 
epitopes in Holm et al. and Spangfort et al., where respective substitutions in Bet v 1 
resulted in a reduced binding of serum IgE (Spangfort et al., 2003; Holm et al., 2004). 
Residues E95 and K96 were identified as potential IgE-binding in previous Δ51NCS 
analyses (Nürnberg, 2014, Master thesis) and Y149 belongs to different mimotopes 
identified by Mittag et al. (Mittag et al., 2006). N77, E95, K96 could be assigned to 
epitope VI and Y149 to epitope III, respectively. To analyze the influence of 
substitutions on IgE binding the rGly m 4 variants were purified (Figure 24 A) and 
secondary structure content analyzed by CD spectroscopy (Figure 24 B). 
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Figure 24: Purity and circular dichroism of substitutional rGly m 4 variants. 
(A) Purified rGly m 4 and substitutional variants were analyzed in Coomassie-stained gels upon SDS-PAGE. 
Arrow head (◄) mark recombinant target proteins. (B) CD spectra of rGly m 4 and 4x, 9x, 10x, 11x and 14x 
variant recorded at 5 µM each. Spectra are presented as mean residual ellipticity*10
-3
 at a given wavelength and 
baseline corrected. 
 
Furthermore amino acid sequences of rGly m 4 and rGly m 4_11x variant were 
analyzed according to LC-MS analyses (see 2.4.19) and MS data confirmed identities 
of both proteins (Table 17). Details of peptides detected by MS verifying relevant 
amino acid substitutions of rGly m 4_11x variant are shown in Figure A 1 in the 
appendix. 
Table 17: Summary of the MS data of the confirmation of rGly m 4 and rGly m 4_11x variant. 
Protein Acc.No.* Score# Peptides§ Coverage$ 
Mass 
Error" 
      rGly m 4  PEI015 16135 16 74% 4.2ppm 
      rGly m 4_11x PEI014 14715 17 95% 3.9ppm 
 
Listed are results of LC-MS analyses for confirmation of amino acid sequence of rGly m 4 and rGly m 4_11x with 
* internal accession number; 
#
 protein score by PLGS; 
§
 number of tryptic peptides detected by MS; 
$
 Percentage 
of sequence covered by MS; " average precursor mass error. 
 
Since all rGly m 4 variants exhibited Gly m 4-type circular dichroism spectra, the 
proteins were considered suitable for IgE binding analyses as described in the 
following chapter.  
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3.6.3 Analysis of IgE binding of substitutional variants of rGly m 4 
Amino acid substitutions of rGly m 4 were analyzed for their relevance in IgE binding 
with immunoblot and ELISA inhibition. Reduced IgE binding to rGly m 4 variants as 
compared to wild type rGly m 4 would suggest contribution of substituted amino acids 
in interaction with the IgE antibody. To identify such functional IgE epitopes several 
sera of patients with (group 1) and without (group 2) birch-related allergy to soy were 
tested. First, rGly m 4_11x variant was analyzed for reduced IgE binding in 
comparison to wild type rGly m 4 with a total number of 16 patients of which twelve 
were allergic to soy and 4 were tolerant. Therefore immunoblot analysis was 
performed with both proteins incubated in parallel with patients’ sera (Figure 25). 
 
Figure 25: IgE binding of rGly m 4 versus rGly m 4_11x. 
Serum IgE binding of 12 patients allergic (group 1, left panel) and 4 patients not allergic to soy (group 2, right 
panel) was analyzed with rGly m 4 and rGly m 4_11x. Immunoblot results were divided into subjects with no (A), 
minor (B) and strong (C) binding of serum IgE to rGly m 4_11x compared to wild type allergen. At each blot the 
specific serum number is indicated. 
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Analyzed patients were classified according to their IgE binding with rGly m 4_11x. 
Strong reduction in IgE binding to the rGly m 4 variant was observed in 63% (10/16) 
of all patients. Regarding both groups analyzed, 67% (8/12) of patients with and 50% 
(2/4) of patients without soybean allergy, respectively, showed a strong reduction in 
IgE binding with rGly m 4_11x. In comparison, a clearly reduced IgE binding to the 
rGly m 4 variant was observed in 31% (5/16) of all patients, 25% (3/12) of group 1 
and 50% (2/4) of group 2, respectively. A comparable IgE binding of both studied 
rGly m 4 proteins was only observable in one patient (8%) with clinical allergy to soy. 
These results indicate the impact of substituted amino acids on IgE binding. At least 
one IgE epitope was affected in several patients through amino acid substitutions 
causing reduced binding of IgE antibodies compared to wild type rGly m 4. 
Nevertheless, remaining IgE binding to rGly m 4_11x especially in patient 11 
suggested the presence of further epitopes of Gly m 4. To get a more detailed view 
on influence of substituted residues for IgE binding several sera were tested with 
rGly m 4_4x, 9x, 10x and 14x. Because of their overlapping substitutions it might be 
possible to localize important residues for IgE binding. Additional analyses were 
performed in solution using ELISA inhibition. Again, same 16 patients of group 1 and 
2 were analyzed with results shown in Figure 26. 
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Figure 26: Reduced IgE binding to rGly m 4 in presence of recombinant substitutional Gly m 4 variants. 
Binding of serum IgE to 200 ng rGly m 4 was inhibited with 500 ng rGly m 4, rGly m 4_4x, 9x, 10x or 14x variant 
in ELISA. Sera of 12 subjects allergic (A) and 4 subjects not allergic to soybean (B) were used. Number of each 
patient is indicated. The average of two measurements is shown. n.d.: not determined. 
 
ELISA analysis revealed different IgE binding patterns with rGly m 4 variants in both 
groups of patients irrespective of their allergic symptoms. As control IgE binding to 
rGly m 4 can be inhibited with rGly m 4 to 63.9-92.3%. For all rGly m 4 proteins only 
a single-point measurement using 2.5 time excess of inhibitor compared to rGly m 4 
present on ELISA plate was performed. Comparable results to rGly m 4 were 
obtained with rGly m 4_4x variant showing inhibition to 45.6-92.1% of IgE binding in 
analyzed subjects. In contrast stronger inhibition of IgE binding was observed with 
rGly m 4_9x, 10x and 14x variant. rGly m 4_9x which is based on substitutions 
present in rGly m 4_4x variant inhibited IgE binding to 16.2-60.3% indicating the 
importance of additional substitutions for binding of IgE antibodies in several sera 
(No. 5, 8, 10, 33, 37, 16, 24, 47). With a inhibition of IgE-allergen binding to 
23.8-73.9% rGly m 4_10x is comparable to rGly m 4_9x which both show six shared 
substitutions. rGly m 4_14x which was tested only in six patients of group 1 exhibited 
four additional substitutions compared to rGly m 4_10x and inhibited IgE binding to 
11.0-62.6%. Interestingly, in some patients (No. 5, 28, 37) rGly m 4_14x showed a 
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lower inhibition level compared to rGly m 4_10x. In patient 11 only small differences 
with all rGly m 4 variants was observable showing IgE binding inhibited from 52.3% 
with rGly m 4_14x to 71.2% with rGly m 4. Overall, a patient-specific pattern of 
inhibition was observed in both groups of patients analyzed. Summary of results 
determined by inhibition ELISA experiments are listed in Table 18. 
Table 18: Inhibition of IgE binding to rGly m 4 with substitutional rGly m 4 variants. 
A 
Decrease in IgE binding (%) with 
substitutional variants compared to wild type 
rGly m 4 as inhibitor 
Variant 
No. of analyzed 
patients 
≥40% 20-40% <20% 
4x 12 0 0 
12 
(100%) 
9x 12 6 
(50%) 
5 
(42%) 
1 
(8%) 
10x 12 
2 
(17%) 
7 
(58%) 
3 
(25%) 
14x 6 
3 
(50%) 
2 
(33%) 
1 
(17%) 
  
B 
Decrease in IgE binding (%) with 
substitutional variants compared to wild type 
rGly m 4 as inhibitor 
Variant 
No. of analyzed 
patients 
≥40% 20-40% <20% 
4x 4 0 0 
4 
(100%) 
9x 4 
3 
(75%) 
1 
(25%) 
0 
10x 4 
3 
(75%) 
0 
1 
(25%) 
14x 0 - - - 
 
Decrease in IgE binding in % with rGly m 4_4x, 9x, 10x and 14x variants compared to inhibition determined with 
wild type rGly m 4 as inhibitor. Values are categorized in strong (≥40%), medium (20-40%) and weak (<20%) 
reduction of IgE binding. Sera of 12 subjects sensitized and soy allergic (A) and 4 subjects sensitized but without 
clinical soybean allergy (B) were used.  
 
Comparing the decrease in IgE binding obtained with different rGly m 4 variants as 
inhibitors in correlation with rGly m 4 wild type protein an increased number of 
substitutions comes along with a considerable decrease in IgE binding in most of the 
patients. Especially rGly m 4_9x, 10x and 14x variants showed reduced binding to 
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serum IgE directed against rGly m 4 in all patients analyzed. Therefore amino acids 
substituted in these variants seemed to be critical for binding IgE antibodies and thus 
might be part of several IgE epitopes. Nevertheless there are still sera of patients 
observable in both groups showing only slightly decreased IgE binding even with 
rGly m 4_10x or 14x as inhibitors indicating the presence of further IgE epitopes left 
on Gly m 4 not influenced by introduced substitutions. A detailed analysis of which 
residue actually contributes to antibody binding is not possible but first hints on 
putative functional epitopes can be concluded. For example with patient 5 a strong 
decrease in IgE binding with rGly m 4_9x (21.4%) compared to rGly m 4_4x (71.3%) 
which differs in residues E6, K32, S39, D60 and E126 was observed. Therefore at 
least one of these residues might be important for serum IgE binding in this subject. 
Same holds true for patients 10, 33 and 37 of group 1 as well as patients 16, 34 and 
47 of group 2. Furthermore a considerably decreased IgE binding was observed with 
rGly m 4_14x (11%) compared to rGly m 4_10x (64.2%) in patient 37. Both variants 
only differ in additional substitutions E44S, N77K, N108K and K133E introduced in 
rGly m 4_14x indicating their potential relevance for binding IgE antibodies. As shown 
for patient 37 these differences were also observed in patient 28. Despite the missing 
results of rGly m 4_14x in patients without soybean allergy no characteristic 
differences of one group of patients could be determined. Therefore no differences in 
the epitope profiles between both groups of patients were observed with 
substitutional rGly m 4 variants. In sum, the analysis of the substitutional variants of 
Gly m 4 revealed 18 potential functional epitopes, i. e. amino acids which might 
dominate the energetics of allergen-IgE binding, as defined in chapter 3.3. 
 
3.7 Analyzing IgE binding avidity with rGly m 4 
For a thorough analysis of potential differences between patients with and without 
clinical allergy to soy, IgE antibody avidity needs to be addressed. A higher avidity of 
Gly m 4-specific IgE in patients with allergy compared to patients sensitized but 
tolerant to soybean could be a potential explanation for the presence of allergic 
reactions. Therefore IgE binding avidity between rGly m 4 and two pools of patients 
representing sera of group 1 and 2, respectively, was determined by inhibition ELISA. 
According to previous results where no differences in serum IgE level was observed 
in both groups of patients (see 3.1), inhibition of IgE binding to rGly m 4 in both pools 
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of sera should show comparable results indicating no differences in IgE binding 
avidity with rGly m 4. Results of inhibition ELISA are shown in Figure 27. 
 
Figure 27: Inhibition of IgE binding to immobilized rGly m 4 with rGly m 4 as inhibitor.  
Binding of IgE antibodies of serum pools generated from 27 subjects with (group 1, positive pool – green) and 
20 subjects without (group 2, negative pool – red) soybean allergy. IgE binding to immobilized rGly m 4 was 
inhibited by increasing concentrations of rGly m 4 in ELISA. All curves were fitted by a 4-parameter, logistic 
sigmoidal curve fit. 
 
With both serum pools a comparable inhibition curve with rGly m 4 as inhibitor was 
observable. EC50 values, the Gly m 4 concentrations needed for half-maximum 
inhibition of IgE-Gly m 4 binding for positive and negative pool were 5.06 ± 0.47 ng 
and 1.84 ± 0.14 ng for rGly m 4. With rGly m 4 the pool of negative sera revealed a 
slightly decreased EC50 value compared to the pool generated from positive patients. 
Overall no differences in avidities regarding both analyzed serum pools with rGly m 4 
could be detected which did not support the hypothesis of a potential importance of 
avidity comparing patients with and without allergy to soy at least in this study 
population. 
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3.8 Misfolded allergen variants 
3.8.1 Generation of a misfolded variant of Gly m 4 and Bet v 1a 
It is widely accepted that IgE-mediated allergy to birch pollen is caused by IgE 
binding to conformational epitopes of Bet v 1, the major allergen of birch. In birch-
associated food allergy however, allergic symptoms may arise up to two hours after 
ingestion of the allergenic food raising the question whether allergen processing 
through the gastrointestinal tract and loss of native folding in general might modulate 
allergen protein conformation and thus IgE binding capability (Bohle et al., 2006). To 
analyze whether native protein conformation is required for serum IgE-binding in the 
study population analyzed here, two variants of each rBet v 1a and rGly m 4 lacking 
the typical Bet v 1-type fold were generated and characterized for physicochemical 
and immunobiological properties. In detail, two proline residues were introduced into 
both allergens by site-directed mutagenesis. First substitution was serine at 
position 112 in Bet v 1a and corresponding residue S111 in Gly m 4 and was already 
shown to cause a significant change in protein folding for Bet v 1a (Son et al., 1999). 
In addition, one residue of long C-terminal α-helix was changed to disrupt this 
secondary element. For Bet v 1a arginine 145 and for Gly m 4 leucine 150 were each 
substituted to a proline residue. Resulting variants rBet v 1aS112P/R145P and 
rGly m 4S111P/L150P are shown in Figure 28. 
 
Figure 28: Secondary structure topology of Bet v 1a (A, pdb: 1BV1) and Gly m 4 (B, pdb: 2K7H).  
Amino acids S112 (green) and R145 (orange) of Bet v 1a as well as S111 (green) and L150 (purple) of Gly m 4 
were exchanged for proline, respectively. 
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Both variants were heterologously expressed in E. coli BL21(DE3) and purified from 
bacterial inclusion bodies with N-terminal His-tag and affinity chromatography. For 
comparability reasons rBet v 1a, which was expressed in both, inclusion bodies and 
soluble fraction, was also purified from E. coli inclusion bodies. Only rGly m 4 was 
derived from soluble fraction as mentioned above (see 3.6.1). In Figure 29 SDS-
PAGE with both fractions after cell expression, as well as purified allergens are 
shown.  
 
Figure 29: Expression of misfolded variants rGly m 4S111P/L150P and rBet v 1aS112P/R145P in E. coli.  
Coomassie-stained gel of bacterial lysates of E. coli expressing rGly m 4 and rBet v 1a as well as their respective 
misfolded variants rGly m 4S111P/L150P and rBet v 1aS112P/R145P and purified target proteins analyzed by SDS-PAGE. 
Soluble fractions (SF) and inclusion bodies (IB) obtained by cell lysis using BugBuster extraction kit are shown. 
Arrow heads (◄) mark purified recombinant target proteins with N-terminal His-tag removed by thrombin cleavage 
(-His). 
 
Purified proteins and their respective variants were furthermore treated with thrombin 
to cleave off the N-terminal His-tag (-His). This caused a reduction in molecular 
weight from 18.8 kDa to 17.1 kDa for proteins expressed in pET15b vector. Overall 
the recombinant allergens were highly pure with only minor degradation products of 
rBet v 1a and rBet v 1aS112P/R145P. Using LC-MS/MS the amino acid sequences of 
both misfolded variants could be confirmed with a sequence coverage of 
78% (score 7985) for rBet v 1aS112P/R145P and 86% (score 17230) for 
rGly m 4S111P/L150P, respectively. Results are shown in Table 19. Details of peptides 
detected by MS verifying relevant amino acid substitutions of rBet v 1aS112P/R145P and 
rGly m 4S111P/L150P variant are shown in Figure A 1 in the appendix. 
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Table 19: Summary of the MS data of the confirmation of rBet v 1aS112P/R145P and rGly m 4S111P/L150P. 
Protein Acc.No.* Score# Peptides§ Coverage$ 
Mass 
Error" 
      rBet v 1a PEI037 8297 14 72% 8.3 ppm 
rBet v 1aS112P/R145P PEI043 7985 13 78% 3.4 ppm 
      rGly m 4 PEI015 25161 14 72% 4.4 ppm 
rGly m 4S111P/L150P PEI059 17230 18 86% 5.7 ppm 
 
Listed are results of LC-MS analyses for confirmation of amino acid sequence of rBet v 1a, rBet v 1aS112P/R145P, 
rGly m 4 and rGly m 4S111P/L150P with * internal accession number; 
#
 protein score by PLGS; 
§
 number of tryptic 
peptides detected by MS; 
$
 Percentage of sequence covered by MS; " average precursor mass error. 
 
3.8.2 Characterization of rBet v 1aS112P/R145P and rGly m 4S111P/L150P 
For a detailed analysis of both, rBet v 1aS112P/R145P and rGly m 4S111P/L150P, 
physicochemical as well as immunological characteristics were evaluated. Firstly, 
secondary and tertiary structures of each allergen were analyzed by CD and 1D-1H-
NMR spectroscopy shown in Figure 30. 
 
Figure 30: Circular dichroism and 1D-
1
H-NMR spectra of rBet v 1aS112P/R145P and rGly m 4S111P/L150P. 
Circular dichroism of rBet v 1a and rBet v 1aS111P/R145P (A) as well as rGly m 4 and rGly m 4S112P/L150P (B). 1D-
1
H-
NMR spectra of 30 µM of rBet v 1a and rBet v 1aS112P/R145P (C) and 40 µM of rGly m 4 and rGly m 4S112P/L150P (D). 
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Both allergens rBet v 1a and rGly m 4 showed typical CD spectra with a high content 
of α-helices and β-sheets as already shown in Figure 22. In contrast respective 
variants indicated different secondary structures. Both rBet v 1aS112P/R145P and 
rGly m 4S111P/L150P showed negative mean residual ellipticities between 240 and 
185 nm with a maximal negative ellipticity at 200 nm, characteristic for unstructured 
proteins. Consistent results were obtained when the tertiary structures of the 
recombinant allergens were analyzed by NMR spectroscopy. rBet v 1a and rGly m 4 
had spectra with a high degree of resonance dispersion resulting from amid 
(6-10 ppm) as well as α- (3.5-6 ppm) and methyl protons (-0.5-1.5 ppm) indicating a 
characteristic Bet v 1-type protein fold for both allergens. Furthermore these proteins 
showed well-separated peaks in overall spectra. In contrast, the spectra recorded 
with rBet v 1aS112P/R145P and rGly m 4S111P/L150P exhibited less peaks with reduced 
dispersion especially in the amide region and no signals from 5.0-6.5 ppm and below 
0.5 ppm which is characteristic for misfolded proteins or unstructured polypeptides 
(Page et al., 2005). Therefore substitutions of S112 and R145 (Bet v 1a) or S111 and 
L150 (Gly m 4) to proline residues disrupted the native protein folds of Bet v 1a and 
Gly m 4, respectively. For analysis of potential protein aggregation, dynamic light 
scattering (DLS) was used to determine the hydrodynamic radii of rBet v 1a and 
rGly m 4 as well as their respective misfolded variants. As already stated in 3.6.1 
rBet v 1a and rGly m 4 had comparable RH of 2.81 ± 0.27 nm (rGly m 4) and 
2.49 ± 0.39 nm (rBet v 1a), respectively. In contrast increased hydrodynamic radii of 
3.10 ± 0.56 nm for rBet v 1aS112P/R145P and 3.54 ± 0.46 nm for rGly m 4S111P/L150P were 
observed, suggesting a more unfolded protein conformation as compared to the wild 
type proteins. The hydrodynamic radii indicated that the proteins did not aggregate 
and were mono-disperse in solution. 
 
3.8.3 IgE binding of misfolded variants 
According to inhibition ELISA analyses with rGly m 4 shown in Figure 27, IgE binding 
avidity was furthermore determined between rGly m 4S111P/L150P and the two pools of 
patients with and without clinical allergy to soy, respectively. Results of inhibition 
ELISA with rGly m 4S111P/L150P is shown in Figure 31. 
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Figure 31: Inhibition of IgE binding to immobilized rGly m 4 with rGly m 4S111P/L150P as inhibitor.  
Binding of IgE antibodies of serum pools generated from 27 subjects with (group 1, positive pool – green) and 
20 subjects without (group 2, negative pool – red) soybean allergy. IgE binding to immobilized rGly m 4 was 
inhibited by increasing concentrations of rGly m 4S111P/L150P in ELISA. All curves were fitted by a 4-parameter, 
logistic sigmoidal curve fit. 
 
rGly m 4S111P/L150P showed EC50 values of 89.73 ± 11.69 ng for positive and 
120.40 ± 17.28 ng for negative serum pool, respectively. Therefore with both serum 
pools a comparable inhibition curve with rGly m 4S111P/L150P as inhibitor was 
observable, similar to the usage of rGly m 4 as inhibitor (see 3.7), indicating no 
differences in avidities regarding both analyzed serum pools. In contrast, a more 
potent inhibition of IgE binding was detected with rGly m 4 compared to 
rGly m 4S111P/L150P (see Figure 27). Overall no potential importance of avidity 
comparing patients with and without soybean allergy was observable with both 
rGly m 4 and rGly m 4S111P/L150P at least in this study population.  
Next, IgE binding characteristics of both misfolded variants rBet v 1aS112P/R145P and 
rGly m 4S111P/L150P were addressed. For this, ten sera of patients with specific IgE 
against Bet v 1a or birch pollen were tested in combination with rBet v 1aS112P/R145P 
variant. ImmunoCAP™ data of the respective patients are shown in Table 20. 
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Table 20: IgE levels determined by ImmunoCAP of ten subjects with sensitization to Bet v 1a or birch 
pollen.  
  IgE (kUA/L) determined by ImmunoCAP™ 
Patient 
No. 
sex Total 
Birch-specific 
(class) 
sIgE Bet v 1 
(class) 
1 f 51 n.d. 21.5 (4) 
2 m 206 n.d. 48.2 (4) 
3 m >5000 n.d. 32.2 (4) 
4 m >5000 n.d. 13.7 (3) 
5 f 138 n.d. 67.3 (5) 
6 f 825.0 >100 (6) n.d. 
7 m 858.0 >100 (6) n.d. 
8 m 498.0 >100 (6) n.d. 
9 f 699.0 >100 (6) n.d. 
10 f 852.0 >100 (6) n.d. 
 
Patient number, sex and levels of total serum IgE, birch- or Bet v 1-specific IgE in kUA/L with resulting CAP class 
shown in brackets. All measurements were performed with a Phadia250 ImmunoCAP™. n.d. – not determined. 
 
All patients showed a level of total IgE between 51 and >5000 kUA/L with a median of 
762 kUA/L. For patients 1-5 level of Bet v 1-specific IgE was determined. These 
subjects are sensitized to Bet v 1 with an median of 32.2 kUA/L and IgE levels 
between 13.7 and 67.3 kUA/L. For remaining five subjects (patients 6-10) specific IgE 
level against birch pollen was determined with >100 kUA/L (CAP class 6) classifying 
them as high responders to birch pollen. All patients (1-10) had a convincing history 
of pollinosis to early flowering tree pollen. At the time of this PhD thesis the detailed 
information on allergic symptoms of patients as well as information on allergic 
reactions to further allergens from food or pollen had not yet been revealed. Analysis 
of IgE binding with rBet v 1aS112P/R145P and birch-sensitized patients in immunoblot is 
shown in Figure 32. 
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Figure 32: rBet v 1a but not rBet v 1aS112P/R145P show IgE binding with birch-allergic patients. 
Ten sera of subjects with birch pollen allergy (lanes 1-10) analyzed in immunoblotting for IgE binding with 
rBet v 1a (A) and rBet v 1aS112P/R145P (B). Control experiments with a serum of a non-allergic patient (lane 11) and 
buffer control (lane 12) are shown as well as detection of Bet v 1-specific IgG antibodies (lane 13). 
 
rBet v 1a but not rBet v 1aS112P/R145P was able to bind serum IgE from patients 1-10 in 
immunoblot analysis. Therefore native protein conformation was necessary for IgE 
binding at least with tested serum samples and misfolded protein conformation of 
rBet v 1aS112P/R145P might cause hindrance of interaction with IgE due to changes in 
existing IgE epitopes. As expected no IgE binding with both proteins was observable 
with serum of a non-allergic patient and buffer control with no serum used. Both 
rBet v 1a and rBet v 1aS112P/R145P were able to bind polyclonal Bet v 1-specific IgG in 
comparable intensity. This verifies the ability of rBet v 1aS112P/R145P to generally 
interact with immunoglobulin antibodies. Analysis with Bet v 1-specific IgG antibody 
revealed an additional signal below 18 kDa representing a degradation product of 
rBet v 1aS112P/R145P. In addition to patients sensitized only to Bet v 1a and/or birch 
pollen allergen 36 subjects (groups 1 and 2), which were already analyzed with NCS 
and rGly m 4 proteins, were tested for IgE binding with rBet v 1aS112P/R145P and 
rGly m 4S111P/L150P. In Figure 33 examples of nine patients are shown. 
3 Results    105 
 
 
Figure 33: IgE binding of rGly m 4 and rBet v 1a variants. 
Five representative patients sensitized and soy allergic (A) as well as four representative patients sensitized but 
without soybean allergy (B) and purchased DLab71S serum from a subject with birch and soy sensitization (C) 
were analyzed in immunoblot with rGly m 4, rGly m 4S111P/L150P and rBet v 1aS112P/R145P. Number of each patient is 
indicated below each blot. 
 
As already shown in 3.1 and 3.6.3 most patients of both groups showed IgE binding 
with rGly m 4. Different binding characteristics were observed in patients with and 
without soybean allergy concerning both misfolded variants. Some patients of 
group 1 (No. 2, 8, 9, 13, 33, 34 and 37) and group 2 (No. 20, 25, 45, 46 and 48) 
exhibited IgE binding with only rBet v 1aS112P/R145P or rGly m 4S111P/L150P. In contrast 
both misfolded variants bound serum IgE in 59% (13/22) of subjects with and in 
50% (7/14) of subjects without soy allergy. Only patients 7 and 40 from group 1 and 
patient 24 from group 2 had IgE binding only with rGly m 4 and neither with 
rBet v 1aS112P/R145P nor rGly m 4S111P/L150P. Therefore both misfolded variants were still 
able to bind IgE antibodies but binding was dependent on subject’s specific IgE 
antibody repertoire. Patient 44 from group 2 only had serum IgE against 
rBet v 1aS112P/R145P but showed no IgE binding with rGly m 4 and rGly m 4S111P/L150P. 
Table 21 lists the results of immunoblots with sera of both groups of patients and 
both misfolded allergen variants. In addition a commercially available serum of a 
subject sensitized against Gly m 4 and Bet v 1 (DLab71S) was tested showing IgE 
interaction with rGly m 4 and rGly m 4S111P/L150P but not with rBet v 1aS112P/R145P. 
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Table 21: Summary of IgE binding with misfolded variants of rGly m 4 and rBet v 1a.  
 No. rGly m 4 
rGly m 4 
S111P/L150P 
rBet v 1a 
S112P/R145P 
No. rGly m 4 
rGly m 4 
S111P/L150P 
rBet v 1a 
S112P/R145P 
G
ro
u
p
 1
 
1 X X X 22 X X X 
2 X  X 28 X X X 
3 X X X 30 X X X 
4 X X X 33 X X  
5 X X X 34 X X  
7 X   35 X X X 
8 X X  36 X X X 
9 X X  37 X X  
10 X X X 38 X X X 
11 X X X 40 X   
13 X  X 41 X X X 
G
ro
u
p
 2
 
16 X X X 44   X 
20 X  X 45 X X  
24 X   46 X X  
25 X X  47 X X X 
26 X X X 48 X X  
27 X X X 49 X X X 
43 X X X 50 x X X 
 
Sera of patients with (22 subjects, group 1) and without (14 subjects, group 2) soybean allergy were analyzed in 
immunoblots with rGly m 4, rGly m 4S111P/L150P and rBet v 1aS112P/R145P. Detected IgE binding is marked with (X). 
 
3.8.4 Analysis of different molar ratios of misfolded variants 
Because of different results obtained with folded and misfolded variants concerning 
IgE binding the impact of misfolded allergen on interaction with IgE was studied in 
more detail. For this, mixtures with defined molar ratios of rBet v 1a and 
rBet v 1aS112P/R145P or rGly m 4 and rGly m 4S111P/L150P were tested for their IgE 
binding characteristics. Results of physicochemical and immunobiological assays can 
then be transferred to purified allergen preparations used in diagnosis and therapy of 
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birch/soy allergy. During the purification process of a recombinant protein often an 
unknown ratio of misfolded protein might be generated in parallel not able to bind IgE 
compared to native-folded protein. Therefore, to ensure suitability and stability of 
allergen preparations it is important to verify the extent of misfolded protein and 
associated changes in IgE binding characteristics. For each rBet v 1a and 
rBet v 1aS112P/R145P three protein preparations were used to generate three 
independent combinations between both allergens. For rGly m 4 and respective 
variant rGly m 4S111P/L150P only one combination was used.  
First, mixtures of folded and misfolded allergens of rBet v 1a and rGly m 4 were 
analyzed in CD spectroscopy. Ratios from 100% to 0.01% of misfolded variant were 
measured with a total number of ten and 14 molar ratios of rBet v 1a and rGly m 4, 
respectively. In Figure 34 CD spectra of rBet v 1a (A) and rGly m 4 (B) as well as 
changes at characteristic wave lengths are shown. 
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Figure 34: Circular dichroism of different molar ratios of rBet v 1a and rGly m 4 with their respective 
misfolded variants. 
Spectra of combinations between rBet v 1a and rBet v 1aS112P/R145P (A) as well as rGly m 4 and 
rGly m 4S111P/L150P (B) are shown. For rBet v 1a ten and for rGly m 4 14 combinations from 0% to 100% 
rBet v 1aS112P/R145P or rGly m 4S111P/L150P were measured, respectively. Mean residual ellipticities at 193 nm, 
195 nm, 200 nm, 218 nm and 222 nm are indicated for rBet v 1a and rGly m 4 with 95% confidence interval and 
statistical evaluations for measurements with rBet v 1a which were performed in three individual allergen 
combinations. 
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With increasing ratio of misfolded variant, spectra of both allergens changed from 
Bet v 1-type to one characteristic for unstructured proteins. Mixtures of 
rBet v1a/rBet v 1aS112P/R145P and rGly m 4/rGly m 4S111P/L150P both showed an 
isodichroic point at about 208 nm. For detailed analysis specific wavelengths 
characteristic for secondary structure elements were examined. 193 nm and 222 nm 
with positive and negative bands in α-helical proteins as well as 195 and 218 nm 
characteristic for positive and negative ellipticities in β-sheets were analyzed 
(Holzwarth & Doty, 1965; Greenfield & Fasman, 1969). In addition wave length at 
200 nm showing negative bands characteristic of both misfolded variants was used 
(Venyaminov et al., 1993). An increase (193, 195, 200 nm) or decrease (218, 
222 nm) with increasing ratio of well-folded allergen was observable in both allergen 
combinations. For rBet v 1a mixtures a comparison between actual and theoretical 
measurements was possible. Measured ellipticities at analyzed characteristic wave 
lengths correlated well with those of theoretical combinations, at least from 100% to 
10% of rBet v 1a. Below 10% of rBet v 1a only low correlation of actual-theoretical 
comparison is observable. Statistical analysis of rBet v 1a combinations revealed that 
mixtures containing 60% of rBet v 1aS112P/R145P could be resolved from 100% 
rBet v 1a at wave lengths 193, 195, 200 and 218 nm with 95% confidence interval. At 
222 nm however only 40% of rBet v 1aS112P/R145P was well-separated from 100% 
rBet v 1a. Due to analysis of only one combination between rGly m 4 and 
rGly m 4S111P/L150P no comparison of actual/theoretical values and statistical 
evaluation was possible.  
Combinations of both rBet v 1a/rBet v 1aS112P/R145P and rGly m 4/rGly m 4S111P/L150P 
were further analyzed for IgE binding in immunoblots. For rBet v 1a a pool of ten 
subjects (see Table 20) was used while DLab71S serum (see Figure 33) was applied 
for rGly m 4. Results of both immunochemical analyses are shown in Figure 35. 
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Figure 35: Increasing ratios of misfolded variants show a decrease in IgE binding in both rBet v 1a and 
rGly m 4 combinations. 
Immunoblot of ten mixtures of rBet v 1a/rBet v 1aS112P/R145P (A) and 14 combinations between 
rGly m 4/rGly m 4S111P/L150P (B) were analyzed with pool serum of ten patients and DLab71S serum, respectively. 
Increasing ratios of each misfolded variant were transferred and Ponceau S stained. Chemiluminescence after 
100 ms and 2 min for rBet v 1a and 20 s for rGly m 4 are shown.  
 
With increasing ratio of misfolded variants a decrease of IgE binding is observable in 
both rBet v 1a and rGly m 4 mixtures, as expected. However, a difference in IgE 
signals was found at 100% of rBet v 1aS112P/R145P and rGly m 4S111P/L150P, respectively. 
Concerning the pool of sera no IgE binding could be detected at 100% of 
rBet v 1aS112P/R145P confirming results of immunoblot with each individual serum 
alone. In contrast 100% rGly m 4S111P/L150P showed residual IgE binding. This also 
verifies the results obtained earlier (see 3.8.3) where DLab71S serum showed IgE 
binding with both rGly m 4 and rGly m 4S111P/L150P. Comparison of actual and 
theoretical data for rBet v 1a mixtures revealed an over-interpreted signal of IgE 
binding especially at ratios of rBet v 1a ≤ 1%.  
IgE binding of different molar ratios of rBet v 1a and rBet v 1aS112P/R145P was 
furthermore analyzed in ELISA experiments shown in Figure 36. 
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Figure 36: Increasing ratio of rBet v 1aS112P/R145P causes a decrease in inhibition of IgE binding.  
Binding of IgE antibodies from a serum pool of ten subjects (see Table 20) to immobilized rBet v 1a was inhibited 
by different concentrations of mixtures between rBet v 1a and rBet v 1aS112P/R145P in ELISA. All curves were fitted 
by a 4-paramter, logistic sigmoidal curve fit with same slope as well as same lower and upper asymptote. 
 
As expected from previous results in immunoblot experiments rBet v 1a but not 
rBet v 1aS112P/R145P is able to inhibit IgE binding with rBet v 1a. Combinations of both 
allergens showed a concentration-dependent decrease in inhibition of IgE binding 
verified by a shift in half-maximal inhibition (EC50). Each curve was fitted with a 
4-parameter logistic model assuming sigmoidal curve fit with same lower and higher 
asymptote. Estimated common slope was 0.91 with a 95% confidence interval of 
0.85-0.96. Comparison between actual an theoretical EC50 values were between 1.09 
at 20% rBet v 1aS112P/R145P and 0.29 at 99.9% rBet v 1aS112P/R145P. No correlation 
could be determined at concentrations of 99.99% and 100% rBet v 1aS112P/R145P due 
to non-evaluable inhibition curves.  
Next, a cellular system using humanized rat basophil leukaemia (RBL) cells was 
used to determine the biological activity of different molar ratios of rBet v 1a and 
rBet v 1aS112P/R145P. With RBL cell release assay the release of mediator molecules of 
cells sensitized with serum IgE can be measured in correlation to added allergen. 
Resulting release curves are shown in Figure 37. 
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Figure 37: Increasing concentrations of rBet v 1aS112P/R145P cause a reduction in release of mediator 
molecules in rat basophil leukaemia cells.  
Humanized rat basophil leukaemia cells were sensitized with the pool of ten subjects showing IgE against 
rBet v 1a and/or birch pollen. Release of β-hexosaminidase molecules was determined dependent on 
concentration of different ratios between rBet v 1a and rBet v 1aS112P/R145P causing a cross-linking of membrane-
bound IgE molecules.  
 
Again EC50 values for each combination of rBet v 1a and rBet v 1aS112P/R145P were 
measured and compared with theoretical values. Overall, a release of mediator 
molecules was observable at concentrations of 100% to 1% rBet v 1a. Hereby actual-
theoretical values ranged from 0.86 to 1.32 (80-1% rBet v 1a). No reliable release 
could be determined at ratios of 0.1% rBet v 1a and below. No significant differences 
could be observed between the EC50 values for 100% rBet v 1a and all 
rBet v 1a/rBet v 1aS112P/R145P compositional protein preparations. According to a 
confidence interval of 95% only the rBet v 1a/rBet v 1aS112P/R145P protein combination 
containing 1% rBet v 1a resolved analytically from the mediator release obtained with 
100% rBet v 1a.  
Finally, actual/theoretical values of CD spectroscopy, immunoblot, ELISA and RBL 
cell release assay were compared for rBet v 1a/rBet v 1aS112P/R145P ratios between 
10-100% rBet v 1a (Figure 38).  
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Figure 38: Summary of actual/theoretical comparisons in CD, immunoblot, ELISA and RBL cell release. 
Values of actual/theoretical measurements concerning different molar ratios between rBet v 1a and 
rBet v 1aS112P/R145P from 10% to 100% rBet v 1a are shown. Dotted line indicates identical actual/theoretical 
values. 
 
Values for actual/theoretical comparison were comparable between CD spectroscopy 
at 218 nm and ELISA with underestimation especially at concentrations ≤20% 
rBet v 1a. In contrast, results of immunoblot analysis showed overestimated values at 
ratios of ≤40% rBet v 1a but a good actual/theoretical correlation at high amounts of 
rBet v 1a. Weakest correlation between actual and theoretical values was found in 
RBL cell release assay with underestimation increasing from 80% to 10% of 
rBet v 1a. Overall, a large variation especially in measurements with concentrations 
below 10% of rBet v 1a was observable. Total values are 0.86 for CD spectroscopy 
at a wavelength of 218 nm, 1.74 for immunoblotting, 0.72 for ELISA and 0.3 for RBL 
cell release assay. Values for all actual-theoretical comparisons for each assay are 
shown in Table A 4 in the appendix. 
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4 DISCUSSION 
4.1 Correlation of serum antibody levels and clinical phenotype 
After thorough anamnesis and skin prick tests, measurement of allergen-specific 
serum IgE level is often the first immunological parameter to be determined in allergy 
diagnosis. Patient’s serum is analyzed with a standardized assay like ImmunoCAP™ 
or any related test system. Often the resulting quantitative allergen-specific IgE levels 
are correlated directly with the respective allergy and even with the severity of allergic 
symptoms (Sampson & Ho, 1997; Sampson, 2001). However, a direct link between 
IgE level and clinically confirmed allergy remains controversial (Asero et al., 2007; 
Guhsl et al., 2015). Recently it has been shown that IgE levels specific for Bet v 1-
related allergen Mal d 1 which causes birch-related allergy to apples do not correlate 
with allergic symptoms (Ebo et al., 2010). Nevertheless a proper diagnosis of the 
allergy is indispensable to avoid putative unnecessary medication or restrictions in 
the patient’s life. Furthermore the level of allergen-specific IgG4 antibodies in sera of 
patients receiving SIT is often accompanied with a reduction of allergic symptoms 
due to blocking of IgE-mediated allergic symptoms (Tomicić et al., 2009).   
In this study the IgE and total IgG levels specific for Bet v 1, Gly m 4, Gly m 5 and 
Gly m 6 in sera of patients with and without clinically confirmed soybean allergy were 
determined to analyze a possible correlation between serum antibody levels and 
allergy (see 3.1). A total number of 47 patients sensitized to Gly m 4 and allergic to 
birch pollen were included in the study. 27 subjects (group 1) showed mild to severe 
symptoms after soybean consumption and 20 patients (group 2) were sensitized to 
Gly m 4 but not allergic to soy, as confirmed by provocation testing.  
In ImmunoCAP™ analysis two patients (No. 34 and 48) did not have sIgE to Bet v 1 
or Gly m 4 despite a diagnosed birch pollen allergy. For patient 34 a true relationship 
between birch and soy allergy was already questioned (Kleine-Tebbe et al., 2002). In 
addition patient 48 had no IgE against Gly m 4 or Bet v 1 but had been clinically 
characterized as allergic to soy. ImmunoCAP™ data of residual 45 patients were 
characteristic for subjects with birch pollen allergy showing sIgE levels for the major 
allergen of birch Bet v 1 ≥CAP class 3. Furthermore these patients had sIgE against 
soybean allergen Gly m 4. Therefore, irrespective of clinical symptoms after soy 
consumption, majority of patients were sensitized to both allergens. This is a 
common phenomenon as allergen-specific IgE per se does not indicate clinical 
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relevance of a sensitization (Guhsl et al., 2015). Nevertheless some controversial 
studies about a potential correlation between severity of symptoms and allergen-
specific IgE levels are discussed. In contrast to birch-related allergy to apple where 
no correlation between specific IgE levels and the severity of symptoms was found, 
allergic reactions in peanut allergy correlate well with specific IgE level (Sampson & 
Ho, 1997; Sampson, 2001; Asero et al., 2007).   
Only one patient of the study group had low levels of sIgE directed against Gly m 5 
and Gly m 6 but high levels of Bet v 1- and Gly m 4-specific IgE, suggesting a birch-
related soy allergy rather than a class I soybean allergy. Therefore symptoms after 
DBPCFC with soybean can be linked to a pollen-related soybean allergy rather than 
a classical allergy to soy. Comparing the median levels of sIgE, patients of group 1 
had higher levels of sIgE against both Bet v 1 (37.0 kUA/L) and Gly m 4 (9.3 kUA/L) 
compared to 29.6 kUA/L for Bet v 1 and 4.5 kUA/L for Gly m 4 in subjects merely 
sensitized but without clinical soy allergy. In contrast, in both groups sIgE levels 
ranging from 0 to >100 kUA/L for Bet v 1 and Gly m 4 were observed. Concerning 
presence and level of sIgE directed against Bet v 1 and Gly m 4 no difference in both 
groups of patients was observable. These observations confirmed that a birch-related 
soybean allergy cannot be diagnosed based on allergen-specific IgE against Gly m 4 
only. Furthermore 70% of subjects from group 1 had severe symptoms like dyspnea, 
flush, face swelling, throat tightness or urticaria after soybean consumption but sIgE 
levels did not correlate with severity of allergic symptoms. Patients with high levels of 
sIgE against Gly m 4 (46.3 kUA/L, patient 2) had mild symptoms like OAS, whereas 
subjects with a relatively low amount of Gly m 4-specific IgE (4.0 kUA/L, patient 33) 
exhibited severe reactions like face swelling and throat tightness. Similar results were 
shown in birch-related apple allergy, were no correlation between sIgE and the 
severity of allergic symptoms after apple consumption was observed (Ebo et al., 
2010). Until today the results of several studies performed to differentiate between 
patients with and without birch pollen-allergic food allergy by measurement of 
allergen-specific IgE remain controversial (Reuter et al., 2006; Asero et al., 2007; 
Hansen et al., 2009; Ebo et al., 2010; Ballmer-Weber et al., 2012; Tolkki et al., 2013; 
Guhsl et al., 2015).  
Furthermore IgE immunoblotting was performed as basic and serum-saving method 
to screen all patients of the study population in a short period of time. Major 
drawback of immunoblot compared to ELISA experiments is the use of denatured 
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allergens but for IgE binding to rGly m 4 a native protein conformation is required and 
therefore only properly refolded allergens are detected via immunoblot. Results 
obtained by ImmunoCAP™ were in line with allergen profiles generated by 
immunoblots. Again there was no correlation between the presence of birch-related 
soy allergy and Gly m 4-specific IgE antibodies. This was already shown by Ballmer-
Weber et al. where no correlation between symptoms and IgE immunoblotting results 
was detected in birch-soy allergy (Ballmer-Weber et al., 2007). In total 83% (30/36) of 
patients from groups 1 and 2 showed IgE binding to rGly m 4 in immunoblot. 
Residual six patients exhibited low Gly m 4-specific IgE levels according to 
ImmunoCAP™ with no (subjects 25, 45, 46, 48 and 49) or mild (patient 34) 
symptoms upon consumption of soy. It is conceivable that the Gly m 4-specific IgE 
levels of the sera of these patients were below the detection limit of the immunoblot 
system used. These results indicate the potential of a more sensitive analysis of IgE 
levels with ImmunoCAP™ compared to immunoblot using recombinant allergens 
which was already demonstrated by Mittag et al. (Mittag et al., 2004b). Nevertheless, 
presence of IgE antibodies directed against Gly m 4 in both assays does not 
necessarily refer to a birch-related soybean allergy. Thus the evaluation of Gly m 4-
specific IgE levels per se is not recommended as diagnostic tool for birch-related 
soybean allergy. However, quantitative rGly m 4-specific IgE signals obtained by 
immunoblot analysis correspond with the IgE levels determined in ImmunoCAP™. 
In immunoblots a complex pattern of different IgE-binding proteins was observed 
when analyzing soy extract. These signals refer to at least 18 different known IgE-
binding proteins present in soybean extract. To date only Gly m 1 to Gly m 8 are 
accepted as allergens by IUIS. Patients might have IgE antibodies against multimeric 
soy seed storage proteins Gly m 5 or Gly m 6 which have a monomeric molecular 
weight in the range of 50-70 kDa and could be measured at least in small amounts 
(between 0 and 0.35 kUA/l) in ImmunoCAP™. Furthermore presence of antibodies 
directed against cross-reactive carbohydrate determinants (CCD), carbohydrate 
moieties of allergenic molecules, which might be able to induce an allergic response, 
are possible. Availability of such antibodies might be verified with western blot 
inhibition experiments or specific ImmunoCAP™ measurements. Furthermore 
ImmunoCAP™ performed with soybean extract might be used, for example with 
patients 5, 40, 41 and 43, to measure IgE binding to other proteins than only Gly m 4. 
In total, IgE binding patterns to soy proteins of subjects from both groups are very 
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individual and complex without any correlation to the severity of allergic reactions. 
Again several patients with sensitization to Gly m 4, as determined by 
ImmunoCAP™, did not show an IgE signal representing Gly m 4 in immunoblot using 
soy extract. This might be caused by the low amount of Gly m 4 protein present in 
soybean extract as already determined by Mittag et al. using soybean ImmunoCAP™ 
analyses (Mittag et al., 2004b).  
Both groups of patients had comparable levels of total Gly m 4-specific IgG as 
determined in ImmunoCAP™. Neither a correlation of sIgE levels nor Gly m 4-
specific IgG levels and clinical reactivity to soybean was observed. Highest level of 
IgG directed against Gly m 4 was found in a patient of group 2 (patient 16) without 
symptoms to soy. This is in line with findings that IgG antibodies might act as 
blocking antibodies inhibiting allergen-IgE binding causing no/mild allergic symptoms 
(James et al., 2011; Jutel et al., 2013). Patients with mild symptoms like OAS might 
have high or low Gly m 4-specific IgG levels of 36.9 mgA/L (patient 11) and 7.3 mgA/L 
(patient 2). These Gly m 4-specific IgG levels were also observed in sera of patients 
exhibiting severe reactions to soy. Patient 37 with 35.8 mgA/L of Gly m 4-specific IgG 
exhibited dyspnea while patient 28 with only 8.0 mgA/L sIgG showed face swelling 
after soy consumption. For a thorough allergen profile, measurement of IgG4 levels 
for both Bet v 1 and Gly m 4 is necessary. Recently it was shown that ratios between 
IgG4 and IgE in Bet v 1-related food allergens correlate with tolerance to several 
foods (Geroldinger-Simic et al., 2011). Therefore analysis of correlation between IgG4 
level or IgG4/IgE ratio and allergic symptoms might be interesting in birch-related soy 
allergy. Nevertheless influence of IgG4 in outbreak and severity of allergies remains 
controversial as in 2015, Guhsl et al. reported a comparable level of IgG4 and 
IgG4/IgE ratio in patients with and without soybean allergy while an increase in sIgG4 
levels during SIT is often observed in successful immunotherapy (Guhsl et al., 2015). 
 
4.2 Generation of a preliminary epitope profile of Gly m 4 
For the identification of IgE epitopes a variety of different approaches and methods 
have been used to date. Briefly, these methods differ mainly in their effort, 
bioinformatical content, costs and output data. In this study, a combination of 
experimental and bioinformatically-based methods were used to identify putative IgE 
epitopes of Gly m 4. 
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4.2.1 Identification of candidate residues involved in IgE binding 
Before distinct IgE epitope profiles can be determined properly, candidate residues 
which might dominate the energetic of allergen-antibody binding (functional epitope) 
need to be identified to generate a preliminary epitope profile (Dall'Acqua et al., 
1998). This concept was already proven by changing few surface-exposed residues 
in a non-IgE-binding protein with structural homology to Bet v 1 to a cross-reactive 
binding site for IgE (Berkner et al., 2014). Such residues may be located all over 
Gly m 4 amino acid sequence making a thorough analysis of Gly m 4 necessary. This 
was carried out by a combination of experimental and theoretical approaches (see 
3.2).  
Phage-display technology is an experimental-based method to identify antibody-
binding peptides by usage of a phage-displayed peptide library. Phage-display was 
used successfully with several allergens like Ara h 1, Ara h 8, Bet v 1, Gly m 4 or 
Pru av 1 (Mittag et al., 2006; Bøgh et al., 2014). Based on an established protocol, 
described by Mittag et al., phage-display and competitive immunoscreening with 
rGly m 4 was performed (see 3.2.1) (Mittag et al., 2006). However analysis of the 
data always revealed a minimum of 20% of false-positives, which are eluted phages 
without any presented peptide. Such phages are present with a ratio of 10% in 
commercially available library, as stated by manufacturer, but should not be eluted by 
Gly m 4-specific elution because an inserted peptide is a prerequisite for binding of 
phages to the IgE antibody molecule. For an increase in specificity of eluted phages 
several modifications were included in the established protocol. But neither an 
increased number of washing steps nor the usage of different washing and blocking 
buffers containing additional Tween20 and/or BSA reduced number of unspecifically 
eluted phages. Furthermore additional controls were performed by amplification and 
growth on IPTG/Xgal-plates to check for the presence of unspecifically eluted 
phages. Finally, negative selection process, where amplified phages after competitive 
elution with rGly m 4 were incubated with magnetic beads and anti-human IgE-
coupled beads to remove unspecific phages was introduced. Despite these 
modifications in phage-display protocol the total number of false-positives could not 
be reduced. Furthermore false-positives were also observed when buffer or a non-
atopic serum control instead of a serum containing Gly m 4-specific IgE antibodies 
was used. This indicates an unspecific interaction of phages with any of the materials 
used in experimental setup. Possible unspecific binding of phages might occur with 
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magnetic beads or anti-IgE antibodies. According to this, the phage-display approach 
was no longer pursued. Nevertheless published Gly m 4-based mimotope data from 
Mittag et al. were used for the identification of candidate residues (Mittag et al., 
2006).  
These mimotopes were compared with results obtained by a theoretical 
bioinformatical approach where overlapping 7mer peptides representing total amino 
acid sequence of Gly m 4 were mapped onto allergen’s molecular surface 
(see 3.2.1). Mimotopes are peptides that bind antibodies and thus mimic at least in 
part a conformational epitope of an antigen. In both approaches peptides were used, 
either identified experimentally via phage-display or based on amino acid sequence, 
as input data followed by usage of EpiSearch algorithm to map the peptide sequence 
onto the molecular surface of the allergen (Negi & Braun, 2009). Usage of linear 
peptides is currently performed in epitope analysis for identification of linear IgE-
binding sites (Reese et al., 2001; Shreffler et al., 2005; Vereda et al., 2010). 
Nevertheless even conformational IgE epitopes often show stretches of amino acids 
which are adjacent in primary sequence of the allergen. Therefore mapping of linear 
peptides might lead to the identification of putative conformational epitopes as well. 
This is in line with the mechanism of allergic response where the allergen is digested 
during gastrointestinal uptake into small peptides which are then presented e. g. on 
the surface of dendritic cells interacting with T cells resulting finally in an allergic 
response. Both approaches resulted in largely overlapping putative epitopes with 
center residues 29, 30, 37, 94, 119 and 150 identified most frequently and with a total 
number of 8-17 amino acids of each predicted epitope. For a further analysis of 
Gly m 4-specific IgE epitopes single residues rather than mimotopes were used to 
analyze specific amino acids potentially involved in IgE binding. Such functional 
epitopes dominate the energetics of allergen-IgE binding and substitution of a single 
residue might have a tremendous effect on interaction with antibody. Together a total 
number of 69 amino acids with potential impact on IgE binding was identified as 
candidate residues using both approaches.  
In an additional analysis all residues of Gly m 4 were considered for potential IgE-
binding ability theoretically (see 3.2.2). This was done using several inclusion criteria 
to choose only residues with potential relevance for IgE binding. Together with 
69 candidate residues identified by experimental/theoretical screening as well as 
already published data of potential IgE-binding residues of Bet v 1 a resulting number 
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of 51 amino acids were chosen. Most of identified candidate residues showed a side 
chain with either charged or functional groups enabling for potential molecular 
interactions. Therefore especially aspartate, glutamate but also lysines were chosen. 
Lysine with its long side chain might act as an anchor by making the first contact with 
IgE antibodies. Furthermore amino acids with hydroxyl-, amino-groups or aromatic 
rings located on side chains were identified as putative IgE-binding residues. 
Candidate residues were distributed over the complete protein structure. The 
mechanism of effector cell activation in type I allergy requires at least two distinct IgE 
epitopes being present on Gly m 4 allowing simultaneous binding of two different IgE 
molecules for cross-linkage of the FCεRI receptor via allergen. Therefore the 
complete protein surface of Gly m 4 was considered to identify all possible putative 
IgE-binding sites. Within both approaches amino acids might be identified as 
candidate residues e. g. because of a characteristic side chain with potential 
importance for antibody binding, but with only a minor role in actual allergen-IgE 
interaction. Nevertheless all candidate residues need to be considered to minimize 
the risk of missing any putative binding site. False-positive candidate residues can be 
identified and removed by the next step in this analysis where each single amino acid 
is checked individually for its potential IgE binding in the context of a properly folded 
protein structure.  
 
4.2.2 Generation of a NCS-based protein library 
In this study, epitope grafting was used to test whether specific amino acids of 
Gly m 4 are critical for binding of IgE antibodies. Epitope grafting in the context of this 
study describes the transfer of putative or known antibody-binding sites from Gly m 4 
to the Gly m 4-type non-allergenic recombinant derivative of norcoclaurine 
synthase (NCS) from meadow rue (see 3.3). NCS exhibits no/low binding of Bet v 1-
specific serum IgE while being structurally homologous to Bet v 1 and Gly m 4 
(Berkner et al., 2014). If NCS variants presenting Gly m 4-specific amino acids bind 
IgE, the grafted residues are most likely critical for the interaction with IgE antibodies. 
Here I used a C- and N-terminally truncated variant of native NCS (Δ51NCSN42/P49, 
Nürnberg, 2014, Master thesis) with an internal deletion of 22 amino acids and an 
insertion and substitution of two amino acids to ensure a PR10 protein-type length of 
160 amino acids and secondary/tertiary structure. To date, the only known IgE 
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epitope of Gly m 4 was identified by epitope grafting using a variant of the NCS 
model protein that presented an epitope which is recognized by the Bet v 1-specific 
murine monoclonal antibody BV16 (Mirza et al., 2000; Berkner et al., 2014). 
Therefore, only individual candidate residues of Gly m 4 were grafted onto NCS. In 
this experimental setup individual amino acids of Gly m 4 which dominate the 
energetics of allergen-IgE binding within a structural epitope (functional epitopes) can 
be identified and analyzed. Thus, these grafted amino acids might mimic an antibody-
binding site of Gly m 4 inducing specific binding of serum IgE with model protein 
NCS. Nevertheless these single residues do not bind an IgE antibody alone but might 
adapt the surrounding molecular surface of NCS to a more Gly m 4-type binding site 
enabling the interaction of NCS variants with IgE antibodies. Epitope grafting onto a 
non-antibody binding allergen-type model protein is superior to classical mutational 
epitope analysis of the allergenic protein, as it circumvents a polyclonal IgE response 
which might mask the impact of individual epitopes with low antibody binding 
frequency. For epitope grafting a detailed structural overlay of both proteins, NCS 
and Gly m 4, was required to identify structurally homologous residues that might be 
suitable as candidates for a comprehensive epitope analysis of Gly m 4.  
 
4.3 Screening of NCS library 
To identify functional IgE epitopes, variants from a NCS protein library were used for 
a systematic and comprehensive epitope analysis (see 3.4). With this initial 
screening, it is possible to identify NCS variants with IgE-binding characteristics 
which can be characterized in a more detailed analysis using purified NCS variants 
afterwards. In this study, screening of non-purified inclusion bodies of NCS variants 
was performed in immunoblot, suitable for screening of 48 variants together with sera 
of 47 patients with (27 subjects) and without (20 subjects) soybean allergy 
(see 3.4.2). Assuming that recombinant NCS variants show correct refolding and 
therefore Bet v 1-type protein conformation, observed IgE binding directly correlates 
with the substitutions of Gly m 4-specific amino acids. Whenever a single residue 
within an epitope dominates the energetic of binding to serum IgE, this particular 
amino acid might act as a functional epitope for IgE. In Dall’Acqua et al. this concept 
of functional epitopes was described the other way round, where a structural epitope 
comprising 12 amino acids of lysozyme interacting with an antibody fragment was 
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determined and with a thorough analysis using single variants of lysozyme showing 
individual substitutions in this structural epitope, two residues, namely Q121 and 
R125, could be identified as those amino acids energetically critical for antibody 
binding (Dall'Acqua et al., 1998). This observation justifies the use of Gly m 4-specific 
NCS variants to identify and analyze functional epitopes of Gly m 4. Major drawback 
of immunoblot compared to ELISA experiments is the use of denatured allergens but 
for IgE binding to rGly m 4 a native protein conformation is required and therefore 
only properly refolded allergens are detected via immunoblot 
 
4.3.1 Characterization of identified potential functional IgE epitopes 
In total 46 putative functional IgE epitopes were identified via immunoblot analysis 
(see 3.4.2). Using immunoblot together with inclusion bodies of expressed NCS 
variants a reliable and time-saving initial screening of all sera/NCS variants 
combinations was possible. As IgE binding requires native protein conformation only 
NCS variants which were able to properly refold into Bet v 1-type conformation upon 
SDS-PAGE and subsequent transfer to nitrocellulose membrane were detected. 
Consequently some differences in serum IgE binding due to an increased variability 
of blotted allergens or difficult evaluation of positive/negative signals in immunoblot of 
NCS variants as well as NCS model protein might occur but usage of immunoblot as 
initial experiment is justified because identified putative functional epitopes were 
critically analyzed via purified NCS variants using dot blot (see 3.5.2) and ELISA 
(see 3.5.3) afterwards. In addition inhibition experiments might be useful to verify 
Gly m 4 specificities of IgE signals, as single amino acid substitutions in NCS 
theoretically could result in binding of IgE antibodies directed against further 
allergens present in patient’s serum (e. g. allergens directed against house dust 
mite). Taken together immunoblot analysis represents the most straight forward and 
crude approach considering a careful interpretation of observed IgE signals and a 
cautious analysis of obtained results via control experiments. Overall, selection of 
candidate residues by mapping of mimotopes and rational mutagenesis represented 
a suitable approach for identification of putative IgE-binding functional epitopes.  
Only grafted residues E95/K96 and D140 did not induce IgE binding in any of the 
patients’ sera analyzed. 50% of identified putative functional IgE epitopes are 
Gly m 4-specific amino acids that are not found in Bet v 1a. Gly m 4-specific residues 
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are distributed over the molecular complete surface of Gly m 4. For initial contact 
between IgE and allergen, Gly m 4-specific residues but also residues identical in 
Gly m 4 and Bet v 1a can act as anchor to initiate IgE binding. Nevertheless 
distribution of Gly m 4-specific functional IgE epitopes indicates that IgE epitope 
patches might not be composed only by Gly m 4-specific residues. IgE interaction 
sites on Gly m 4 are more likely composed of both, Gly m 4-specific and 
Bet v 1a/Gly m 4-homologous residues. This is in line with the course of the allergic 
disease, where sensitization to Gly m 4 does not occur in patients without prior birch 
pollen sensitization. Patients with soybean allergy showed an average of 21 
compared to 18 putative functional epitopes identified for subjects without allergic 
symptoms to soy. In addition to a slightly increased average number of potential 
functional IgE epitopes, patients with clinically confirmed soybean allergy also 
presented an increased range in putative functional epitopes. This is 12-32 compared 
to 14-26 putative functional epitopes in patients without soy allergy. From this a 
potential correlation between number of functional IgE epitopes and clinical reactivity 
might exist although differences between both groups are relatively small. Only three 
putative functional epitopes were identified individually with one group of patients. 
Grafted residues D92/T93 and E147 showed IgE binding solely with three patients 
having soybean allergy. In contrast N108 only gave IgE signal together with one 
serum of subjects sensitized but not soy allergic. Nevertheless relevance of these 
group-specific residues needs to be further evaluated. Both, D92/T93 and E147 are 
conserved in Bet v 1a, while N108 is only present in Gly m 4. D92 and T93 were 
already identified as parts of IgE-binding Bet v 1a peptides (Gieras et al., 2011). 
E147 belongs to a putative epitope of Bet v 1a interacting with a monoclonal antibody 
(Jahn-Schmid et al., 2005; Hecker et al., 2012). Furthermore D92, T93 and E147 
belong to different mimotopes identified by Mittag et al. (Mittag et al., 2006). N108 
was reported by Ganglberger et al. as part of an IgE epitope of Bet v 1 identified 
using mimotopes from a phage library (Ganglberger et al., 2001). Besides this, no 
characteristics for the two groups of patients could be found concerning occurrence 
of potential functional epitopes. Rather, each patient showed an individual pattern of 
identified putative functional IgE epitopes.   
Regarding subjects with soybean allergy no correlation between any putative 
functional epitopes or their total number and clinical symptoms could be found. 
Patients 9 and 11, both exhibiting OAS after soybean consumption differed markedly 
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regarding total number of IgE signals, with 26 and 14 different potential identified 
functional IgE epitopes, respectively. Subjects with severe symptoms like dyspnea 
and urticaria or dyspnea and face swelling as observed for patients 28 and 35, 
respectively, showed large differences with 11 compared to 20 identified putative 
functional epitopes in total. Overall only small differences in IgE binding frequencies 
regarding all patients as well as regarding subjects from group 1 or 2 were found. 
Therefore, analysis of putative functional epitope pattern did not lead to any 
conclusions concerning presence or severity of birch-related soy allergy. Rather a 
patient- or symptom-specific distribution of IgE epitopes is more likely.  
NCS variants Δ51NCSF3/N42/P49 and Δ51NCSF5/N42/P49/D100 showed IgE binding with all 
used sera at least within initial screen using immunoblot. F3 is located at the 
N-terminus of primary sequence in first β-sheet and was introduced for a lysine in 
NCS. Phenylalanine is an aromatic and hydrophobic amino acid without any 
functional groups contributing especially to secondary structure stability via 
intramolecular interaction with lysine or arginine residues. These bindings arise from 
cation π-interactions between negative electrostatic potential of aromatic ring and 
cations like positively charged amino acids. Nevertheless phenylalanine can 
contribute to ligand binding via its cation π-interaction, too. One example is the 
interaction between neurotransmitters and their cognate neuroreceptors with several 
cation π-interactions involved (Dougherty, 2007). In Crouch et al. a critical 
involvement of a phenylalanine from surfactant protein D in binding with 
glycoconjugates was found (Crouch et al., 2006). This indicated that, without any 
charge or functional group located at its side chain, F3 from Gly m 4 might be 
relevant for binding of IgE antibodies in the context of a Gly m 4-type molecular 
surrounding provided by the NCS model protein. Same holds true for F5 which was 
identified as potential functional epitope in combination with D100. Both are close to 
each other on Gly m 4 surface with F5 located in first and D100 in sixth β-sheet. 
Aspartate residues with their acidic carboxyl group at their side chain often contribute 
to protein-protein bindings via ionic interactions. Therefore both residues, F5 and 
D100, might be important for IgE binding and their combination might even increase 
IgE signal intensity. But involvement of each single residue in IgE interactions can 
only be evaluated with NCS variants showing only one grafted putative functional 
epitope. Together, F3, F5 and D100 are parts of mimotopes identified by Mittag et al., 
while D100 is also in the region of corresponding Bet v 1 peptides identified by IgE 
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inhibition experiments performed by Gieras et al. (Mittag et al., 2006; Gieras et al., 
2011).  
Potential functional epitopes for IgE identified in ≥75% of all patients are residues 
K20, D25/D27, N28/K32, D60 and N128. Concerning these residues, only D60 was 
not identified with mimotope analysis performed by Mittag et al. (Mittag et al., 2006). 
In addition K20 was already identified as part of a mimotope binding anti-Bet v 1 IgE, 
while N28 and K32 were mentioned as putative IgE-binding by different analysis with 
Bet v 1 (Ganglberger et al., 2001; Spangfort et al., 2003; Holm et al., 2004). Several 
studies using phage-display or monoclonal Bet v 1-directed antibodies identified G61, 
which is structurally homologous in Bet v 1 to D60 in Gly m 4 as IgE binding (Jensen-
Jarolim et al., 1998; Ganglberger et al., 2001; Levin et al., 2014). Recently, using a 
software tool, N128 was predicted as IgE-binding in Bet v 1-homologous cherry 
allergen Pru av 1 (Dall'Antonia et al., 2011). Only amino acids D25 and D27 were not 
described as putative functional epitopes or parts of any known IgE binding patch in 
literature. Besides several residues already known for their potential IgE binding 
throughout literature, additional amino acids could be identified as putative functional 
IgE epitopes. As expected, potential functional IgE epitopes are distributed over 
complete Gly m 4 surface and can be used as initial results for subsequent analyses 
(see 4.3.3 and 4.4). 
 
4.3.2 Known BV16 epitope as minor IgE-relevant epitope in Gly m 4 
Δ51NCSN42/E44/N46/P49/K54 was already described as capable of binding BV16 antibody 
as parts of the known BV16 epitope were grafted onto the molecular surface of this 
variant. Therefore Δ51NCSN42/E44/N46/P49/K54 was analyzed for IgE binding together 
with sera of patients used in this study (see 3.4.1). Not only IgE binding with non-
purified cell supernatant but also purified protein was evaluated by immunoblots. 
Both results are in great accordance whereas only patient 43 showed IgE binding 
with purified Δ51NCSN42/E44/N46/P49/K54 but not when using non-purified cell 
supernatant. For the screening of IgE binding to Δ51NCSN42/E44/N46/P49/K54 immunoblot 
was preferred over ELISA analysis because of reduced amounts of allergen and 
patients’ sera needed considering the more descriptive readout derived from ELISA 
experiments. Since IgE binding to NCS variants only occurs if proteins show Bet v 1-
type protein conformation only variants which were able to properly refold upon 
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denaturing SDS-PAGE and transfer to nitrocellulose membrane are detected. If no 
detectable signal could be observed even after an increased exposure time of 10 min 
no binding between Δ51NCSN42/E44/N46/P49/K54 and serum IgE was concluded. 
Δ51NCSN42/E44/N46/P49/K54 showed three grafted residues conserved in both Bet v 1a 
and Gly m 4 compared to the NCS model protein. E44, N46 and K54 are in close 
proximity and seem to present an IgE-binding patch, because 41% of patients with 
and 29% without soy allergy exhibited IgE binding to Δ51NCSN42/E44/N46/P49/K54. In 
contrast to a major relevance of these functional epitopes determined in patients with 
birch-pollen allergy, where 71% showed significant IgE binding, BV16 epitope might 
be of minor relevance concerning birch-related soy allergy (Berkner et al., 2014). 
Relevance of BV16 epitope for IgE binding via Bet v 1a was shown by several other 
publications, too (Mirza et al., 2000; Spangfort et al., 2003; Holm et al., 2004). IgE 
binding with Δ51NCSN42/E44/N46/P49/K54 was increased in patients with clinically 
confirmed soy allergy, indicating higher levels of IgE antibodies directed against 
BV16 epitope in this group of patients. But in total no correlation between grafted 
residues and birch-related soy allergy could be drawn, as subjects without soy allergy 
showed IgE binding to this epitope, too. 
 
4.3.3 Definition of six different IgE epitopes 
Regarding published crystal structures of antigen-antibody complexes the area of 
one allergen epitope was described with 600-900 Å2 (Davies et al., 1990; Braden et 
al., 1995). Furthermore two independent or distinct epitopes are necessary for 
simultaneous binding of two antibodies resulting in membrane receptor cross-linking, 
which represents a crucial step in the pathomechanism of IgE-mediated allergy. 
Distinct means that two IgE molecules can bind simultaneously to the allergen. 
Regarding these aspects the identified functional IgE epitopes were clustered into six 
different putative epitope patches manually (see 3.5). The six patches are located on 
each side of the protein just like the six faces of a cubical die with an average of 
651.2 Å2 (311.4-967.3 Å2) which is in the expected range of 600-900 Å2 for antibody-
antigen binding sites. Smallest epitope patch V is below 600 Å2 but presents parts of 
known BV16 epitope identified by a monoclonal antibody (Berkner et al., 2014). The 
frequency of six epitope patches based on most frequent amino acid ranged between 
56% and 100%. With this arrangement of putative IgE epitope patches it is possible 
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that different IgE antibodies bind at the same time to Gly m 4, which is a prerequisite 
for eliciting allergic symptoms. This model also emphasizes that not the presence of 
one IgE antibody in patient’s serum can correlate with clinical soybean allergy, but 
the combination of different IgE molecules binding to distinct IgE epitopes 
simultaneously is relevant for an allergic response (cf. 1.1). With additional 
experiments e. g. RBL release assays this questions might be addressed in more 
detail. In this context of interaction between different IgEs and a specific allergen the 
sterical hindrance between large IgE molecules (190 kDa) interacting with small 
allergens (16.6 kDa) needs to be considered. Binding of an IgE antibody to one 
epitope on Gly m 4 might prevent binding of a second antibody directed to another 
epitope in close proximity. Therefore no allergic response is observable concerning 
these two antibodies although both epitopes are present on Gly m 4 and the patient 
has increased levels of both IgE antibodies. Sterical hindrance not only occurs 
between different IgE molecules but also via binding of other immunoglobulins. In this 
context especially the blocking ability of IgG4 in allergen-specific immunotherapy is 
discussed to date (James et al., 2011; Jutel et al., 2013). Therefore a future thorough 
allergic diagnosis might not only consider allergen-specific IgE levels, but also the 
allergen-specific epitope repertoire for IgE, as well as levels and epitopes for specific 
IgG4, IgM or IgA molecules. 
 
4.4 NSC variants and IgE epitope profile 
To further evaluate the identified potential functional IgE epitopes several NCS 
variants combining multiple functional epitopes were characterized (see 3.5.1). Out of 
14 generated variants eleven exhibited native-type secondary structure as revealed 
by CD spectroscopy. Therefore amino acid substitutions likely did not alter Bet v 1-
type protein fold in these variants which is a prerequisite for correlation of grafted 
residues with IgE binding. ΔNCSN42/P49 variants presented either one individual 
epitope patch (ΔNCSN42/P49_1-5) or a combination of grafted residues belonging to 
2-5 different IgE epitope patches (ΔNCSN42/P49_6-11). With these variants a suitable 
toolbox for a detailed analysis of Gly m 4-specific IgE epitope profile was generated.  
To determine the IgE binding of each ΔNCSN42/P49 variant, all patients of groups 1 
and 2 were analyzed by dot blotting (see 3.5.2). Dot blot analysis was comparable to 
IgE-binding assay performed for evaluation of candidate residues with several 
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differences: i) all ΔNCSN42/P49 variants were purified to homogeneity out of E. coli 
inclusion body fractions rather than used from non-purified cell supernatants, 
ii) additional step of protein separation via SDS-PAGE was left out and iii) IgE signals 
could be quantified using densitometry. As expected, all ΔNCSN42/P49 variants were 
expressed solely in E. coli inclusion bodies as already described for Δ51NCSN42/P49 
model protein and Δ51NCSN42/P49 variants with only single grafted residues. Due to 
usage of purified proteins showing only one potential specific IgE signal in 
immunoblot, time-consuming SDS-PAGE could be avoided and ΔNCSN42/P49 variants 
were blotted directly onto nitrocellulose membrane. As IgE binding requires native 
protein conformation only NCS variants which were able to properly refold into 
Bet v 1-type conformation upon transfer to nitrocellulose membrane were detected. 
Therefore dot blot analysis resembles an easy and fast approach for analysis of 
eleven ΔNCSN42/P49 variants with all patients’ sera compared to ELISA or 
ImmunoCAP™ for IgE detection where, in addition, markedly increased amounts of 
patients’ sera is needed. Nevertheless IgE ELISA might provide more reliable results 
or data read-outs compared to dot blot analysis and might be used as additional tool 
for further IgE-binding analyses using ΔNCSN42/P49 variants. Furthermore each IgE 
signal was quantified via densitometric analysis. This allows identification of IgE-
binding variants in relation to the background signal obtained with Δ51NCSN42/P49 
model protein and allowed exclusion of signals close to background noise.   
In total, IgE binding frequencies differed markedly between subjects with and without 
soybean allergy for several ΔNCSN42/P49 variants. For patients with soy allergy 
ΔNCSN42/P49_4, 7, 9 and 10 showed highest binding frequencies. In the group of 
patients without soybean allergy ΔNCSN42/P49_4, 7 and 10 were identified most 
frequently. Comparable frequencies (≤20% difference) were observed in both groups 
concerning variants ΔNCSN42/P49_1, 2, 3, 4, 5, 7, 10 and 11. ΔNCSN42/P49_7, 10 and 
11 present epitopes of combinational IgE patches while in ΔNCSN42/P49_1-5 solely 
one epitope patch was grafted. This emphasizes again that patients of both group did 
not differ mainly in their IgE levels at least directed against epitope patches 1-5. A 
difference in binding frequency of 29% was observed for ΔNCSN42/P49_6. Furthermore 
ΔNCSN42/P49_1, 3, 5, 8 and 11 showed different IgE-binding pattern as IgE binding 
was observable in 1-7 of patients with and in none of patients without soybean 
allergy. A large difference was observed with ΔNCSN42/P49_9 showing an IgE binding 
frequency of 68% (15/22) in patients with and only 7% (1/14) in patients without 
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birch-related soy allergy. Therefore residues of this epitope might be more relevant in 
the group of subjects with clinically confirmed soybean allergy. In dot blot analysis, 
ΔNCSN42/P49_9 yields a sensitivity of 68% and a specificity of 93% resulting in positive 
(PPV) and negative predicted values (NPV) of 94% and 65%, respectively, at least 
with the study population and the NCS control protein used in this study. High values 
for both specificity and PPV indicate a potential use of ΔNCSN42/P49_9 as biomarker 
for soy allergy. With ΔNCSN42/P49_9 a differentiation between patients with soybean 
allergy and patients only sensitized to soy might be possible. Reference protein 
Δ51NCSN42/P49 showed weak IgE binding with sera of several patients in both, initial 
immunoblot screening and dot blot analysis, most likely because of identical amino 
acids present in Δ51NCSN42/P49 and Gly m 4 or Bet v 1a primary sequence with 
potential importance for interaction with IgE antibodies. In total Δ51NCSN42/P49 shares 
31 and 35 residues with Gly m 4 and Bet v 1a, respectively, whereas 15 and 
16 amino acids might be involved in IgE binding because of their side chain 
characteristics (E, F, H, K, N, S, T, Y).  
Again, as already stated in initial screening (see 3.4), patients of both groups can 
show a low or a high number of identified ΔNCSN42/P49 variants binding patients’ IgEs. 
In total, patients with one single positive IgE signal but also patients with IgE binding 
to at least 5 out of 11 ΔNCSN42/P49 variants were identified in both groups of patients. 
Nevertheless, as already shown for screening of NCS library, no group-specific 
binding pattern could be found in dot blot analysis, too. Rather a patient-specific IgE 
epitope profile is supposed, as majority of patients exhibited individual binding 
patterns. Only patients without soybean allergy showed comparable IgE binding 
patterns. Nevertheless most frequently identified variants ΔNCSN42/P49_4, 7 or 10 in 
this group of patients do not allow a differentiation between patients with and without 
soy allergy, as these variants were identified as IgE binding with comparable 
frequencies in the group of patients with soybean allergy as well. Only ΔNCSN42/P49_9 
presents a potential marker for soybean allergy and emphasizes that epitope-
resolved in vitro diagnosis might allow a more accurate correlation with clinical 
symptoms compared to component-resolved diagnosis using ImmunoCAP™ for 
example. As no statistical analyses were conducted within my study population the 
usability of this system needs to be analyzed statistically in further studies.  
Overall dot blot results were in accordance with results of initial screening and 
emphasize the need of a more patient-specific diagnosis to evaluate presence and 
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symptomatology of birch-related soybean allergy. Only with ΔNCSN42/P49_9 a 
correlation between IgE binding and clinically confirmed soybean allergy was 
observable in majority of patients. Despite of this, only by measuring IgE binding to 
identified IgE epitopes of Gly m 4, no conclusions on clinical relevance and severity 
could be drawn. Furthermore number of identified epitope patches or functional IgE 
epitopes does not necessarily correlate with appearance of soybean allergy or 
specific symptoms in this study population. Nevertheless, determination of IgE-
binding epitopes in each patient might predict relevant combinations of epitopes for 
birch-related soy allergy. For example, binding of an antibody directed against 
epitope I prevents interaction of the allergen with IgE via epitope VI due to a potential 
sterical hindrance (cf. Figure 13). Analyzing these patient-specific selective 
combinations e. g. by RBL cell release experiments, might give additional information 
on IgE epitope profile of Gly m 4.  Comparable analyses were performed by 
Christensen et al. showing that natural occurring isoallergen variations as well as 
total and specific IgE repertoire results in different IgE binding affinities (Christensen 
et al., 2008; Christensen et al., 2010).  
In summary, dot blot results with purified ΔNCSN42/P49 variants were more specific for 
diagnosis of birch-related soy allergy compared to the initial screening using NCS 
variants but also ImmunoCAP™ analysis. With both, ImmunoCAP™ and initial 
screening of variants, no correlation between the two groups of patients, their 
individual symptoms or the severity of symptomatology with identified functional IgE 
epitopes or specific IgE level was possible. Only by using dot blot with ΔNCSN42/P49 
variants presenting characteristic epitope patches a possible correlation between IgE 
signals and presence of soybean allergy was observed. In this regard ΔNCSN42/P49_9 
was identified as potential marker for soybean allergy. Component-resolved 
diagnosis like ImmunoCAP™ measurements but also initial screening of NCS 
variants only revealed sensitization profiles of patients to specific recombinant 
allergens but no correlation between sensitization and clinical relevance in birch-
related soybean allergy could be drawn. This is in line with several studies where no 
predictions on clinical outcome of an individual patient were possible using 
component-resolved diagnosis (Reuter et al., 2006; Hansen et al., 2009; Ebo et al., 
2010; Ballmer-Weber et al., 2012; Guhsl et al., 2015). According to this, the usage of 
an epitope library might represent a potential tool to differentiate between birch 
pollen-allergic subjects with and without clinically confirmed birch-associated allergy 
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to soybean or further related allergens. Nevertheless no correlation between IgE 
binding pattern and specific symptoms or severity of allergic reactions was found in 
dot blot analysis.  
 
4.5 Evaluating Gly m 4 specificity of identified IgE epitopes 
By analyzing binding of serum IgEs from a pool of patients with and without soybean 
allergy with NCS variants a specificity to Gly m 4 was found (see 3.5.3). Using eleven 
generated ΔNCSN42/P49 variants a reduction of Gly m 4-specific IgE binding of at least 
70% was observed (cf. Figure 20). This illustrates that identified IgE epitopes and 
grafted residues are specific for interaction with IgE antibodies present in patients 
with sensitization to Gly m 4. Self-inhibition with rGly m 4 resulted in a reduction to 
2.7 ± 2.1% and 7.6 ± 3.0% of the IgE binding in patients with and without soybean 
allergy, respectively. Furthermore these results suggest that the vast majority of IgE 
epitopes of Gly m 4 are covered by our model protein-based Gly m 4-specific epitope 
library containing a total number of 25 amino acid substitutions towards Gly m 4. 
Differences in IgE inhibition using ΔNCSN42/P49 variants and rGly m 4 might be 
caused by an additional IgE epitope present on Gly m 4 and not identified via NCS 
analysis. This not identified epitope might be the cause for remaining IgE binding of 
20.0 ± 5.3% and 30.0 ± 5.3% in pools depleted with NCS variants while only 
2.7 ± 2.1% and 7.6 ± 3.0% of IgE binding was observed with rGly m 4-depleted IgE 
antibodies. Further explanation might be a decreased affinity in binding between IgEs 
and NCS variants compared to IgEs and Gly m 4 in both groups. Such a decrease 
might be caused by an incomplete transfer of IgE epitopes from Gly m 4 to NCS. In 
addition increased concentrations of inhibitors might result in full inhibition especially 
using rGly m 4 while in this experimental set-up only single point inhibitions were 
performed. Characteristic residues of each identified IgE epitope were grafted from 
Gly m 4 to NCS but several amino acids additionally contributing to allergen-antibody 
interaction are still missing. These residues might also be relevant for binding IgE 
and therefore cause a decreased antibody affinity. As only 25 residues grafted from 
Gly m 4 to Δ51NCSN42/P49 model protein are analyzed in these depletion experiments 
a increased inhibition might be observed using additional Δ51NCSN42/P49 variants 
presenting further identified functional IgE epitopes. Δ51NCSN42/P49 model protein 
lead to a minor reduction of Gly m 4-specific binding to IgE as well. Again, as already 
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discussed (see 4.4), this indicates the presence of several residues in original NCS 
sequence with IgE-binding capability. 
 
4.6 Functional IgE epitopes identified with rGly m 4 variants 
In addition to epitope analysis using NCS library further studies with rGly m 4 and five 
substitutional rGly m 4 variants were performed (see 3.6). In contrast to NCS system 
where grafting of functional epitopes lead to an increase in IgE signal, rGly m 4 
variants with critical substitutions showed a reduced binding of antibodies. In this 
study, five variants of rGly m 4 were generated with four to 14 amino acid 
substitutions belonging to 2-6 of the identified putative IgE epitope patches (see 
3.6.2). With this, a total number of 18 residues were addressed. Most residues were 
substituted to alanine not relevant for the initiation of antibody binding due to the 
absence of any functional group or charged residues. Four residues, E44, N77, N108 
and K133, showed conservative substitutions to serine, lysine or glutamate 
representing residues with contradictory characteristics than original amino acids, 
already described for respective residues in Bet v 1 (Spangfort et al., 2003; Holm et 
al., 2004). rGly m 4_9x was based on rGly m 4_4x variant and rGly m 4_11x and 
rGly m 4_14x both included substitutions of rGly m 4_10x variant. CD spectra of 
rGly m 4 variants were comparable to native Gly m 4 and typical for PR10-proteins 
indicating a Gly m 4-type secondary structure with minor deviations due to the amino 
acid substitutions. Nevertheless a tendency to unstructured proteins was observable 
with increasing number of substitutions. Native-type protein folding is essential for 
studying influence of amino acid substitutions on IgE binding because an altered 
protein conformation often reduces binding of serum IgE (Holm et al., 2004; Wallner 
et al., 2011). To study the impact of substituted residues on IgE binding, purified 
proteins were used together with patients’ sera (see 3.6.3). Instead of being 
expressed in both soluble fraction and E. coli inclusion bodies, as shown for rGly m 4 
(see 3.6.1), the corresponding variants showed target protein expression for the most 
part in bacterial inclusion bodies. Therefore introduced amino acid substitutions 
influenced protein expression and caused an increase in formation of inclusion 
bodies. rGly m 4 and its variants showed high purity with some minor degradation 
products according to SDS-PAGE.  
Western blot and inhibition ELISA were used to determine IgE binding of rGly m 4 
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variants with serum IgE (see 3.6.3). In both assays a reduction in IgE signals 
compared to native Gly m 4 was observable. Majority of patients (94%, 15/16) 
analyzed with rGly m 4_11x in immunoblot showed a reduced IgE binding, while only 
one patient with comparable IgE signals could be identified. At least some of 
substituted residues might represent amino acids crucial for IgE binding and are part 
of one or more epitopes on Gly m 4. Nevertheless further epitopes need to be 
present because, as expected, eleven substitutions did not reduce IgE signal 
completely in all patients. Especially patient 11, not responding to any of introduced 
residues might contain IgE antibodies directed solely against epitopes different from 
ones addressed with rGly m 4_11x. As IgE binding requires a native protein 
conformation all rGly m 4 variants were able to properly refold into their native 
conformation upon transfer to nitrocellulose membrane and possible differences in 
refolding behaviors between the rGly m 4 variants were addressed via ELISA 
experiments where soluble allergens are used. In ELISA rGly m 4_4x showed only 
minor differences in IgE binding compared to native Gly m 4 indicating that 
substituted residues T93, E95, K96 and E120 did not present putative functional IgE 
epitopes or at least their effect on IgE signal is very low compared to overall binding 
of serum IgEs. This is in line with initial screening of NCS library were 
Δ51NCSN42/P49/E95/K96 was one out of two NCS variants not binding IgE in any of used 
serum. In contrast a decrease in IgE binding was observed with rGly m 4_9x, 10x, 
11x and 14x as inhibitors. Often with increasing number of substitutions a stronger 
decrease in IgE signals was observable. Additional information on IgE inhibition 
potency of used variants might be achieved using dose-related inhibitions rather than 
single inhibitor concentrations but substituted residues contributed at least to some 
extend to binding of IgEs. In none of studied patients a complete reduction of IgE 
binding was possible with any of the used inhibitors. This emphasizes the presence 
of further IgE epitopes still allowing interaction with IgE antibodies. Again, as already 
shown with NCS-based analysis, no correlation between identified IgE epitope 
pattern and a group of patients or specific symptoms was found. Rather, this 
approach again suggests a patient-specific IgE epitope profile. Most of 18 substituted 
residues were identified as putative functional IgE epitopes with NCS analysis, too. 
Only N77 and Y149, which were not included as candidate residues in initial 
screening of NCS library had potential IgE binding in rGly m 4 variants. NCS variants 
Δ51NCSD25/D27/N42/P49, Δ51NCSN28/K32/N42/P49 and Δ51NCSN42/P49/D60 showing grafted 
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residues D27, K32 and D60 bound serum IgE of at least 75% of all sera in initial 
screening. K32 and D60 were also substituted in rGly m 4_9x whereas all three 
residues were changed to alanine in rGly m 4 variants 10x, 11x and 14x. Therefore 
D27, K32 and D60 might play a key role in binding of IgE antibodies probably due to 
their surface-exposed position or their charged side chains enabling for easy 
interaction with antibody ligands.  
Overall, both assays indicated that usage of rGly m 4 variants with PR10-type protein 
conformation is a suitable approach to identify residues contributing to IgE binding. In 
this study 18 putative functional IgE epitopes could be identified but usage of multiple 
substitutional rGly m 4 variants requires further experiments to verify importance of 
each single amino acid. Nevertheless, generated variants can be used anyway as a 
basis for thorough studies on IgE epitope profile.  
 
4.7 Analysis of IgE antibody avidity in study population 
In addition to IgE repertoire and IgE epitope profile, differences in antibody affinity 
and avidity are discussed as potential reason for clinical reactions to allergens. 
Different IgE antibodies might bind epitopes on allergen surface with a range of 
affinities. Several high affinity epitopes are for example known for peanut allergen 
Ara h 3 and melon allergen Cuc m 2 (Rougé et al., 2009; Tordesillas et al., 2010). In 
this study, both groups of patients with and without birch-related soybean allergy 
were analyzed according to differences in IgE avidity (see 3.7 and 3.8.3). For this, 
binding between IgE and rGly m 4 was inhibited with rGly m 4 and the misfolded 
variant rGly m 4S111P/L150P. Overall no differences in avidity were observable between 
both groups of patients regarding each allergen. Using rGly m 4 a complete inhibition 
in IgE binding was possible. rGly m 4S111P/L150P was able to inhibit binding of IgE to 
rGly m 4 with >80% in both groups as well. This is in line with analysis of misfolded 
rGly m 4S111P/L150P exhibiting IgE binding with several patients of study population. 
Due to less patients showing IgE binding with rGly m 4S111P/L150P compared to 
rGly m 4 in immunoblot, a shift in IgE inhibition to higher concentrations of misfolded 
variant was observable in ELISA. For rGly m 4 an increase in IgE avidity might not be 
relevant for outbreak of soybean allergy in the study population. Rather affinity of 
specific IgE epitopes should be considered in combination with patient-specific IgE 
epitope profile. High affinity epitopes causing allergic symptoms might be present 
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only in patients with clinical allergy while patients sensitized but not allergic to soy 
show no immunodominant epitopes. Therefore thorough analysis of IgE epitopes and 
their antibody affinities might be useful to determine allergic potential. 
 
4.8 Misfolded variants of Gly m 4 and Bet v 1a 
Recombinant preparations of Gly m 4 and especially Bet v 1a are used in both 
diagnostic and scientific applications. In basic research rBet v 1a is often used as 
reference material for biological and physicochemical analysis with its well 
established purification protocol also existing for rGly m 4. Furthermore both 
allergens are used in in vitro diagnostics for example in ImmunoCAP™ 
measurements to determine allergen-specific IgE or IgG amounts in patients’ sera. 
Recombinant Bet v 1a is available as a reference standard preparation from the 
European Directorate for the Quality of Medicines and Health Care (EDQM). For 
diagnostic purpose and laboratory use a consistent quality of both allergen 
preparations needs to be maintained. In this study I analyzed the physicochemical 
and immunological characteristics of both rBet v 1a and rGly m 4 and the influence of 
different molar ratios of a respective misfolded variant concerning structure and IgE 
binding ability (see 3.8). With this, a correlation between experimental and 
theoretically expected data for both allergen combinations is possible. Furthermore 
the precision according to the confidence intervals of 95% chosen with the actual IgE 
binding protein moiety is resolved quantitatively by the respective analytical method. 
The variants generated of both, Bet v 1a and Gly m 4, showed two substitutions to 
proline located in seventh β-sheet and C-terminal α-helix, respectively (see 3.8.1). 
Substitution S112P in Bet v 1a and its homologue Mal d 1 in apple was already 
characterized by Son et al. as a protein variant with decreased IgE binding capacity 
and drastically reduced protein folding (Son et al., 1999). Hence, these observations 
were also expected for Gly m 4. An additional substitution to proline was introduced 
in C-terminal α-helix of both proteins to prevent formation of this secondary structure 
element. Resulting variants rBet v 1aS112P/R145P and rGly m 4S111P/L150P showed an 
unfolded protein structure in CD and NMR spectroscopy (see 3.8.2). Both were 
analyzed for allergen-antibody interaction via immunoblot and as IgE binding requires 
native protein conformation only allergens which were able to properly refold into 
Bet v 1-type conformation upon SDS-PAGE and subsequent transfer to nitrocellulose 
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membrane were detected (see 3.8.3). Misfolded variant rBet v 1aS112P/R145P was not 
able to bind IgE antibodies of patients sensitized to Bet v 1a or birch pollen. In 
contrast, in subjects with sensitization to Bet v 1a and Gly m 4 a binding between IgE 
and at least one misfolded variant was possible in the majority (92%, 33/36 subjects) 
of patients analyzed. Thereby no difference between subjects with or without clinical 
reactivity to soybean or specific symptoms could be observed. Binding characteristics 
of rBet v 1aS112P/R145P and rGly m 4S111P/L150P did not correlate with clinical soybean 
allergy or any allergic symptoms. If no detectable signal could be observed even after 
an increased exposure time of 10 min no binding between misfolded variant and 
serum IgE was concluded, but usage of a quantitative readout of IgE-binding might 
result in more detailed conclusions. The remaining potential of interaction between 
misfolded variants and IgE antibodies suggests the presence of at least one linear 
IgE epitope in Bet v 1aS112P/R145P and Gly m 4S111P/L150P sequence. This linear stretch 
of adjacent amino acids might be IgE binding in both native allergens or became 
accessible due to protein unfolding and shows no IgE binding in both well-folded 
rBet v 1a and rGly m 4. A further explanation for IgE binding with both misfolded 
variants might be the presence of at least one intact secondary structural element 
forming a linear or conformational IgE epitope. The structural element which is 
potentially maintained is however not detectable in both CD and NMR spectroscopy 
indicating its small ratio in comparison to total unfolded protein structure. The 
presence of a very low amount of fully folded material in the misfolded variant can be 
excluded as no IgE binding could be detected with several sera and the identical 
batch of purified misfolded variant. To answer this question, further investigations are 
required. For example using RBL cell release assay it would be possible to analyze if 
only one or at least two distinct epitopes are present. Only presence of two or more 
epitopes allows cross-linkage of IgE antibodies binding to different epitopes causing 
release of mediator molecules. If no release would be detected this emphasizes that 
only one single IgE epitope is left on Gly m 4. Analysis of ten birch-sensitized patients 
which did not show IgE binding with rBet v 1aS112P/R145P indicates the absence of 
antibodies directed against the linear or conformational epitope remaining in 
misfolded variant at least in this study population.  
Analysis of different molar ratios of rBet v 1a/rBet v 1aS112P/R145P and 
rGly m 4/rGly m 4S111P/L150P in CD spectroscopy revealed comparable results 
(see 3.8.4). With increasing amount of misfolded variant a shift from Bet v 1-type CD 
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spectrum to spectra characteristic for unstructured proteins was observable. In 
immunoblots both allergens showed a successive reduction in IgE binding from 
native allergen to their respective misfolded variant. Both methods are well-suited to 
trace protein characteristics of native allergens to misfolded variants showing 
unstructured secondary structures and no/low IgE binding.  
Statistical analysis were only performed for rBet v 1a/rBet v 1aS112P/R145P ratios where 
three independent preparations of both proteins were generated resulting in three 
pairs with incrementally increasing ratios of rBet v 1aS112P/R145P. In immunoblot, CD 
spectroscopy, ELISA and RBL mediator release assay mixtures with <10% of 
rBet v 1a showed large differences between measured and theoretical values. In this 
range CD, ELISA and mediator release assay underestimated the ratio of rBet v 1a 
while in immunoblotting an overestimation was found. In contrast, all assays showed 
good correlations from 100-90% rBet v 1a. Furthermore the 95% confidence intervals 
of each assay were determined. CD spectroscopy and ELISA performed comparable 
where a reduction from 100% to 60% rBet v 1a revealed an accuracy of 1.03 and 
0.93, respectively. In contrast, in immunoblot and RBL mediator release assay 20% 
or even only 1% rBet v 1a could be differentiated in 95% confidence interval from 
total IgE binding with 100% rBet v 1a. Statistical significance was found in all assays 
except RBL mediator release assay, probably because of its biological background. A 
significant reduction in secondary structure or IgE binding was observable at 60% 
rBet v 1a in CD spectroscopy, 80% and 20% rBet v 1a in both immunological assays 
which are immunoblot and ELISA. Overall obtained results of both CD spectroscopy 
and ELISA correlated best with theoretically expected values at least for the range 
between 100-10% rBet v 1a, making them most suitable for determination of allergen 
concentration. Larger differences appeared when analyzing actual/theoretical data 
from immunoblot as well as RBL mediator release assay. These assays required 
large differences in concentrations of allergen and misfolded variant for identification 
of IgE binding moiety. Taken together, all assays used in this study are well-suited to 
trace changes in ratios of active and misfolded variant or detect even weak IgE 
signals in protein samples. However the list of applied methods is not complete in this 
study and further applications should be considered to detect traces of misfolded 
variants in allergen preparations. Using surface plasmon resonance, isothermal 
titration calorimetry, infrared spectroscopy or usage of the recently identified 
physiological ligand of Bet v 1a might represent reasonable methods to analyze the 
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quality of allergen preparations (Seutter von Loetzen et al., 2014). IgE binding of 
allergen preparations might also be influenced by additional effects like storage 
conditions or modifications in amino acid side chains. Taken together the misfolded 
variants rBet v 1aS112P/R145P and rGly m 4S111P/L150P might be used as quality reference 
standards for example in screening of hypoallergenic molecules with potential use in 
treatment of allergies using several applications to measure IgE binding capacity and 
quality of allergen preparations. 
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5 SUMMARY 
Individuals with birch pollinosis may show allergic reactions after consumption of 
soybean-containing food. This is caused by cross-reaction of IgE directed against the 
major birch pollen allergen Bet v 1 with the structurally homologous allergen Gly m 4 
from soybean. Hypersensitivity reactions in birch-soy allergy range from mild 
reactions to severe systemic reactions. Sera of birch pollen-allergic subjects may 
contain IgE to Gly m 4, even though no allergy to soy is present. Thus Gly m 4-
specific IgE per se is not a suitable biomarker for birch-related soy allergy. To 
develop novel approaches for improved diagnosis and therapy of birch-soy allergy, 
knowledge on epitopes and IgE epitope profile of Gly m 4 for is needed. To date, 
data on epitopes of Bet v 1 and its homologous allergen Gly m 4 is very limited.  
In this study, birch pollen-allergic patients with (27 subjects) and without (20 subjects) 
clinically confirmed allergy to soybean were included and analyzed regarding 
Gly m 4-specific serum IgE/IgG levels and epitope profiles of Gly m 4 for IgE. Specific 
IgE levels against Bet v 1, Gly m 4 and further soy allergens Gly m 5 and Gly m 6 
were determined by ImmunoCAP™ and IgE binding to rGly m 4 and soy extract was 
tested in western blot. To analyze putative IgE epitopes of Gly m 4, non-allergenic 
Norcoclaurine synthase (NCS) from meadow rue was used as a model protein. NCS 
is structurally homologous to Gly m 4 but exhibits none to very little binding of 
Gly m 4-specific IgE antibodies enabling grafting of Gly m 4 epitopes onto the model 
protein. Potential candidate residues of Gly m 4 were selected by bioinformatic 
analysis of antibody-binding phage-displayed peptides and mapping of segments of 
Gly m 4 primary structure onto the molecular surface of the allergen. As a result a 
library of recombinant NCS variants with potential IgE binding was generated. In 
addition, five multiple substitutional variants of rGly m 4 with a total number of 
18 amino acid substitutions crucial for IgE binding were generated and analyzed for 
antibody binding with patients’ sera. Furthermore a misfolded variant of each 
rBet v 1a and rGly m 4 was generated and defined molar ratios of folded/misfolded 
variants were compared in different immunological and physicochemical assays. 
Gly m 4-specific median IgE and IgG levels of allergic (IgE: 9.3 kUA/L, 
IgG: 8.1 mgA/L) and non-allergic (IgE: 4.5 kUA/L, IgG: 8.3 mgA/L) subjects were 
comparable. The specific IgE levels did not correlate to the (severity of) clinical 
phenotypes. 51 candidate residues of Gly m 4 were selected for IgE epitope analysis 
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and 46 potential functional IgE epitopes, single residues within a structural IgE 
epitope which dominate the energetics of allergen-IgE binding, were identified with 
IgE binding to ΔNCSN42/P49 variants. The putative functional IgE epitope pattern was 
individual for each patient and not distinguishable between allergic and non-allergic 
subjects. Using five rGly m 4 variants parts of the results of the NCS-based analyses 
could be confirmed with 18 potential functional IgE epitopes identified. 46 potential 
functional IgE epitopes clustered into six distinct putative IgE-binding areas on 
Gly m 4 and eleven NCS variants (ΔNCSN42/P49_1-11) presenting parts of these 
epitope areas were purified, showing a Gly m 4-type secondary structure according 
to CD measurements. Densitometric analysis for binding of IgE antibodies was 
performed via dot blot with sera of the study population but no characteristic IgE 
epitope pattern could be found. In contrast ΔNCSN42/P49_9 was identified as most 
suitable marker to distinguish soy allergic from tolerant patients in birch-related 
soybean allergy with a sensitivity and specificity of 68% and 93%, respectively. Using 
a pool of ΔNCSN42/P49 variants a depletion of Gly m 4-specific IgE binding to about 
80% and 70% in pooled sera of patients with and without soybean allergy, 
respectively, was possible. Therefore identified putative functional IgE epitopes are 
specific for interaction with IgE antibodies in study population. With ΔNCSN42/P49_9 a 
differentiation between sensitization to Gly m 4 and clinically confirmed soybean 
allergy might be possible. The usage of a Gly m 4-specific epitope library might be a 
more promising tool for evaluating birch-related soybean allergy compared to 
ImmunoCAP™ and screening of substitutional Gly m 4 variants alone. However no 
correlations between patient’s IgE epitope profile and specific symptoms to soy or 
severity of allergic reactions could be found using NCS-based epitope library. Rather 
patient-specific epitope pattern might be relevant for birch-related soybean allergy. 
Therefore a thorough diagnosis by the combination of component-resolved diagnosis 
and profound epitope analysis might be mandatory in the future. 
Using two misfolded variants of rBet v 1a and rGly m 4 the impact of unstructured 
allergens in rBet v 1a/rGly m 4 preparations was addressed with physico- and 
immunological assays. Both rBet v 1aS112P/R145P and rGly m 4S111P/L150P showed a 
highly disordered protein conformation and reduced IgE binding frequencies with 
analyzed patients’ sera. With CD spectroscopy, immunoblot, ELISA and RBL cell 
release assay defined combinations of native and unstructured allergen were 
assessed concerning secondary structure and IgE binding. Correlation of rBet v 1a 
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content with secondary structure and IgE binding was suitable only at high 
rBet v 1aS112P/R145P levels in mixtures. CD spectroscopy and ELISA performed more 
precise compared to immunoblot and rat basophil cell mediator release assay where 
larger deviations between native and unstructured allergen were necessary. In 
addition, quantification of IgE-binding allergen was difficult for concentrations of 
rBet v 1a ≤10% in all assays. Overall, CD, ELISA and RBL cell release assay 
underestimated while immunoblot overestimated the actual level of rBet v 1a. Results 
of both misfolded variants rBet v 1aS112P/R145P and rGly m 4S111P/L150P might be used 
within screening of hypoallergenic molecules with potential use in treatment of 
allergies or in quality assessment of recombinant allergen preparations. 
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6 DEUTSCHE ZUSAMMENFASSUNG 
Patienten mit einer Birkenpollenallergie zeigen oftmals auch allergische Reaktionen 
auf sojahaltige Nahrungsmittel oder Getränke. Grund ist eine Kreuzreaktion von IgE-
Antikörpern gerichtet gegen das Hauptallergen der Birke, Bet v 1, und dem 
strukturhomologen Allergen Gly m 4 der Sojabohne. Die klinischen Symptome 
können in der Birkenpollen-assoziierten Sojaallergie bis hin zu schweren Reaktionen, 
wie einem anaphylaktischen Schock, reichen. Patienten mit einer Birkenpollen-
assoziierten Sojaallergie weisen demnach sowohl IgE-Antikörper gegen Bet v 1 als 
auch Gly m 4 auf. Auffällig ist hierbei, dass Birkenpollenallergiker ohne assoziierte 
Sojaallergie oft auch diese beiden Allergen-spezifischen IgEs besitzen. Deshalb kann 
die Präsenz von Gly m 4-gerichteten IgEs an sich nicht als geeigneter Marker für 
eine Sojaallergie eingesetzt werden. Um eine exakte Diagnose und wirkungsvolle 
Therapie zur Behandlung solcher Allergien zu ermöglichen, sind neben 
Patientendaten auch detaillierte Informationen über die IgE-bindenden Bereiche, die 
sogenannte Epitope, auf Gly m 4 nötig. Bis heute ist jedoch nur wenig über IgE-
Epitope von Bet v 1 und seinem Homolog Gly m 4 bekannt.  
In diese Arbeit wurden 27 bzw. 20 Birkenpollenallergiker mit bzw. ohne eine klinisch 
bestätigte Sojaallergie eingeschlossen und hinsichtlich ihrer Gly m 4-spezifischen 
IgE- und IgG-Konzentrationen im Serum, sowie IgE-Epitopprofile untersucht. 
Bet v 1-, Gly m 4-, Gly m 5- und Gly m 6-gerichtete IgE-Level wurden mittels 
ImmunoCAP™ gemessen und die IgE-Bindung an rGly m 4 sowie Sojaextrakt 
anhand Western Blots bestimmt. Um mögliche IgE-Epitope analysieren zu können, 
wurde die nicht-allergene Norcoclaurinsynthase (NCS) aus der gelben Wiesenraute 
als Modelprotein eingesetzt. NCS ist strukturhomolog zu Gly m 4 zeigt aber nur 
wenig bis gar keine Bindung an Gly m 4-spezifische IgEs und kann daher für das 
Epitopgrafting von Gly m 4 auf NCS verwendet werden. Aminosäuren von Gly m 4, 
die als mögliche IgE-bindende Reste in Frage kommen, wurden mittels einer 
bioinformatischen Analyse von IgE-bindenden Peptiden einer Phagenbibliothek 
sowie durch das Mappen von Primärstrukturabschnitten von Gly m 4 auf dessen 
Proteinoberfläche identifiziert. So konnte eine Bibliothek von rekombinant 
hergestellten NCS Varianten mit potenzieller IgE-Bindung erzeugt werden. 
Außerdem wurden fünf Varianten von rGly m 4, die insgesamt 18 potentiell IgE-
relevante Aminosäureaustausche zeigen, erzeugt und hinsichtlich ihrer Bindung an 
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Patienten-IgE untersucht. Zusätzlich wurden zwei ungefaltete Varianten von 
rBet v 1a und rGly m 4 hergestellt und in unterschiedlichen Mischungen mit korrekt 
gefaltetem rBet v 1a/rGly m 4 anhand diverser immunologischer und physiko-
chemischer Verfahren untersucht.  
Hinsichtlich ihrer mittleren Gly m 4-spezifischen IgE- und IgG-Konzentrationen 
konnte kein Unterschied zwischen Patienten mit (IgE: 9.3 kUA/L, IgG: 8.1 mgA/L) und 
ohne (IgE: 4.5 kUA/L, IgG: 8.3 mgA/L) Sojaallergie gefunden werden. Weiterhin 
korrelierten diese spezifischen IgE-Konzentrationen nicht mit dem klinischen 
Phänotyp der Patienten. Insgesamt konnten aus 51 Gly m 4-spezifischen 
Aminosäuren 46 potentiell funktionale IgE-Epitope identifiziert werden. Bei 
funktionalen Epitopen handelt es sich um einzelne Aminosäuren, welche innerhalb 
eines strukturellen IgE-Epitops die Energetik der Allergen-IgE-Bindung dominieren. 
Das potentielle, funktionale IgE-Epitopprofil jedes Patienten war individuell und nicht 
charakteristisch für die Unterscheidung zwischen Allergikern und Nicht-Allergikern. 
Durch die Analyse mittels der fünf Substitutionsvarianten von rGly m 4 konnten Teile 
der Ergebnisse der NCS-Epitopanalyse bestätigt werden. Insgesamt ergaben sich 
hier 18 potentielle, funktionale IgE-Epitope. Alle 46 potentiell funktionalen IgE-
Epitope konnten in sechs mögliche Epitopbereiche auf Gly m 4 zusammengefasst 
werden. Elf NCS-Varianten (ΔNCSN42/P49_1-11), die Teile dieser Epitopbereiche 
aufweisen, wurden hergestellt und zeigten zu Gly m 4 vergleichbare CD-Spektren. 
Eine densitometrische Analyse der IgE-Bindung in Patientenseren wurde mittels 
eines Dot Blots durchgeführt, jedoch konnte kein charakteristisches IgE-Epitopprofil 
ermittelt werden. Hingegen konnte die NCS Variante ΔNCSN42/P49_9 mit einer 
Sensitivität bzw. Spezifität von 68% bzw. 93% als vielversprechender Marker 
identifiziert werden, um Sojaallergiker von toleranten Patienten zu unterscheiden. 
Weiterhin war mit einer Mischung aus allen ΔNCSN42/P49 Varianten eine Depletion der 
Gly m 4-spezifischen IgE-Bindung in den Seren der Patienten mit bzw. ohne 
Sojaallergie auf etwa 80% bzw. 70% möglich. Demnach sind die identifizierten 
potentiell funktionalen IgE-Epitope spezifisch für die Bindung von IgE-Antikörpern in 
der Studiengruppe. ΔNCSN42/P49_9 scheint die passendste Variante zu sein, mit der 
eine Unterscheidung zwischen Sensibilisierung auf Gly m 4 und klinisch bestätigter 
Sojaallergie möglich ist. Der Einsatz einer Gly m 4-spezifischen Epitopbibliothek kann 
somit eine vielversprechendere Möglichkeit zur Analyse von Birkenpollen-assoziierter 
Sojaallergie, verglichen zu ImmunoCAP™ oder der Untersuchung von Gly m 4-
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Substitutionsvarianten darstellen. Jedoch konnte auch mit der NCS-Epitopbibliothek 
keine Korrelation zwischen dem IgE-Epitopprofil der Patienten und ihren allergischen 
Symptomen sowie dem Schweregrad der Symptome ermittelt werden. Vielmehr 
scheint ein patientenspezifisches Epitopprofil Grundlage für eine Birkenpollen-
assoziierte Sojaallergie zu sein. Somit könnte also eine Kombination aus 
rekombinant hergestellten Allergenen und der detaillierten Untersuchung mittels einer 
Epitopbibliothek zukünftig zu einer genaueren Diagnose führen.  
Mittels der beiden Allergenvarianten von rBet v 1a und rGly m 4 konnte der Einfluss 
von ungefaltetem Protein durch physikochemische und immunologische Methoden in 
Präparaten aus rBet v 1a bzw. rGly m 4 untersucht werden. Beide Varianten 
rBet v 1aS112P/R145P und rGly m 4S111P/L150P zeigten eine ungefaltete Proteinstruktur 
sowie eine reduzierte IgE-Bindung in den eingesetzten Patientenseren. In CD-
Spektroskopie, Immunoblot, ELISA und RBL-Zellassay wurden definierte 
Mischungen aus nativem und ungefaltetem Allergen hinsichtlich Sekundärstruktur 
und IgE-Bindung untersucht. Eine Korrelation von rBet v 1a-Konzentration mit der 
Sekundärstruktur des Allergens sowie der IgE-Bindung war nur bei hohen 
Konzentrationen an rBet v 1aS112P/R145P möglich. Hier lieferten CD-Spektroskopie und 
ELISA präzisere Ergebnisse als der Immunoblot und RBL-Zellassay. Bei letzteren 
waren größere Unterschiede zwischen nativem und ungefaltetem Allergen für eine 
eindeutige Korrelation nötig. Weiterhin war die Bestimmung an IgE-bindendem 
Allergen in allen Assays für rBet v 1a-Konzentrationen ≤10% schwierig. CD-
Spektroskopie, ELISA und RBL-Zellassay führten zu einer Unterschätzung des 
tatsächlichen Gehalts an rBet v 1a, wohingegen mit dem Immunoblot mehr rBet v 1a 
gemessen wurde als tatsächlich in der Probe vorhanden war. Die Ergebnisse der 
beiden Faltungsvarianten rBet v 1aS112P/R145P und rGly m 4S111P/L150P könnten für das 
Screening von hypoallergenen Molekülen zur möglichen Behandlung von Allergien 
oder in der Qualitätskontrolle von Allergenpräparaten eingesetzt werden. 
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8 APPENDIX 
8.1 Supporting information 
Table A 1: Peptide and mimotope data resulting from Mittag et al. using phage-display and competitive immunoscreening with rGly m 4 (Mittag et al., 2006). 
Peptide Mimotope Center residue Score Length 
LEKGTPW 
G1, T4, L90, T93, E95, K96, T98, K118, E120, T121, E126, P127, L132; 
G1, G86, G87, L90, P91, T93, E95, K96, E120, T121, K122, G123, P127; 
119 
94 
1 13 
AAKGTPW G1, G86, G87, A88, A89, P91, T93, A94, K96, T121, K122, G123, A125, P127; 94 1 14 
QVELPKG E41, V43, K53, K54, V66, L67, K69, V84, V85, G86, G87, L90, P91; 67 1 13 
KLPLTKG G1, G86, G87, L90, P91, T93, K96, T121, K122, G123, P127; 94 1 11 
QKTAASY S72, Y80, S81, Y82, T98, S101, K102, K114, T116, K118 ; 100 1 10 
EAAKQGE G1, G86, G87, A88, A89, A94, E95, K96, E120, K122, G123, A125; 94 1 14 
IKLPALF A26, I30, P31, K32, A33, L34, F37, K38, I55, F57, L58, A141, L142, A145; 37 1 14 
KNLEEPK 
L90, E95, K96, K118, E120, E126, P127, L132; 
K20, L22, N28, P31, K32, L34, L142, L150; 
N10, P12, L22, L142, K144, E147, L150, L151; 
N10, L22, L115, K136, K138, L142, K144, E147; 
119 
29 
147 
143 
1 8 
KYLEEPV 
V2, V84, L90, E95, K96, V117, K118, Y119, E120, E126, P127, L132; 
V66, Y82, V84, V85, L90, E95, K96, V117, K118, Y119, E120, P127; 
V2, K69, E71, Y82, V84, V85, E95, K96, V117, K118, Y119, E120; 
119 
97 
98 
1 12 
TPIRHRS P49, H68, S72, I73, S81, I97, T98, S101; 82 1 8 
QYPWRLA P12, A14, A21, L22, A145, A148, Y149, L150, L151, A152, P154, Y156; 150 1 12 
FDMATNP 
F3, F5, A89. T93, A94, T121, A125, P127, N128, D130; 
F3, T4, F5, T93, A94, T98, F99, T121, A125, P127; 
A21, T24, D25, A26, D27, N28, P31, A33, F37, A145; 
F3, A88, A89, P91, D92, T93, A94, T121, A125, P127; 
A26, D27, P31, A33, D35, F37, T56, F57, A141, A145; 
F3, T4, F5, D7, T98, F99, D100, T116, P127, A139 ; 
127 
119 
129 
94 
37 
117 
1 10 
SLYELTH 
L22, T24, E71, S72, E75, L78, Y80, S81, Y82, S101; 
T4, L90, T93, E95, T98, Y119, E120, T121, E126, L132; 
H68, E71, Y80, S81, Y82, T98, S101, L115, T116, Y119; 
E6, E71, S72, Y80, S81, Y82, T98, S101, L115, T116; 
80 
119 
99 
100 
1 10 
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TAIHAVW V66, H68, V84, V85, A88, A89, A94, I97, T98, V117, T121; 97 1 11 
DHLPSPW 
L22, D25, D27, P31, L34, S36, S39, L142; 
D27, P31, L34, D35, S36, S39, L58, L142; 
30 
37 
1 8 
YKSDNIR 
S72, I73, D74, N77, Y80, S81, Y82, D100, S101, K102; 
K53, K69, S72, I73, Y80, S81, Y82, I97, D100, S101; 
D25, D27, N28, I30, K32, S39, N42, K53, K54, I55; 
S72, I73, D74, N77, Y80, S81, D100, S101, K102, K114; 
80 
82 
27 
79 
1 10 
SKTDNLT T4, D7, S81, T98, D100, S101, K102, K114, L115, T116, K118; 116 1 11 
AFNRASD 
A21, D25, A26, D27, N28, A33, S36, F37, S39, A145; 
A26, D27, A33, D35, S36, F37, S39, F57, A141, A145; 
30 
37 
1 10 
YLMEVQK V2, K69, E71, Y82, V84, V85, E95, K96, V117, K118, Y119, E120; 98 1 12 
YEMDAPK A88, A89, P91, D92, A94, E95, K96, Y119, E120, K122, A125, P127; 94 1 12 
ERHLTFT F3, T4, F5, L90, T93, E95, T98, F99, E120, T121, E126, L132; 119 1 12 
 
21 peptides for soybean allergic patients were identified and mapped onto Gly m 4 surface using EpiSearch resulting in 40 potential IgE-binding mimotopes. Resulting from 
EpiSearch analysis, center residue, score and total length of each identified mimotope are listed. 
 
Table A 2: Peptide and mimotope data from bioinformatical approach using 7mer peptides representing total amino acid sequence of Gly m 4. 
Peptide Mimotope Center residue Score Length 
MGVFTFE G1, V2, F3, T4, F5, V84, T93, E95, T98, F99, V117, E120, T121, E126; 119 1 14 
GVFTFED G1, V2, F3, T4, F5, V84, T93, E95, T98, F99, V117, E120, T121, E126; 119 1 14 
VFTFEDE V2, F3, T4, F5, V84, T93, E95, T98, F99, V117, E120, T121, E126; 119 1 13 
FTFEDEI F3, T4, F5, T93, E95, I97, T98, F99, E120, T121, E126; 119 1 11 
TFEDEIN F3, T4, F5, T93, E95, I97, T98, F99, E120, T121, E126; 119 1 11 
FEDEINS 
E71, S72, I73, D74, E75, N77, S81, F99, D100, S101; 
D35, S36, F37, S39, I55, F57, E59, D60, E62, F65; 
80 
57 
1 10 
EDEINSP 
E71, S72, I73, D74, E75, N77, S81, D100, S101; 
D25, D27, N28, I30, P31, S39, E41, N42, I55; 
80 
27 
1 9 
DEINSPV 
D25, D27, N28, V29, I30, P31, S39, V40, E41, N42, I55; 
D27, S39, V40, E41, N42, V43, E44, I52, I55, V66, V85; 
27 
54 
1 11 
EINSPVA A21, A26, N28, V29, I30, P31, A33, S36, S39, V40, I55, A145; 30 1 12 
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INSPVAP A21, A26, N28, V29, I30, P31, A33, S36, S39, V40, I55, A145; 30 1 12 
NSPVAPA A21, A26, N28, V29, P31, A33, S36, S39, V40, A145; 30 1 10 
SPVAPAT 
V2, T4, V84, T93, A94, T98, V117, T121, A125, P127; 
P12, V13, A14, T17, A21, V29, A145, A148, A152, P154; 
V66, V84 V85, A88, A89, A94, T98, V117, T121, P127; 
A26, V29, P31, A33, S36, S39, V40, T56, A141, A145; 
119 
150 
97 
37 
1 10 
PVAPATL P12, V13, A14, T17, A21, L22, V29, A145, A148, L150, L151, A152, P154; 150 1 13 
VAPATLY P12, V13, A14, T17, A21, L22, V29, A145, A148, Y149, L150, L151, A152, P154, Y156; 150 1 15 
APATLYK 
P12, A14, T17, A21, L22, A145, A148, Y149, L150, L151, A152, P154, Y156; 
K20, A21, L22, T24, A26, P31, K32, A33, L34, L142, A145, Y149, L150; 
150 
29 
1 13 
PATLYKA 
P12, A14, T17, A21, L22, A145, A148, Y149, L150, L151, A152, P154, Y156; 
K20, A21, L22, T24, A26, P31, K32, A33, L34, L142, A145, Y149, L150; 
150 
29 
1 13 
ATLYKAL 
K20, A21, L22, T24, A26, K32, A33, L34, L142, A145, Y149, L150; 
A21, K32, A33, L34, K144, A145, A148, Y149, L150, L151, A152, Y156; 
29 
149 
1 12 
TLYKALV 
V2, T4, V84, L90, T93, A94, K96, T98, V117, K118, Y119, T121, A125, L132; 
K20, A21, L22, T24, A26, V29, K32, A33, L34, V40, L142, A145, Y149, L150; 
V13, A21, V29, K32, A33, L34, K144, A145, A148, Y149, L150, L151, A152, Y156; 
V66, Y82, V84, V85, A88, A89, L90, A94, K96, T98, V117, K118, Y119, T121, 
119 
29 
149 
97 
1 14 
LYKALVT 
V2, T4, V84, L90, T93, A94, K96, T98, V117, K118, Y119, T121, A125, L132; 
K20, A21, L22, T24, A26, V29, K32, A33, L34, V40, L142, A145, Y149, L150; 
V13, A21, V29, K32, A33, L34, K144, A145, A148, Y149, L150, L151, A152, Y156; 
V66, Y82, V84, V85, A88, A89, L90, A94, K96, T98, V117, K118, Y119, T121; 
119 
29 
149 
97 
1 14 
YKALVTD K20, A21, L22, T24, D25, A26, D27, V29, K32, A33, L34, V40, L142, A145, Y149, L150; 29 
 
16 
KALVTDA K20, A21, L22, T24, D25, A26, D27, V29, K32, A33, L34, V40, L142, A145, L150; 29 1 15 
ALVTDAD A21, L22, T24, D25, A26, D27, V29, A33, L34, V40, L142, A145, L150; 29 1 13 
LVTDADN A21, L22, T24, D25, A26, D27, N28, V29, A33, L34, V40, L142, A145, L150; 29 1 14 
VTDADNV A21, T24, D25, A26, D27, N28, V29, A33, V40, A145; 29 1 10 
TDADNVI 
A21, D25, A26, D27, N28, V29, I30, A33, V40, I55, A145; 
A21, T24, D25, A26, D27, N28, V29, I30, A33, V40, A145; 
A26, D27, V29, I30, A33, D35, V40, I55, T56, A141, A145; 
30 
29 
37 
1 11 
DADNVIP A21, D25, A26, D27, N28, V29, I30, P31, A3 , V40, I55, A145; 30 1 12 
ADNVIPK 
A26, D27, V40, V43, I52, K53, K54, I55, V66, K69, V84, V85, I97; 
A21, D25, A26, D27, N28, V29, I30, P31, K32, A33, V40, I55, A145; 
D25, A26, D27, N28, V29, I30, P31, K32, V40, N42, K53, K54, I55; 
K20, A21, D25, A26, D27, N28, V29, I30, P31, K32, A33, V40, A145; 
A26, D27, V29, I30, P31, K32, A33, D35, K38, V40, I55, A141, A145; 
68 
30 
27 
29 
37 
1 13 
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DNVIPKA 
A26, D27, V40, V43, I52, K53, K54, I55, V66, K69, V84, V85, I97; 
A21, D25, A26, D27, N28, V29, I30, P31, K32, A33, V40, I55, A145; 
D25, A26, D27, N28, V29, I30, P31, K32, V40, N42, K53, K54, I55; 
K20, A21, D25, A26, D27, N28, V29, I30, P31, K32, A33, V40, A145; 
A26, D27, V29, I30, P31, K32, A33, D35, K38, V40, I55, A141, A145; 
68 
30 
27 
29 
37 
1 13 
NVIPKAL K20, A21, L22, A26, N28, V29, I30, P31, K32, A33, L34, V40, L142, A145, L150; 29 1 15 
VIPKALD 
K20, A21, L22, D25, A26, D27, V29, I30, P31, K32, A33, L34, V40, L142, A145, L150; 
A26, D27, V29, I30, P31, K32, A33, L34, D35, K38, V40, I55, L58, A141, L142, A145; 
29 
37 
1 16 
IPKALDS A26, D27, I30, P31, K32, A33, L34, D35, S36, K38, S39, I55, L58, A141, L142, A145; 37 1 16 
PKALDSF A26, D27, P31, K32, A33, L34, D35, S36, F37, K38, S39, F57, L58, A141, L142, A145; 37 1 16 
KALDSFK A26, D27, K32, A33, L34, D35, S36, F37, K38, S39, F57, L58, A141, L142, A145; 37 1 15 
ALDSFKS 
A21, L22, D25, A26, D27, K32, A33, L34, S36, F37, S39, L142, A145; 
K20, A21, L22, D25, A26, D27, K32, A33, L34, F37, L142, A145, L150; 
30 
29 
1 13 
LDSFKSV D27, V29, K32, L34, D35, S36, F37, K38, S39, V40, F57, L58, L142; 37 1 13 
DSFKSVE 
D35, S36, F37, K38, S39 F57, E59, D60, E62, K64, F65, V66, K138; 
V2, K69, E71, S81, V84, V85, E95, K96, F99, D100, V117, K118, E120; 
57 
98 
1 13 
SFKSVEN 
V2, K69, E71, S81, V84, V85, E95, K96, F99, V117, K118, E120; 
S39, V40, E41, N42, V43, E44, K53, K54, F65, V66, K69, V85; 
98 
54 
1 12 
FKSVENV 
V2, K69, E71, S81, V84, V85, E95, K96, F99, V117, K118, E120; 
S39, V40, E41, N42, V43, E44, K53, K54, F65, V66, K69, V85; 
98 
54 
1 12 
KSVENVE 
V2, K69, E71, S81, V84, V85, E95, K96, V117, K118, E120; 
S39, V40, E41, N42, V43, E44, K53, K54, V66, K69, V85; 
98 
54 
1 11 
SVENVEG S39, V40, E41, N42, V43, E44, V66, V85, G86, G87; 54 1 10 
VENVEGN 
V40, E41, N42, V43, E44, G45, G47, G50, V66; 
V40, E41, N42, V43, E44, V66, V85, G86, G87; 
53 
54 
1 9 
ENVEGNG 
V40, E41, N42, V43, E44, G45, G47, G50, V66; 
V40, E41, N42, V43, E44, V66, V85, G86, G87; 
53 
54 
1 9 
NVEGNGG 
V40, E41, N42, V43, E44, G45, G47, G50, V66 
V40, E41, N42, V43 , E44, V66, V85, G86, G87; 
53 
54 
1 9 
VEGNGGP 
V40, E41, N42, V43, E44, G45, G47, G50, V66; 
G1, V84, G86, G87, P91, E95, E120, G123, P127; 
N42, V43, E44, G45, N46, G47, G48, P49, G50; 
V40, E41, N42, V43, E44, V66, V85, G86, G87; 
53 
94 
45 
45 
1 9 
EGNGGPG 
E44, G45, N46, G47, G48, P49, G50, E71; 
G1, G86, G87, P91, E95, E120, G123, P127; 
N42, E44, G45, N46, G47, G48, P49, G50; 
N42, E44, G45, N46, G47, G48, P49, G50; 
50 
94 
47 
45 
1 8 
GNGGPGT 
G1, G86, G87, P91, T93, T121, G123, P127; 
T24, N42, G45, N46, G47, G48, P49, G50; 
94 
47 
1 8 
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NGGPGTI T24, N42, G45, N46, G47, G48, P49, G50, I52, I73; 47 1 10 
GGPGTIK G1, G86, G87, P91, T93, K96, I97, T121, K122, G123, P127; 94 1 11 
GPGTIKK G1, G86, G87, P91, T93, K96, I97, T121, K122, G123, P127; 94 1 11 
PGTIKKI G1, G86, G87, P91, T93, K96, I97, T121, K122, G123, P127; 94 1 11 
GTIKKIT 
G1, G86, T93, K96, I97, T98, T121, K122, G123; 
K38, K54, I55, T56, G61, T63  K64, G86, G87; 
K53, K54, I55, T56, T63, K64, G86, G87, I97; 
G1, G86, G87, T93, K96, I97, T121, K122, G123; 
95 
65 
66 
94 
1 9 
TIKKITF 
F3, T4, F5, T93, K96, I97, T98, F99, K118, T121; 
I30, F37, K38, K53, K54, I55, T56, F57, T63, F65; 
119 
55 
1 10 
IKKITFL F3, T4, F5, L90, T93, K96, I97, T98, F99, K118, T121, L132; 119 1 12 
KKITFLE F3, T4, F5, L90, T93, E95, K96, I97, T98, F99, K118, E120, T121, E126, L132; 119 1 15 
KITFLED F3, T4, F5, L90, T93, E95, K96, I97, T98, F99, K118, E120, T121, E126, L132; 119 1 15 
ITFLEDG G1, F3, T4, F5, L90, T93, E95, I97, T98, F99, E120, T121, E126, L132; 119 1 14 
TFLEDGE G1, F3, T4, F5, L90, T93, E95, T98, F99, E120, T121, E126, L132; 119 1 13 
FLEDGET G1, F3, T4, F5, L90, T93, E95, T98, F99, E120, T121, E126, L132; 119 1 13 
LEDGETK 
G1, T4, L90, T93, E95, K96, T98, K118, E120, T121, E126, L132; 
G1, G86, G87, L90, D92, T93, E95, K96, E120, T121, K122, G123; 
119 
94 
1 12 
EDGETKF 
G1, F3, T4, F5, T93, E95, K96, T98, F99, K118, E120, T121, E126; 
D35, F37, K38, T56, F57, E59, D60, G61, E62, T63, K64, F65, K138; 
119 
57 
1 13 
DGETKFV G1, V2, F3, T4, F5, V84, T93, E95, K96, T98, F99, V117, K118, E120, T121, E126; 119 1 16 
GETKFVL 
G1, V2, F3, T4, F5, V84, L90, T93, E95, K96, T98, F99, V117, K118, E120, T121, E126, 
L132; 
119 1 18 
ETKFVLH V2, F3, T4, F5, V84, L90, T93, E95, K96, T98, F99, V117, K118, E120, T121, E126, L132; 119 1 17 
TKFVLHK V2, F3, T4, F5, V84, L90, T93, K96, T98, F99, V117, K118, T121, L132; 119 1 17 
KFVLHKI V40, V43, I52, K53, K54, I55, F65, V66, L67, H68, K69, V84, V85, I97, F99; 68 1 15 
FVLHKIE V40, V43, I52, K53, K54, I55, F65, V66, L67, H68, K69, E71, V84, V85, I97, F99; 68 1 16 
VLHKIES 
V40, V43, I52, K53, K54, I55, V66, L67, H68, K69, E71, V84, V85, I97; 
S39, V40, E41, V43, E44, I52, K53, K54, I55, V66, L67, H68, K69, V85; 
68 
54 
1 14 
LHKIESI S39, E41, E44, I52, K53, K54, I55, L67, H68, K69; 54 1 10 
HKIESID 
D25, D27, I30, K32, S39, E41, K53, K54, I55, H68; 
D35, S36, K38, S39, I55, E59, D60, E62, K64, K138; 
27 
57 
1 10 
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D27, S39, E41, E44, I52, K53, K54, I55, H68, K69; 
K53, H68, K69, E71, S72, I73, S81, I97, D100, S101; 
54 
82 
KIESIDE D35, S36, K38, S39, I55, E59, D60, E62, K64, K138; 57 1 10 
IESIDEA 
A21, D25, A26, D27, I30, A33, S36, S39, I55, A145; 
A26, D27, I30, A33, D35, S36, S39, I55, A141, A145; 
30 
37 
1 10 
ESIDEAN A21, D25, A26, D27, N28, I30, A33, S36, S39, I55 , A145; 30 1 11 
SIDEANL A21, L22, D25, A26, D27, N28, I30, A33, L34, S36, S39, I55, L142, A145; 30 1 14 
IDEANLG G1, G86, G87, A88, A89, L90, D92, A94, E95, I97, E120, G123, A125; 94 1 13 
DEANLGY G1, G86, G87, A88, A89, L90, D92, A94, E95, Y119, E120, G123, A125; 94 1 13 
EANLGYS 
L22, A26, E71, S72, E75, N77, L78, G79, Y80, S81, Y82, S101; 
G1, G86, G87, A88, A89, L90, A94, E95, Y119, E120, G123, A125; 
80 
94 
1 12 
ANLGYSY A21, L22, A26, N28, A33, L34, S36, S39, L142, A145, Y149; 30 1 11 
NLGYSYS L22, S72, N77, L78, G79, Y80, S81, Y82, S101; 80 1 9 
LGYSYSV V66, L67, Y82, V84, V85, G86, G87, L90, V117, Y119; 84 1 10 
GYSYSVV 
G50, S72, Y80, S81, Y82, V84, V85, S101; 
V66, Y82, V84, V85, G86, G87, V117, Y119; 
82 
84 
1 8 
YSYSVVG 
G50, S72, Y80, S81, Y82, V84, V85, S101; 
V66, Y82, V84, V85, G86, G87, V117, Y119; 
82 
84 
1 8 
SYSVVGG 
V40, V43, V66, Y82, V84, V85, G86, G87; 
G50, S72, Y80, S81, Y82, V84, V85, S101; 
V66, Y82, V84, V85, G86, G87, V117, Y119; 
68 
82 
84 
1 8 
YSVVGGA A26, V40, V43, V66, Y82, V84, V85, G86, G87; 68 1 9 
SVVGGAA G1, V84, G86, G87, A88, A89, A94, G123, A125; 94 1 9 
VVGGAAL 
V66, L67, V84, V85, G86, G87, A88, A89, L90, A94; 
V66, L67, V84, V85, G86, G87, A88, L90, A94, V117; 
V13, A14, A21, L22, V29, A145, A148, L150, L151, A152; 
L22, A26, V29, L34, G135, A137, A139, A141, L142, A145; 
V66, L67, V84, V85, G86, G87, A88, A89, L90, A94; 
A21, L22, A26, V29, A33, L34, V40, L142, A145, L150; 
V13, A21, V29, A33, L34, A145, A148, L150, L151, A152; 
G1, V84, G86, G87, A88, A89, L90, A94, G123, A125; 
V66, L67, V84, V85, G86, G87, A88, A89, L90, A94; 
90 
84 
150 
142 
87 
29 
149 
94 
86 
1 10 
VGGAALP 
P12, V13, A14, A21, L22, V29, A145, A148, L150, L151, A152, P154; 
G1, V84, G86, G87, A88, A89, L90, P91, A94, G123, A125, P127; 
150 
94 
1 12 
GGAALPD G1, G86, G87, A88, A89, L90, P91, D92, A94, G123, A125, P127; 94 1 12 
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GAALPDT G1, G86, G87, A88, A89, L90, P91, D92, T93, A94, T121, G123, A125, P127; 94 1 14 
AALPDTA A21, L22, T24, D25, A26, D27, P31, A33, L34, L142, A145, L150; 29 1 12 
ALPDTAE 
T4, L90, T93, A94, E95, T98, E120, T121, A125, E126, P127, L132; 
A88, A89, L90, P91, D92, T93, A94, E95, T121, A125, E126, P127; 
A21, L22, T24, D25, A26, D27, P31, A33, L34, L142, A145, L150; 
P12, A14, T17, A21, L22, A145, E147, A148, L150, L151, A152, P154; 
A88, A89, L90, P91, D92, T93, A94, E95, E120, T121, A125, P127; 
119 
93 
29 
150 
94 
1 12 
LPDTAEK 
T4, L90, T93, A94, E95, K96, T98, K118, E120, T121, A125, E126, P127, L132; 
K20, A21, L22, T24, D25, A26, D27, P31, K32, A33, L34, L142, A145, L150; 
A88, A89, L90, P91, D92, T93, A94, E95, K96, E120, T121, K122, A125, P127; 
119 
29 
94 
1 14 
PDTAEKI A88, A89, P91, D92, T93, A94, E95, K96, I97, E120, T121, K122, A125, P127; 94 1 14 
DTAEKIT 
T4, T93, A94, E95, K96, I97, T98, K118, E120, T121, A125, E126; 
A88, A89, D92, T93, A94, E95, K96, I97, E120, T121, K122, A125; 
119 
94 
1 12 
TAEKITF F3, T4, F5, T93, A94, E95, K96, I97, T98, F99, K118, E120, T121, A125, E126; 119 1 15 
AEKITFD F3, T4, F5, T93, A94, E95, K96, I97, T98, F99, K118, E120, T121, A125, E126; 119 1 15 
EKITFDS D35, S36, F37, K38, S39, I55, T56, F57, E59, D60, E62, T63, K64, F65, K138; 57 1 15 
KITFDSK D35, S36, F37, K38, S39, I55, T56, F57, D60, T63, K64, F65, K138; 57 1 13 
ITFDSKL 
D35, S36, F37, K38, S39, I55, T56, F57, L58, D60, T63, K64, F65, K138; 
D27, I30, K32, L34, D35, S36, F37, K38, S39, I55, T56, F57, L58, L142; 
F3, T4, F5, D7, I97, T98, F99, D100, S101, L115, T116, K118, L132, K136; 
57 
37 
117 
1 14 
TFDSKLV F3, T4, F5, D7, V84, T98, F99, D100, S101, L115, T116, V117, K118, L132, K136; 117 1 15 
FDSKLVA A26, D27, V29, K32, A33, L34, D35, S36, F37, K38, S39, V40, F57, L58, A141, L142, A145; 37 1 17 
DSKLVAG A26, D27, V29, K32, A33, L34, D35, S36, K38, S39, V40, L58, A141, L142, A145; 37 1 15 
SKLVAGP 
G1, V84, G86, G87, A88, A89, L90, P91, A94, K96, K122, G123, A125, P127; 
A26, V29, P31, K32, A33, L34, S36, K38, S39, V40, L58, A141, L142, A145; 
K54, V66, L67, K69, V84, V85, G86, G87, A88, A89, L90, P91, A94, K96; 
94 
37 
86 
1 14 
KLVAGPN 
K20, A21, L22, A26, N28, V29, P31, K32, A33, L34, V40, L142, A145, L150; 
G1, V84, G86, G87, A88, A89, L90, P91, A94, K96, K122, G123, A125, P127; 
K54, V66, L67, K69, V84, V85, G86, G87, A88, A89, L90, P91, A94, K96; 
29 
94 
86 
1 14 
LVAGPNG 
P12, V13, A14, A21, L22, V29, A145, A148, L150, L151, A152, P154; 
N10, P12, V13, A14, P15, A16, A21, L22, G109, A148, L150, L151; 
A21, L22, A26, N28, V29, P31, A33, L34, V40, L142, A145, L150; 
G1, V84, G86, G87, A88, A89, L90, P91, A94, G123, A125, P127; 
150 
13 
29 
94 
1 12 
VAGPNGG 
N10, P12, A14, P15, V104, A105, G106, P107, N108, G109, A112; 
G1, V84, G86, G87, A88, A89, P91, A94, G123, A125, P127; 
106 
94 
1 11 
AGPNGGS N10, P12, A14, P15, A105, G106, P107, N108, G109, A112; 106 1 10 
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G1, G86, G87, A88, A89, P91, A94, G123, A125, P127; 94 
GPNGGSA 
N10, P12, A14, P15, A105, G106, P107, N108, G109, A112; 
G1, G86, G87, A88, A89, P91, A94, G123, A125, P127; 
106 
94 
1 10 
PNGGSAG 
N10, P12, A14, P15, A105, G106, P107, N108, G109, A112; 
G1, G86, G87, A88, A89, P91, A94, G123, A125, P127; 
106 
94 
1 10 
NGGSAGK G1, G86, G87, A88, A89, A94, K96, K122, G123, A125; 94 1 10 
GGSAGKL L22, A26, L34, S36, G135, A137, K138, A139, A141, L142, K144, A145; 142 1 12 
GSAGKLT G1, G86, G87, A88, A89, L90, T93, A94, K96, T121, K122, G123, A125; 94 1 13 
SAGKLTV 
G1, V2, T4, V84, L90, T93, A94, K96, T98, V117, K118, T121, A125, L132; 
K53, K54, T56, T63, K64, V66, L67, V84, V85, G86, G87, A88, A89, L90; 
G1, V84, G86, G87, A88, A89, L90, T93, A94, K96, T121, K122, G123, A125; 
A26, V29, K32, A33, L34, S36, K38, S39, V40, T56, L58, A141, L142, A145; 
119 
66 
94 
37 
1 14 
AGKLTVK 
G1, V2, T4, V84, L90, T93, A94, K96, T98, V117, K118, T121, A125, L132; 
G1, V84, G86, G87, A88, A89, L90, T93, A94, K96, T121, K122, G123, A125; 
K53, K54, T56, T63, K64, V66, L67, V84, V85, G86, G87, A88, A89, L90; 
119 
94 
66 
1 14 
GKLTVKY 
G1, V2, T4, V84, L90, T93, K96, T98, V117, K118, Y119, T121, L132; 
V66, L67, K69, Y82, V84, V85, G86, G87, L90, K96, T98, V117, Y119, 
119 
84 
1 13 
KLTVKYE V2, T4, V84, L90, T93, E95, K96, T98, V117, K118, Y119, E120, T121, E126, L132; 119 1 15 
LTVKYET V2, T4, V84, L90, T93, E95, K96, T98, V117, K118, Y119, E120, T121, E126, L132; 119 1 15 
TVKYETK V2, K69, E71, Y82, V84, V85, E95, K96, T98, T116, V117, K118, Y119, E120; 98 1 14 
VKYETKG 
G1, V2, T4, V84, T93, E95, K96, T98, V117, K118, Y119, E120, T121, E126; 
V2, K69, E71, Y82, V84, V85, E95, K96, T98, T116, V117, K118, Y119, E120; 
119 
98 
1 14 
KYETKGD G1, G86, G87, D92, T93, E95, K96, Y119, E120, T121, K122, G123; 94 1 12 
YETKGDA G1, G86, G87, A88, A89, D92, T93, A94, E95, K96, Y119, E120, T121, K122, G123, A125; 94 1 16 
ETKGDAE G1, G86, G87, A88, A89, D92, T93, A94, E95, K96, E120, T121, K122, G123, A125; 94 1 15 
TKGDAEP 
G1, G86, G87, A88, A89, P91, D92, T93, A94, E95, K96, E120, T121, K122, G123, A125, 
P127; 
94 1 17 
KGDAEPN G1, G86, G87, A88, A89, P91, D92, A94, E95, K96, E120, K122, G123, A125, P127; 94 1 15 
GDAEPNQ G1, G86, G87, A88, A89, P91, D92, A94, E95, E120, G123, A125, P127; 94 1 13 
DAEPNQD 
A89, A94, A125, E126, P127, N128, Q129, D130, E131; 
A88, A89, P91, D92, A94, E95, A125, E126, P127; 
A88, A89, P91, D92, A94, E95, E120, A125, P127; 
127 
93 
94 
1 9 
AEPNQDE 
A89, A94, A125, E126, P127, N128, Q129, D130, E131; 
A88, A89, P91, D92, A94, E95, A125, E126, P127; 
A88, A89, P91, D92, A94, E95, E120, A125, P127; 
127 
93 
94 
1 9 
8 Appendix          168 
 
EPNQDEL 
N10, P12, L22, D140, L142, E147, L150, L151; 
L22, D25, D27, N28, P31, L34, L142, L150; 
147 
29 
1 8 
PNQDELK K20, L22, D25, D27, N28, P31, K32, L34, L142, L150; 29 1 10 
NQDELKT 
T4, L90, T93, E95, K96, T98, K118, E120, T121, E126, L132; 
T4, E6, D7, E8, T98, D100, K102, K114, L115, T116, K118; 
119 
116 
1 11 
QDELKTG 
G1, T4, L90, T93, E95, K96, T98, K118, E120, T121, E126, L132; 
G1, G86, G87, L90, D92, T93, E95, K96, E120, T121, K122, G123; 
119 
94 
1 12 
DELKTGK 
G1, T4, L90, T93, E95, K96, T98, K118, E120, T121, E126, L132; 
G1, G86, G87, L90, D92, T93, E95, K96, E120, T121, K122, G123; 
119 
94 
1 12 
ELKTGKA G1, G86, G87, A88, A89, L90, T93, A94, E95, K96, E120, T121, K122, G123, A125; 94 1 15 
LKTGKAK 
G1, T4, L90, T93, A94, K96, T98, K118, T121, A125, L132; 
L22, A26, L34, G135, A137, K138, A139, A141, L142, K144, A145; 
L115, L132, K133, T134, G135, K136, A137, K138, A139, A141, L142; 
119 
142 
135 
1 11 
KTGKAKA G1, G86, G87, A88, A89, T93, A94, K96, T121, K122, G123, A125; 94 1 14 
TGKAKAD G1, G86, G87, A88, A89, D92, T93, A94, K96, T121, K122, G123, A125; 94 1 13 
GKAKADA G1, G86, G87, A88, A89, D92, A94, K96, K122, G123, A125; 94 1 11 
KAKADAL K20, A21, L22, D25, A26, D27, K32, A33, L34, L142, A145, L150; 29 1 12 
AKADALF 
L34, D35, F37, K136, A137, K138, A139, D140, A141, L142, F143, K144, A145; 
K32, A33, L34, D35, F37, D140, A141, L142, F143, K144, A145, A148, L150; 
L22, A26, L34, F37, A137, K138, A139, D140, A141, L142, F143, K144, A145; 
K20, A21, L22, D25, A26, D27, K32, A33, L34, F37, L142, A145, L150; 
A26, D27, K32, A33, L34, D35, F37, K38, F57, L58, A141, L142, A145; 
141 
145 
142 
29 
37 
1 13 
KADALFK 
L34, D35, F37, K136, A137, K138, A139, D140, A141, L142, F143, K144, A145; 
K32, A33, L34, D35, F37, D140, A141, L142, F143, K144, A145, A148, L150; 
L22, A26, L34, F37, A137, K138, A139, D140, A141, L142, F143, K144, A145; 
K20, A21, L22, D25, A26, D27, K32, A33, L34, F37, L142, A145, L150; 
A26, D27, K32, A33, L34, D35, F37, K38, F57, L58, A141, L142, A145; 
141 
145 
142 
29 
37 
1 13 
ADALFKA 
L34, D35, F37, K136, A137, K138, A139, D140, A141, L142, F143, K144, A145; 
K32, A33, L34, D35, F37, D140, A141, L142, F143, K144, A145, A148, L150; 
L22, A26, L34, F37, A137, K138, A139, D140, A141, L142, F143, K144, A145; 
K20, A21, L22, D25, A26, D27, K32, A33, L34, F37, L142, A145, L150; 
A26, D27, K32, A33, L34, D35, F37, K38, F57, L58, A141, L142, A145; 
141 
145 
142 
29 
37 
1 13 
DALFKAI A26, D27, I30, K32, A33, L34, D35, F37, K38, I55, F57, L58, A141, L142, A145; 37 1 15 
ALFKAIE L22, A26, I30, L34, F37, A137, K138, A139, A141, L142, F143, K144, A145, E147; 142 1 14 
LFKAIEA L22, A26, I30, L34, F37, A137, K138, A139, A141, L142, F143, K144, A145, E147; 142 1 14 
FKAIEAY 
F3, F5, A94, E95, K96, I97, F99, K118, Y119, E120, A125, E126; 
F3, Y82, A88, A89, A94, E95, K96, I97, F99, K118, Y119, E120; 
119 
97 
1 12 
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KAIEAYL A21, I30, K32, A33, L34, K144, A145, E147, A148, Y149, L150, L151, A152, Y156; 149 1 14 
AIEAYLL A21, I30, A33, L34, A145, E147, A148, Y149, L150, L151, A152, Y156; 149 1 12 
IEAYLLA A21, I30, A33, L34, A145, E147, A148, Y149, L150, L151, A152, Y156; 149 1 12 
EAYLLAH 
A21, A33, L34, A145, E147, A148, Y149, L150, L151, A152, H153, Y156; 
A14, A21, L22, A145, E147, A148, Y149, L150, L151, A152, H153, Y156; 
149 
150 
1 12 
AYLLAHP P12, A14, A21, L22, A145, A148, Y149, L150, L151, A152, H153, P154, Y156; 150 1 13 
YLLAHPD P12, A14, A21, L22, A145, A148, Y149, L150, L151, A152, H153, P154, Y156; 150 1 13 
LLAHPDY P12, A14, A21, L22, A145, A148, Y149, L150, L151, A152, H153, P154, Y156; 150 1 13 
LAHPDYN 
P12, A14, A21, L22, A145, A148, Y149, L150, L151, A152, H153, P154, Y156; 
A21, L22, D25, A26, D27, N28, P31, A33, L34, L142, A145, Y149, L150; 
150 
29 
1 13 
 
152 peptides with an off-set of one amino acid were generated from Gly m 4 amino acid sequence and mapped onto Gly m 4 surface using EpiSearch resulting in 270 potential 
IgE-binding mimotopes. Resulting from EpiSearch analysis, center residue, score and total length of each identified mimotope are listed. 
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Table A 3: Summary of results obtained with dot blot with eleven ΔNCSN42/P49 variants (ΔNCSN42/P49_1-_11) and patients’ sera. 
 Generated ΔNCSN42/P49 variants (ΔNCSN42/P49_x) 
Patient No. 1 2 3 4 5 6 7 8 9 10 11 
1    X  X X X X X  
2    X  X X  X X  
3       X  X X  
4    X X X X  X X  
5       X     
7       X  X X  
8    X   X  X   
9       X  X X  
10       X X    
11    X  X X X  X  
13 X    X X X X    
22       X     
28          X  
30       X X X X  
33       X X X X X 
34   X    X     
35    X  X X X X X X 
36    X   X  X X  
37    X   X  X X  
38    X  X X  X X  
40    X   X  X X  
41    X  X X  X X  
16    X  X X  X X  
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20    X   X   X  
24    X   X   X  
25    X   X   X  
26    X   X   X  
27       X   X  
43    X   X   X  
44    X   X   X  
45          X  
46       X     
47            
48       X   X  
49       X     
50       X     
 
Patients sensitized and clinically soy allergic (group 1) as well as patients sensitized but without soybean allergy (group 2) were analyzed in dot blot together with generated 
ΔNCSN42/P49 variants. X resembles a positive IgE signal as described in 3.5.2. ΔNCSN42/P49_x resembles: 
ΔNCSN42/P49_1=Δ51NCSF3/F5/E6N42/P49/D124/E126, 
ΔNCSN42/P49_2=Δ51NCSD25/D27/N28/V29/K32/N42/P49/A152/D155/Y156, 
ΔNCSN42/P49_3=Δ51NCSK38/S39/N42/P49/E59/D60/K64, 
ΔNCSN42/P49_4=Δ51NCSN42/E44/N46/P49/K54, 
ΔNCSN42/P49_5=Δ51NCSN10/N42/P49/D130/E131/K133/K136/K144/E147/A148, 
ΔNCSN42/P49_6=Δ29NCSK32/N42/E44/N46/P49/K54/D60/E120/E126, 
ΔNCSN42/P49_7=Δ51NCSF3/K38/N42/P49/D60/N128, 
ΔNCSN42/P49_8=Δ51NCST24/S36/N42/P49/S81/D124, 
ΔNCSN42/P49_9=Δ51NCST4/T17/N42/N46/P49/S83, 
ΔNCSN42/P49_10=Δ51NCSF5/T17/T24/S36/N42/P49/K64/S81/K118/D124/K133, 
ΔNCSN42/P49_11=Δ51NCST4/T17/K32/N42/N46/P49/E75/S83 /D100/D124/E126/K144. 
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Figure A 1: Sequence alignments of proteins analyzed with LC-MS.  
(A) Gly m 4 wild type (UniProt accession number P26987) and Gly m 4_11x; (B) Gly m 4 wild type (UniProt accession number P26987) and Gly m 4S111p/L150P; (C) Bet v 1a (UniProt 
accession number P15494) and Bet v 1aS111P/R145P; Peptides that were detected by MS are printed in bold letter. Amino acids that were exchanged are printed in red color. 
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Table A 4: Summary of results from actual and theoretical values of quantitative IgE immunoassays. 
Immunoblot 
rBet v 1a 
(S112P/R145P) 
[%] 
mean estimate 
(actual) in [AU] 
95% CI p-value 
mean estimate 
(theoretical) in 
[AU] 
actual/theoretical 
comparison 
0 1.17*10
7
 6.56*10
6
-2.1*10
7
 -- 1.17*10
7
 1 
20 8.86*10
6
 4.95*10
6
-1.58*10
7
 0.0088 9.39*10
6
 0.94 
40 6.88*10
6
 3.85*10
6
-1.23*10
7
 0.0001 7.04*10
6
 0.98 
60 5.7*10
6
 3.19*10
6
-1.02*10
7
 <0.0001 4.69*10
6
 1.21 
80 3.47*10
6
 1.94*10
6
-6.21*10
6
 <0.0001 2.35*10
6
 1.48 
90 2.04*10
6
 1.14*10
6
-3.66*10
6
 <0.0001 1.17*10
6
 1.74 
99* 2.55*10
4
 1.43*10
4
-4.57*10
4
 <0.0001 1.17*10
5
 0.22 
99.9 4.72*10
4
 2.65*10
4
-8.46*10
4
 <0.0001 1.17*10
4
 4.03 
99.99 1.54*10
4
 8.61*10
3
-2.75*10
4
 <0.0001 1.17*10
3
 13.16 
100 1.56*10
4
 8.75*10
3
-2.8*10
4
 <0.0001 -- -- 
 
Inhibition ELISA 
rBet v 1a 
(S112P/R145P) 
[%] 
actual EC50 
[ng/well] 
95% CI p-value 
theoretical EC50 
[ng/well] 
actual/theoretical 
comparison 
0 2.41 1.97-2.96 -- 2.41 1 
20 3.37 2.75-4.15 0.588 3.01 1.09 
40 3.75 3.05-4.62 0.412 4.02 0.93 
60 5.99 4.83-7.44 0.182 6.03 0.99 
80 10.46 8.32-13.2 0.039 12.05 0.87 
90 17.31 13.55-22.2 0.093 24.1 0.72 
99 144.45 109.57-190.73 0.724 241 0.61 
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99.9 691.05 503.35-954.87 0.002 2410 0.29 
99.99 no slope -- -- 24100 -- 
100 no slope -- -- -- -- 
 
Mediator release (RBL) 
rBet v 1a 
(S112P/R145P) 
[%] 
actual EC50 
[ng/well] 
95% CI p-value 
theoretical EC50 
[ng/well] 
actual/theoretical 
comparison 
0 0.68 0.4-1.17 -- 0.68 1 
20 0.73 0.43-1.25 0.995 0.85 0.86 
40 0.86 0.51-1.51 0.984 1.13 0.76 
60 0.81 0.48-1.4 0.951 1.7 0.48 
80 0.9 0.53-1.58 0.902 3.4 0.26 
90 2.05 1.08-3.87 0.936 6.8 0.3 
99 89.76 44.4-174.8 0.682 68 1.32 
99.9 no slope -- -- 680 -- 
99.99 no slope -- -- 6800 -- 
100 no slope -- -- -- -- 
 
Shown are experimental values, 95% confidence intervals, p-values, theoretical EC50 values and actual/theoretical comparisons for immunoblot, inhibition ELISA and mediator 
release (RBL). 
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